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Contrasting immunopathogenic and immunoprotective effects of TNF 
The pleiotropic cytokine tumor necrosis factor-alpha (TNF) is a major participant in the 
initiation and orchestration of complex events in inflammation and immunity (1). The 
effects of TNF are mediated by two structurally related, but functionally distinct receptors, 
TNFR1 (or p55) and TNFR2 (or p75) (2). In contrast to the ubiquitous expression of 
TNFR1, TNFR2 is more restricted to lymphocytes (3). TNFR1 with its death domain (DD) 
is the primary signaling receptor on most cell types and accounts for the majority of the 
proinflammatory, cytotoxic and apoptotic effects classically attributed to TNF (4, 5). In 
contrast, TNFR2 lacks an intracellular death domain and predominantly mediates signals 
promoting lymphocyte activation and proliferation (6, 7).  
TNF has well-documented proinflammatory effects. Nevertheless, increasing evidence 
reveals that TNF also has unexpected anti-inflammatory and immunosuppressive effect, 
especially after prolonged exposure [reviewed in ref.(8-10)]. Anti-TNF therapy is clearly 
beneficial for most of rheumatoid arthritis (RA) patients. However, perhaps reflecting the 
strikingly contrasting activities of TNF, anti-TNF therapy in patients with RA and 
inflammatory bowel disease (IBD) is accompanied by the development of lupus and 
neuroinflammatory diseases in a minority of patients (11). Furthermore, multiple sclerosis 
(MS) patients treated with anti-TNF agents resulted almost uniformly in immune activation 
and exacerbation of disease (11). To date, the cellular and molecular mechanisms 
underlying the contrasting proinflammatory and immunosuppressive effect of TNF, as well 
as anti-TNF agents, in autoimmunity remain to be clarified and this is the main focus of the 
research described in this thesis.  
Immune equilibrium between regulatory T cells and effector T cells 
determines the outcome of autoimmune responses  
Extensive studies provide compelling evidence that CD4+FoxP3+ regulatory T cells (Tregs) 
play an indispensable role in maintaining immune homeostasis and in suppressing 
deleterious excessive immune responses (12). The induction of Treg suppressive activity is 
antigen specific and requires stimulation through the TCR, however, the suppressive 
function of Tregs is not antigen specific (13). Therefore, a wide range of immune responses 
can be inhibited by Tregs through “bystander” suppression (14). It is known that the 
cellular targets of Tregs include CD4 cells (15), CD8 cells (16), NK cells (17), NKT cells 
Chapter 1. Introduction 
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Figure 1: Generation and cellular targets of Tregs. Naturally occurring Treg cells (nTregs) are 
phenotypically and functionally matured in the thymus from lymphoid progenitor cells. In peripheral, 
naive CD4 cells can be converted into FoxP3-expressing Tregs (induced Tregs, or iTregs) by TGFβ. 
Both nTregs and iTregs are able to inhibit the activation of effector T lymphocytes (Teff cells), 
including both CD4 and CD8 T cells. Furthermore, Treg cells also potently inhibit immunological 
function of DCs, monocytes/macrophages, NK cells and NK T cells, as well as B cells.    
 (18), DCs (19), macrophages (20) and B cells (21). The in vitro suppressive activity of  
Tregs depends on cell-to-cell contact (15), and several molecules, such as IL-10, TGFβ, 
CTLA-4, IDO and granzyme/perforin are reported to contribute to the suppressive activity 
of Tregs [reviewed in ref. (22), Figure 1]. Activation of Tregs has been reported in various 
types of inflammatory responses, which may represent a negative feedback mechanism to 
curtail excessive inflammation and prevent self-tissue destruction (23-26). However, the 
molecular basis of Treg-activating effect of inflammation remains elusive. I hypothesized 
that TNF interaction with its receptors had an important biological effect on the balance 
between T-effector and T-regulatory cells. Therefore, I have asked several important 
questions with regard to the potential effects of TNF/TNFR pathways on the biological 
function of Tregs and its consequential effect in the modulation of inflammation:  
i. Can TNF, through the interaction with its receptors, promote proliferation and 
function of Treg cells? 
ii. Which TNF receptor pathway is responsible for this effect? 
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iii. What is the phenotypic and functional implications of expression of TNF receptors 
on the surface of Treg cells, as well as on T-effector cells? 
iv.  Does TNF play a role in the stabilization of immunosuppressive phenotypes of 
Tregs in the inflammatory environment? 
To answer the first question, I have initiated a study shown in Chapter 2 in which the 
effect of TNF on the proliferation and immunosuppressive function of Tregs was examined. 
Since TNFR2 is preferentially expressed by Tregs, I consequently characterized the 
phenotypic and functional implications of surface TNFR2 expression on mouse Tregs, as 
shown in Chapter 3, as well as on human Tregs, as shown in Chapter 4. Providing the 
important role of TNFR2 in the activation of Tregs, in Chapter 5 I further studied the 
effect of TNF on the expression of TNFR2, as well as other co-stimulatory TNFRSF 
molecules, on Tregs. In order to assess the role of TNF-TNFR2 pathway on the stability of 
Treg phenotype in the inflammatory environment, a colitis model induced by transfer of 
naive CD4 cells into lymphopenic mouse was studied, as presented in Chapter 6. In 
Chapter 7, in order to evaluate the overall role of TNF-TNFR2 pathway on the activation 
of whole CD4 population which contains both Teffs and Tregs, we studied the functional 
consequence of TNFR2 expression on Teffs in the presence of Tregs.      
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Abstract  
Although TNF is a major proinflammatory cytokine, increasing evidence indicates that 
TNF also has immunosuppressive feedback effects. We have demonstrated in this study 
that, in both resting and activated states, mouse peripheral CD4+CD25+ T regulatory cells 
(Tregs) expressed remarkably higher surface levels of TNFR2 than CD4+CD25- T effector 
cells (Teffs). In co-cultures of Tregs and CD4+CD25- T effector cells (Teffs), inhibition of 
proliferation of Teffs by Tregs was initially transiently abrogated by exposure to TNF, but 
longer exposure to TNF restored suppressive effects. Cytokine production by Teffs 
remained continually suppressed by Tregs. The profound anergy of Tregs in response to 
TCR stimulation was overcome by TNF, which expanded the Treg population. 
Furthermore, in synergy with IL-2, TNF expanded Tregs even more markedly up-regulated 
expression of CD25, FoxP3 and phosphorylation of Stat5, and enhanced the suppressive 
activity of Tregs. Unlike TNF, IL-1beta and IL-6 did not upregulate FoxP3 expressing 
Tregs. Furthermore, the number of Tregs increased in wild type, but not in TNFR2-/- mice 
following sublethal cecal ligation and puncture (CLP). Depletion of Tregs significantly 
decreased post-CLP mortality. Thus, the stimulatory effect of TNF on Tregs resembles the 
reported co-stimulatory effects of TNF on Teffs, but is even more pronounced because of 
the higher expression of TNFR2 by Tregs. Moreover, our study suggests that the slower 
response of Tregs than Teffs to TNF results in delayed immunosuppressive feedback 
effects.  
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Introduction 
TNF is a pleiotropic cytokine that is a major participant in the initiation and orchestration of  
inflammation and immunity (1). TNF has been shown to have proinflammatory effects, 
nevertheless, increasing evidence reveals TNF to also have unexpected immunosuppressive 
effects. For example, TNF has been considered as a major proinflammatory mediator of 
sepsis (1). This cytokine is markedly elevated in human infectious diseases (2) and is 
reported to be required for survival following cecal ligation and puncture (CLP) (3), which 
represents a mouse model of polymicrobial peritonitis simulating human sepsis (4). 
However, both TNF and TNFR-deficient mice fail to develop the usual sepsis-induced 
immunosuppression after CLP (5). In addition in chronic inflammatory states TNF-
deficient mice also exhibit more severe inflammation (6-8). We have therefore tested the 
hypothesis that the suppressive effects of TNF on the inflammatory response may involve 
Tregs.  
Tregs actively restrain the inflammatory response, suppress development of autoimmune 
diseases and dampen a wide spectrum of immune responses (9, 10). Tregs express TNFR2 
(11) suggesting that TNF may either overcome or promote the activity of Tregs directly. 
Indeed, it has been reported that neutralization of TNF restored Treg function and reduced 
the spontaneous apoptosis of Tregs in rheumatoid arthritis (RA) patients (12, 13). In 
neonatal NOD mice, administration of TNF also promoted the development of diabetes 
accompanied with reduced number and impaired function of Tregs (14). Paradoxically, 
injection of young adult NOD mice with TNF suppressed the development of diabetes and 
expanded Tregs (14). In one report TNF failed to have any effect on in vitro co-cultures of 
human Tregs and Teffs (12), while in another study TNF blocked inhibition of Teffs by 
Tregs (15). These studies suggest TNF may play an important role in either the down- or 
up-regulation of Treg activity, but the precise effect of TNF on Tregs remains elusive.  
Activation of TNFR2 has direct costimulatory effects on TCR-mediated mouse T cell 
responses and consequently reduces the activation threshold of antigen-driven CD4 T cell 
responses (16). We found initially that the signal mediated by TNFR2 effectively 
stimulated Teffs when co-cultured with Tregs, which may enable TNF-stimulated Teffs to 
escape from Treg-mediated inhibition and consequently mount a TNF-dependent 
inflammatory response. Indeed, it was recently reported that TNF also overcomes the 
immunosuppressive effect of mesenchymal stem cells (MSCs) on T cell proliferation (17). 
Furthermore, anti-TNF is a well known therapeutic for a number of inflammatory 
autoimmune conditions. Thus, liberating Teffs from Treg-mediated inhibition may account 
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for proinflammatory effects of TNF. However, there are paradoxical reports that prolonged 
exposure to TNF actually is protective in some autoimmune states (7, 8, 18) suggesting that 
duration and dose of TNF may modify its effects on Teffs and Tregs. Therefore we 
investigated the effects of different times and doses of TNF exposure on co-cultures of 
Tregs and Teffs, and the response of Tregs in TNFR2-deficient mice to a septic challenge 
to determine if and when TNF stimulated Tregs to reassert their suppressive capacity.  
Materials and Methods  
Mice and reagents. Female C57BL/6 (CD45.2) and C57BL/6 Ly5.2 congenic mice 
(CD45.1) and BALB/c mice, 8 to 12 wk old, were provided by Animal Production Area of 
the NCI (Frederick, MD). NCI-Frederick is accredited by AAALAC International and 
follows the Public Health Service Policy for the Care and Use of Laboratory Animals. 
Animal care was provided in accordance with the procedures outlined in the "Guide for 
Care and Use of Laboratory Animals" (National Research Council; 1996; National 
Academy Press; Washington, D.C.). Mice deficient in TNFR2 (19) were kept and bred in 
the animal facility of the University of Regensburg. Antibodies purchased from BD 
PharMingen (San Diego, CA) consisted of FITC-anti-CD4 (GK1.5), PE-anti-CD25 (PC61), 
PE-anti-Phospho-Stat5 , purified anti-CD3 (145-2C11),  purified anti-CD16/CD32 (2.4G2) 
and anti-CD28 (35.71). PE anti-mouse/rat Foxp3 Staining Set (FJK-16s) was purchased 
from eBioscience. PE-anti-TNFR1 and PE-anti-TNFR2 were obtained from Serotec Ltd 
(Oxford, UK). Purified anti-CD25 (PC61) was a generous gift of W. Falk (University of 
Regensburg). Recombinant mouse cytokines (IL-2, TNF, IL-1β, and IL-6) were purchased 
from PeproTech (Rocky Hill, NJ).  
Purification of cells. CD4+ cells were purified with Mouse CD4 (L3T4) microbeads and LS 
column (Miltenyi Biotec Inc., Auburn, CA). CD4+CD25- and CD4+CD25+ cells were 
purified from lymph node (inguinal, axillary and mesenteric regions) cells using 
Cytomation MoFlo cytometer (Fort Collins, CO), yielding a purity of ~98% for both 
subsets. T-depleted spleen cells were used as APCs and were prepared by depletion of 
CD90+
 
cells with anti-mouse CD90 MicroBead and LD column (Miltenyi Biotec Inc.). APC 
were irradiated with 3000 R.  
Flow Cytometry. After treatment with anti-CD16/CD32 Ab, cells were incubated with 
appropriately diluted antibodies. For CFSE labelling assay, cells were labelled with 2 μM 
CFSE for 8 min at room temperature. FACS analysis was performed on a FACScan (BD 
Biosciences, Mountain View, CA) using CellQuest software.  
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In vitro cell culture and proliferation assay. CD4+CD25- T cells (5×104 
 
cells/well) were 
seeded in a U-bottom 96-well plate in the medium with 2×105 cells/well of APCs plus 
0.5 μg/ml of soluble anti CD3 Ab. CD4+CD25+ T cells were added to the wells at desired 
ratio to CD4+CD25- cells. Cells were pulsed with 1 µCi [3H]thymidine (Amersham 
Pharmacia Biotech, Piscataway, NJ) per well for the last 6 h of culture period. In some 
settings, cells were stimulated with 2 µg/ml of soluble anti-CD3 antibody (without APCs). 
In a parallel experiment, the supernatants were collected and cytokine measurement was 
performed by analysis of supernatants with SearchLight Mouse Cytokine Array (Pierce 
Biotechnology, Woburn, MA). In some experiments, IL-2 (10 ng/ml) was supplemented to 
the medium, with or without TNF (10 ng/ml). In some experiments, CD4+CD25-  T cells 
from C57BL/6 Ly5.2 (CD45.1) mice were labelled with CFSE and then were co-cultured 
with CD4+CD25+ T cells from C57BL/6 (CD45.2) mice. The co-cultures were stimulated 
with APC from C57BL/6 (CD45.2) mice and 0.5 μg/ml of soluble anti CD3 Ab. The 
proliferation of CD4+CD25- T cells was assessed by CFSE dilution using flow cytometry, 
gating on CD45.1+ cells. In some experiments, CFSE-labelled Tregs or CFSE-labelled 
Teffs were cultured alone or CFSE-labelled Teffs were co-cultured with unlabelled Tregs, 
or vice versa unlabelled Teffs were co-cultured with CFSE-labelled Tregs at a 
“physiological” ratio (ratio of Teff/Treg was 10:1) with IL-2 or IL-2 plus TNF. After 
incubation for 72 h, the proliferation of CFSE-labelled cells was analyzed by flow 
cytometry. In some experiments, purified Tregs were cultured with medium alone or with 
TNF (10 ng/ml) for 16 h. The resultant intracellular expression of FoxP3 was analyzed by 
FACS. In some settings, purified Tregs and Teffs were cultured with IL-2 (10 ng/ml) or IL-
2 plus TNF (10 ng/ml, each) for 24 h to 72 h, after washing, the intracellular expression of 
FoxP3 was analyzed by FACS, and the immunosuppressive activity of cultured Tregs was 
determined by co-culturing with freshly isolated Teffs, either using the [3H] thymidine 
incorporation assay or CFSE-labelling assay.    
Cecal ligation and puncture (CLP). C57BL/6 mice were anesthetized by i.p. injection of 
75 mg/kg Ketanest® (Parke, Davis & Company, Munich, Germany) and 16 mg/kg 
Rompun® (Bayer AG, Leverkusen, Germany). The cecum was exteriorized and the distal 
end (< 30%) was ligated and punctured once with a needle (0.4 mm diameter) to achieve a 
sublethal CLP as described previously (2). For Treg depletion mice received 200 µg anti-
CD25 (PC61) or rat IgG, respectively, in 500 µl PBS 3 days prior to CLP. Splenocytes 
were isolated on day 1 or 2 after CLP. 
Statistical analysis. Comparisons of data were analyzed by two-tailed Student’s t test using 
Graphpad Prism 4.0 or using the Mann-Whitney-U-Test. The log-rank test was used to 
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Figure 1. Surface expression of TNFRs on Teffs and Tregs. CD45.1+ Tregs (5×104
 
cells/well, A), 
CD45.2+ Teffs (5×104
 
cells/well, B) were cultured alone (cultured) or co-cultured together (co-
cultured, ratio of Teff/Treg was 2:1). The cells were stimulated with APC and anti-CD3. After 48 h, 
the surface expression of TNFR1 and TNFR2 was analyzed by gating on CD4+ and CD45.1+ (for 
Tregs) or CD4+ and CD45.2+ (for Teffs) population. Freshly isolated cells (resting) were used for 
comparison. The number in the histogram is the percentage of TNFR positive cells. Data shown are 
representative of 2 separate experiments.  
 
compare Kaplan-Meier survival curves. 
Results  
Expression of TNF receptors on resting and activated Tregs and Teffs  
TNF mediates its biological functions through its receptors: TNFR1 and TNFR2; the latter 
is largely confined to cells of the immune system (20). Unlike TNFR1 which contains a 
death domain in its cytoplasmic tail, the primary function of TNFR2 is to promote cellular 
proliferation and survival (1). We were able to confirm the data of Kim and Teh (21) 
showing that mouse splenic CD4+ as well as CD8+ T cell subpopulations express 
moderately high levels of TNFR2. The expression of TNFR2 was further increased by T 
cell activation (data not shown). CD4+ splenocytes from TNFR2-deficient mice were less 
able than those from wild type mice to proliferate in response to anti-CD3 and anti-CD28 
(data not shown). It has been reported that human thymic Tregs expressed high levels of 
surface TNFR2 (11). Consistent with this report, we found considerably higher constitutive 
expression of surface TNFR2 on mouse peripheral Tregs (32%) than on Teffs (8%) (Fig.1). 
Upon TCR stimulation, expression of this receptor on Tregs was further increased to 47% 
and to 33% on activated Teffs. Furthermore, the activation-dependent elevation of TNFR2 
expression by Teffs was not reduced by the presence of Tregs at a ratio of Teffs to Tregs of 
2:1. Unlike TNFR2, the surface expression of TNFR1 was barely detectable by FACS on 
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either resting or activated Teffs or Tregs (Fig.1).  
Effect of TNF on co-cultures of Teffs and Tregs  8 h) exposure of TNF on the outcome of in 
vitro co-cultures of Trergs and Teffs. Exogenous 
Next we evaluated the effect of relative short term (4 TNF markedly increased cell 
proliferation in the co-cultues (Fig. 2A). This effect of TNF was observed over various 
ratios of Tregs to Teffs (data not shown). To exclude potential interference by APC, co-
cultures of Teffs and Tregs were stimulated with soluble anti-CD3 alone. TNF also 
increased the proliferation by these APC-free co-cultures (Fig. 2B). Thus, the proliferative 
effect of TNF is due to direct action on CD4 subsets. TNF not only enhanced proliferation 
of Teffs, but it also overcame the non-responsiveness of Tregs to TCR stimulation (Fig. 
2C), presumably by co-stimulatory signalling through TNFR2 which reduces the threshold 
of both Teffs and Tregs to TCR-dependent activation. At 48 h, TNF stimulated proliferation 
of Teffs and reduced the inhibition of Teffs by Tregs by [3H] thymidine incorporation assay 
in a dose dependent manner (Fig. 2D~E). In contrast, more prolonged exposure of co-
cultures to TNF (72 h) restored the inhibition of proliferation of Teffs by Tregs (Fig. 
2D~E).  
Since both Teffs and Tregs incorporated thymidine by 48 h and 72 h of incubation in the 
presence of TNF, we further examined the impact of TNF on the proliferation of co-
cultured congenic CD45.1+ Teffs by CFSE dilution assay. As shown in Fig 2F, CFSE-
dilution assay were more delayed compared to the [3H]thymidine incorporation assay, 
since DNA synthesis occurs prior to cell replication. The CFSE assay showed considerable 
proliferation by 72 h of incubation because 90% of Teffs by this time replicated. This was 
reduced to 22.2% by the addition of Tregs. When Teffs alone were cultured with TNF, the 
proportion of replicating Teffs similarly was 93.9%, but the number of cells resulting from 
multiple replications by CFSE assay was greater than in the absence of TNF. In the 
presence of Tregs and TNF, replicating Teffs decreased to 38.9%. Based on the proportion 
of replicating Teffs, the percent inhibition by Tregs at 48 h was 57.6% and this was reduced 
to 37.3% in the presence of TNF. At 72 hours, the percent inhibition by Tregs was 75.3% 
and 58.6%, in the absence and presence of TNF, respectively. The reduction in inhibition 
by TNF was therefore 35.2% and 20.8% at 48 h and 72 h, respectively. Since TNF 
stimulated multiple rounds of division by Teffs at 72 h, the precise percent inhibition by 
Tregs in the presence of TNF at this time point was actually greater than 58.6%, and 
consequently, the reduction in inhibition by TNF was actually less than 20.8%. Similar  
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Figure 2. Effect of exogenous TNF on the lymphocyte proliferation in co-cultures. (A) Teffs 
(5×104
 
cells/well) cultured alone or co-cultured with Tregs (ratio of Teff/Treg was 2:1), were 
stimulated with APC and anti-CD3, in the presence of increasing levels of TNF. (B) co-cultures of 
Teffs (5×104
 
cells/well) and Tregs (2.5×104
 
cells/well) were stimulated with soluble anti-CD3 alone, in 
the presence or absence of 10 ng/ml TNF. (C) 5×104
 
cells/well of Teffs or Tregs were cultured alone 
and stimulated with APC/anti-CD3, with or without 10 ng/ml of TNF. The proliferative response was 
determined after 48 h culture (A~C). (D) Cells were cultured and stimulated as in (A) for 48 h or 72 h, 
in the presence or absence of 10 ng/ml of TNF. (E) Cells were cultured and stimulated as in (A) for 48 
h or 72 h in the presence of increasing concentration of TNF. The data shown are percent inhibition 
(%). (F) FACS-sorted Teffs from C57BL/6 Ly5.2 (CD45.1) mice were labelled with CFSE and were 
cultured alone or co-cultured with Tregs from C57BL/6 (CD45.2) mice, in the presence or absence of 
10 ng/ml of TNF. The cells were stimulated with CD45.2+ APC and anti-CD3. After incubation for 48 
h and 72 h, proliferation by Teffs was analyzed by gating on CD45.1+ cells. The data shown are 
representative of at least 3 separate experiments with similar results.  
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Figure 3: Effect of exogenous TNF on cytokine production by co-cultures. 
5×104
 
cells/well of Teffs and Tregs were cultured alone or co-cultured at a ratio 
of 1:1. The cells were stimulated with APC and anti-CD3, in the presence or 
absence of 10 ng/ml of TNF. After incubation for 48 h, IL-4, IFNγ, and IL-2 in 
the supernatant were determined by multiplex mouse cytokine measurement. 
The data shown are representative of at least 3 separate experiments with 
similar results.  
results obtained in three separate experiments. Altogether these results lead us to conclude 
that the shorter duration of treatment with TNF (48 h) showed partial abrogation of 
inhibition of Teffs by Tregs, while more prolonged exposure to TNF (72 h) restored Treg-
mediated inhibition. 
The Treg-mediated 
suppression of 
cytokine production 
by Teffs was 
detected early on. At 
48 h of incubation, in 
the absence of TNF, 
Tregs produced very 
low cytokine levels 
in response to TCR 
stimulation and 
markedly inhibited 
the capacity of Teffs to produce IL-4, INFγ, and IL-2 by 81%, 67%, and 87% (Fig. 3). 
Addition of TNF led to a 3-fold increase in IL-4 and IFNγ production by purified Teffs and 
partially restored the production of IL-4 and IFNγ (but not IL-2) in co-cultures. However, 
in the presence of Tregs plus TNF, the percent inhibition of IL-4, INFγ, and IL-2 
production by Teffs was just still as high as 77%, 67%, and 86%, respectively, which is 
comparable to the inhibitory effect of Tregs in the absence of TNF (Fig. 3). Therefore, short 
term exposure to TNF for up to 48 h reversed inhibition of Teffs proliferation by Tregs, but 
capacity of Tregs to inhibit cytokine production by Teffs occurred even at the earlier time 
point.  
TNF synergizes with IL-2 in activating Tregs  
In order to determine whether TNF acted directly on Tregs, TNF was added to the purified 
Tregs cultured without APC and anti-CD3. Both FoxP3 expression and immunosuppressive 
activity of unstimulated Tregs rapidly decreased after 16 h incubation in medium, but 
addition of TNF partially prevented this decrease in FoxP3 expression (Fig. 4A) and 
partially maintained the immunosuppressive function of Tregs (data not shown). However, 
we could not evaluate the effect of longer incubation periods under such condition since 
TNF was not able to support prolonged survival of Tregs.  
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It has been amply demonstrated that IL-2 is crucial for survival of in vitro cultured Tregs 
(22). We therefore used IL-2 to enable us to observe a more prolonged in vitro effect of 
TNF on Tregs. As predicted, IL-2 alone increased the expression of FoxP3 and CD25 by 
Tregs with time. This effect of IL-2 was markedly enhanced by the addition of TNF, in a 
Figure 4. TNF, synergizing with IL-2, selectively activates Tregs. (A) Tregs were cultured with RPMI-
10 alone (medium) or 10 ng/ml of TNF (TNF). 16 h later, cells were harvested and expression of FoxP3 
was analyzed by FACS, compared with freshly isolated cells. (B-E) Tregs or Teffs were cultured in the 
medium supplemented with 10 ng/ml IL-2, with or without 10 ng/ml TNF for 24 h, 48 h, and 72 h. Kinetic 
expression of FoxP3 (B) and CD25 (C) by Tregs and Teffs cultured in IL-2, with or without TNF, was 
determined by FACS. Typical histogram of FoxP3 (D) and CD25 (E) expression by 72 h cultured Treg or 
Teffs, compared with freshly isolated cells. Dashed line shows isotype control, solid histogram shows 
FoxP3 (D) or CD25 (E) Ab staining. (F) Dose-response of TNF (0.1 to 100 ng/ml) on FoxP3 expression by 
Tregs and Teffs cultured with medium containing IL-2 (10 ng/ml) for 72 h. The number in the histogram is 
MFI (mean fluorescence intensity). The data are representatives of at least 3 separate experiments with 
similar results. (G) Effect of proinflammatory cytokines on FoxP3 expression by IL-2 cultured Tregs. 10 
ng/ml of IL-1β, or IL-6, or TNF on FoxP3 expression (MFI) by Tregs cultured with IL-2 for 72 h. The data 
are shown as percentage of IL-2 culture alone (%), summarized from 3 separate experiments (Mean±SEM). 
Compared with IL-2 culture alone, *P<0.05.  
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time-dependent (Fig. 4B~E) and dose-dependent manner (Fig. 4F). The up-regulation of 
FoxP3 by TNF was unique, since other inflammatory cytokines such as IL-1β and IL-6 did 
not share this property (Fig. 4G). These data indicated that TNF, in combination with IL-2, 
markedly increased Tregs FoxP3 and CD25 expression. In contrast, Teffs did not show 
changes in FoxP3 or CD25 expression in response to IL-2/TNF (Fig. 4B~D), suggesting 
TNF can not support de novo differentiation of Tregs from the non-Treg population.  
We further determined the effect of TNF on the expansion of the physiological level of 
~10% Tregs present in purified CD4 cells. After 72 h of culture with IL-2 alone, the 
proportion of FoxP3+ cells increased by 2-fold above the level in freshly isolated CD4 cells. 
The expression level of FoxP3 (MFI) was also dramatically enhanced by TNF (Fig. 
5A).Addition of IL-2 plus TNF increased the proportion of FoxP3-expressing cells by 4-
fold. The proportion of FoxP3+ cells did not increase further after 5 to 7 days culture, but 
remained high at a 30 to 40% level (data not shown). CFSE-labelling assays indicated that 
IL-2 induced the proliferation of a small population (~ 10%) of Tregs. Supplementation of 
IL-2 with TNF further increased the proportion of proliferating cells by 4-fold over IL-2 
alone in cultures of Tregs and in co-cultures of Teffs and Tregs at a 10:1 ratio (Fig. 5B). In 
Figure 5. In combination with IL-2, TNF preferentially expands Tregs in vitro. (A) Purified CD4 cells 
(pooled from LNs and spleen) were cultured with 10 ng/ml IL-2, with or without 10 ng/ml TNF for 24 h, 
48 h, or 72 h. The expression of FoxP3 was analyzed by FACS. Mean fluorescence intensity (MFI) and the 
percentage of positive cells are indicated in the histograms. (B) CFSE-labelled Tregs or CFSE-labelled 
Teffs were cultured by themselves or CFSE-labelled Teffs were co-cultured with unlabelled Tregs, or vice 
versa unlabelled Teffs were co-cultured with CFSE-labelled Tregs at a “physiological” ratio (ratio of 
Teff/Treg was 10:1) with IL-2 or IL-2 plus TNF. After incubation for 72 h, the proliferation of CFSE 
labelled cells was analyzed by FACS. The proportion of proliferating cells was indicated in the histogram. 
The data shown are representative of 3 separate experiments.  
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contrast, IL-2 or IL-2 plus TNF failed to stimulate the proliferation of Teffs (Fig. 5B).  
TNF increased IL-2-induced phosphorylation of Stat5 and immunosuppressive activity of 
Tregs  
It was recently reported that up-regulation of FoxP3 expression and expansion of Tregs by 
IL-2 involved activation of Stat5 (23). We found that IL-2-stimulated phosphorylation of 
Stat5 in Tregs was further enhanced by TNF (Fig. 6A). This may be based on TNF up-
regulation of CD25 expression, which therefore promotes an IL-2 response by Tregs.  
The effect of IL-2 or IL-2 plus TNF on the inhibitory activity of Tregs was examined in 
co-cultures (72 h) with freshly isolated Teffs. Pre-treatment with IL-2 significantly 
enhanced the immunosuppressive activity of Tregs (data not shown). Tregs pre-treated 
Figure 6. TNF increases IL-2-mediated phosphorylation of 
Stat5 and enhances function of Tregs. Tregs or Teffs were 
cultured in the medium supplemented with 10 ng/ml IL-2, 
with or without 10 ng/ml TNF for 72 h. (A) Intracellular 
expression of phosphorylated Stat5 was determined by FACS. 
Dashed line shows isotype control; grey histogram shows 
cells cultured with IL-2; solid line shows cells cultured with 
IL-2 plus TNF. (B) Inhibitory activity of IL-2-cultured (IL2-
CD25+) or IL-2 plus TNF-pretreated (IL2/TNF-CD25+) Tregs 
(2.5×103 to 2.5×104
 
cells/well) was determined by co-culturing 
with freshly isolated Teffs (5×104 cells/well). The mean cpm 
of Teffs alone was 66280. (C) The susceptibility of IL-2 
cultured (IL2-CD25-) or IL-2 plus TNF-pretreated (IL2/TNF-
CD25-) Teffs (5×104
 
cells/well) was examined by co-culture 
with an increasing number of freshly isolated Tregs (5×103 
~2.5×104
 
cells/well). The proliferation was determined after 
72 h incubation. Compared with proliferation of IL-2 cultured 
cells, *P<0.05, **P<0.01. (D) CD45.1+ Teffs were labelled 
with CFSE and co-cultured with  IL-2-, or IL-2 plus TNF-
pretreated CD45.2+ Treg at ratio of 10:1, 10:5 and 10:10. The 
cells were stimulated with CD45.2+ APC and anti-CD3 for 72 
h. The proliferation of co-cultured Teffs was analyzed by 
FACS, gating on CD45.1+ cells (solid histograms). Dashed 
histograms indicate the proliferation profile of Teffs when 
they were cultured alone. The results shown are 
representatives of at least 3 separate experiments.  
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with IL-2 plus TNF exhibited greater inhibitory activity than Tregs cultured with IL-2 
alone (P<0.01 to 0.05, Fig. 6B). Since Tregs themselves may proliferate in response to 
three days of incubation with IL-2 and TNF, we further examined the inhibitory potential 
of the washed Tregs by co-culturing with CFSE-labelled congenic CD45.1+ Teffs. As 
shown in Fig 6D, at ratios of Teff to Treg of 10:1, 10:5 and 10:10, the percentage of 
replicating Teffs were 58.3%, 35.2% and 28.4% when they were co-cultured with IL-2-
pretreated Tregs, and was reduced to 39.8%, 28.2% and 21.6% respectively when Teffs 
were co-cultured with IL-2/TNF-pretreated Tregs. Thus, the CFSE-dilution assay was 
consistent with [3H] thymidine incorporation assay, and showed that pre-treatment with 
IL-2 plus TNF enhanced the suppressive activity of Tregs. The effect of these cytokines 
on the susceptibility of Teffs to inhibition by Tregs was also examined. As shown in Fig 
6C, the inhibitory effect of freshly isolated Tregs on Teffs pre-treated with IL-2 or IL-2 
plus TNF was similar in potency (P>0.05), indicating that after pretreatment with IL-
2/TNF, Teffs were still fully susceptible to Treg-mediated suppression. Thus, TNF in 
combination with IL-2 selectively activated an increased in number of fully functional 
Tregs.  
TNFR2-/- mice subjected to CLP failed to 
expand Tregs 
In order to further evaluate the in vivo 
relevance of our findings, we investigated the 
Figure 7. In TNFR2-/- mice, the proportion of 
splenic Tregs failed to increase after CLP. (A) 
Wild type and TNFR2-/- mice were subjected to 
sublethal CLP (n = 3 without CLP, n = 6 with CLP 
for each group). Splenocytes were isolated and the 
proportion of CD4+CD25+Foxp3+ Tregs was 
determined by FACS from mice without CLP or on 
day 1 or 2 after CLP. Compared with wild type (wt) 
mice, * P < 0.01. Data shown are representative of 2 
separate experiments. (B) Mice (n = 12 per group) 
were treated with anti-CD25 (PC61) or rat IgG, 
respectively, 3 days before sublethal CLP operation. 
Survival was monitored over 15 days and compared. 
P = 0.03. Data shown are representative of 3 separate 
experiments. 
 
Chapter 2. TNFR2 activation up-regulates Tregs 
 
28 
 
role of Tregs in TNFR2-deficient mice. Since the number and function of Tregs was 
normal in such mice (data not shown), we studied the effect of challenging mice with 
CLP, which exhibit a rapid elevation in TNF level (3, 4, 24). In septic patients, the 
percentage of circulating Tregs is markedly increased, which presumably contributed to 
the post-septic immunosuppression (25, 26). Consistent with those observations, we found 
that the number of splenic Tregs significantly increased in wild type mice at 1 and 2 days 
after CLP. In contrast, Tregs failed to increase in the TNFR2-deficient mice which were 
subjected to CLP (Fig. 7A). Furthermore, treatment of wild type mice with PC61 
antibodies directed against CD25 to deplete Tregs resulted in a remarkable reduction in 
the early lethality following the CLP procedure (Fig 7B). Our data indicate that in vivo 
expansion of Tregs by interaction of TNF with TNFR2 may play an important role in the 
induction of post septic immunosuppression, which results in the failure of bacterial 
clearance and lethality.   
Discussion 
It was recently reported that ligands for TLR2, but not for TLR4 or TLR9, in conjunction 
with TCR stimulation induce proliferation of Tregs in vitro and in vivo (27). This is 
associated with a transient loss of suppressive activity by the Tregs, which is subsequently 
restored in an amplified manner. Another group reported TLR2 activation to result in a 
transient suppression of FoxP3 mRNA expression by mouse Tregs in association with 
resistance of Teffs to suppression by Tregs by 8-15 h (28). Similarly, our study suggests 
that short term effects of TNF, as seen in the early phases of inflammatory response, may 
enable Teffs to expand despite the presence of Tregs, whereas more prolonged exposure 
to TNF may favor expansion and activation of Tregs. These recent results concerning the 
effect of TLR2 expression and signalling on the expansion and function of Tregs suggest 
that during acute infection, pathogen-induced TLR2 activation promote IL-2-dependent 
Treg proliferation in parallel with temporarily abrogating the suppression of the ongoing 
immune response by Tregs (27, 28). Since activated T cells are a good source of TNF, it 
is likely that TNF and TNFR2 participate in these TLR2 responses. The initial transient 
loss of suppressive activity of Tregs presumably favors elimination of pathogens. Tregs 
subsequently regain their suppressive capabilities and/or Teffs become more susceptible, 
thus down-regulate inflammation and contributing to the balance between tolerance and 
immunity.  
The capacity of TNF to stimulate Tregs may underlie the temporal role of TNF in the 
inflammatory response and account for the opposing effects of TNF in inflammation (29) 
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and autoimmune diseases (30). For example, wild type mice responded promptly with 
granuloma formation and hepatosplenomegaly to a microbial agent followed by subsequent 
resolution of inflammation, while similarly treated TNF-/- mice showed little or no initial 
response, but subsequently developed a vigorous, disorganized and lethal inflammatory 
response (29). In experimental autoimmune encephalomyelitis (EAE), TNF-/- mice had a 
delayed onset of disease; however, once developed, the disease was more severe than in 
wild-type controls (30). It is possible that in the absence of TNF, Teffs are unable to initiate 
an effective immune response. However, in the later phase of inflammatory response, 
deficiency of TNF may result in failure to expand and activate Tregs and cause excessive 
self destructive inflammation.  
TNF has been implicated in the pathogenesis of sepsis for decades as a major mediator of 
inflammation (1, 2). It is well established that sepsis deeply perturbs immune homeostasis 
by inducing an initial tremendous systemic inflammatory response that is rapidly followed 
by immunosuppression (31) and correlated with a fatal outcome (32). Tregs suppress a 
broad spectrum of immune responses, including dampening host defence against microbial 
infection (9, 10). Recently, it has been reported that the percentage of circulating Tregs in 
sepsis-induced immunosuppression is markedly increased which correlates with the 
progression of sepsis (25, 26). Consistent with these human sepsis studies, we found that 
the number of Tregs significantly increased in wild type mice, but not in TNFR2-deficient 
mice, with CLP. Furthermore, we observed that depletion of Tregs prevented CLP-induced 
mortality. Our data suggest that elevated levels of TNF, by interacting with TNFR2 which 
predominantly expressed by Tregs, together with the sepsis-induced expansion of Tregs 
contribute in the post-septic immunosuppression and fatal consequences. In contrast with 
our observation, a recent report observed that adoptive transfer of in vitro-stimulated Tregs 
(but not unstimulated Tregs) improved the survival in the mouse CLP model (33). 
However, as the author indicated, the protective effect of adoptive transferred Tregs was 
not attributable to the classic immunosuppressive effects of Tregs, because rather than 
inducing local or systemic immunosuppression, Treg transfer resulted in greater peritoneal 
cytokine production and mast cells accumulation (33). Their findings may be due to 
contamination by Teffs, because MACS is subeffecient purification approach.    
Our findings that TNF up-regulated FoxP3 expression and immunosuppressive activity of 
Tregs contrasts with another study of human Tregs which reports that TNF down-
regulates FoxP3 expression and blocks suppressive function of Tregs (15). This 
discrepancy is unlikely due to the species difference of Treg response to TNF, since we 
observed that TNF in combination with IL-2 also enhanced FoxP3 expression by human 
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CD4+CD25+ T cells (data not shown). Valencia et al (15) found that circulating 
CD4+CD25hi Tregs incubated with relatively high concentrations of TNF (50 ng/ml) and 
IL-2 (100 U/ml) lost immunosuppressive activity, probably reflecting only the early 
transient immunstimulatory phase of TNF.  
Our in vitro and in vivo data are compatible with the observation of Wu and McDevitt’s 
that administration of TNF to adult NOD mice resulted in expansion of Tregs in vivo and 
inhibited diabetes (14). Thus, TNF not only up-regulated FoxP3 and CD25 expression, 
but also contributed to expanding the Treg pool in mice subjected to an autoimmune or 
infectious challenge.  
In conclusion, TNFR2 preferentially expressed by Tregs endows Tregs with greater 
capability to use TNF for cellular activation and expansion. Although TNFR2-/- mice have 
normal numbers of functional Tregs, these fail to expand when challenged by sepsis. 
Activated T cells are major sources of TNF as well as IL-2 and these two cytokines 
synergize in promoting the capacity of Tregs to temper both innate and adaptive immune-
mediated inflammatory reactions. It is surprising that of the pro-inflammatory cytokine 
TNF, but not IL-1β or IL-6, up-regulate Tregs. Perhaps this is because TNF is the “master 
regulator” and is the upstream inducer of the other cytokines (34). The stimulatory effect of 
TNF mediated by TNFR2 on Treg activity resembles the co-stimulatory effect of TNF on 
Teffs (16), but is even greater because Tregs express higher levels of TNFR2.  
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Abstract 
TNFR2 is predominantly expressed by a subset of human and mouse CD4+CD25+FoxP3+ 
Tregs. In this study, we characterized the phenotype and function of TNFR2+ Tregs in 
peripheral lymphoid tissues of normal and tumor bearing C57BL/6 mice. We found that 
TNFR2 was expressed on 30%-40% of peripheral activated/memory subset of Tregs that 
were most highly suppressive. In contrast, TNFR2- Tregs exhibited the phenotype of naïve 
cells and only had minimal suppressive activity. Although not typically considered to be 
Tregs, CD4+CD25-TNFR2+ cells nevertheless possessed moderate suppressive activity. 
Strikingly, the suppressive activity of TNFR2+ Tregs was considerably more potent than 
that of reportedly highly suppressive CD103+ Tregs. In the Lewis lung carcinoma model, 
more highly suppressive TNFR2+ Tregs accumulated intratumorally than in the periphery. 
Thus, TNFR2 identifies a unique subset of mouse Tregs with an activated/memory 
phenotype and maximal suppressive activity which may account for tumor-infiltrating 
lymphocyte mediated immune evasion by tumor. 
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Introduction 
TNF is a pleiotropic cytokine that is a major participant in the initiation and orchestration of  
inflammation and immunity (1). TNF is also implicated in inflammation-associated 
cancers, produced either by tumor cells and/or by infiltrating leukocytes (2). TNF mediates 
its biological functions through its receptors: TNFR1 and TNFR2. TNFR1 through its death 
domain mediates the cytotoxic effect while TNFR2 is largely confined to cells of the 
immune system and its biological role is still not fully understood (1). TNF has been shown 
to have proinflammatory effects, nevertheless, increasing evidence reveals TNF also has 
unexpected immunosuppressive effects and this may be based on the capacity of TNF in 
concert with IL-2 to activate and expand mouse CD4+CD25+ T regulatory cells (Tregs) (3), 
presumably by interacting with TNFR2 which is preferentially expressed by both human 
and mouse Tregs (3, 4). Thus, up-regulation of Treg activity by TNF may mediate the 
delayed immunosuppressive effect of TNF on inflammatory responses and the expansion of 
Tregs in the tumor microenvironment. Consequently, we hypothesized that TNFR2 
expression may identify the more functionally active Tregs in tumor-infiltrating 
lymphocytes (TILs).   
Materials and Methods 
Mice, cells and reagents. Female wild type C57BL/6 mice, 8 to 12 wk old, were provided 
by the Animal Production Area of the NCI (Frederick, MD). NCI-Frederick is accredited by 
AAALAC International and follows the Public Health Service Policy for the Care and Use 
of Laboratory Animals. Animal care was provided in accordance with the procedures 
outlined in the "Guide for Care and Use of Laboratory Animals" (National Research 
Council; 1996; National Academy Press; Washington, D.C.). C57BL/6-derived Lewis lung 
carcinoma (LLC) cell line was obtained from ATCC. Antibodies purchased from BD 
Biosciences (San Diego, CA) consisted of anti-CD3 (145-2C11), CD4 (GK1.5), anti-CD25 
(PC61), CD45RB (16A), CD62L (MEL-14), CD44 (IM4), CD69 (H1.2F3), CD103 
(M290), TNFR2 (TR75-89), CTLA4 (UC10-4F10-11) and CD16/CD32 (2.4G2). Anti 
CD3e (145-2C11), Foxp3 Staining Set (FJK-16s), GITR (DTA-1) Abs were purchased 
from eBioscience (San Diego, CA).  
Mouse tumor inoculation and separation of tumor infiltrating lymphocytes (TILs). C57BL/6 
mice were inoculated subcutaneously in the right rear flank with 100,000 LLC cells. After 
two weeks, tumors were excised, minced and digested in RPMI 1640 supplemented with 1 
mg/ml collagenase IV, 0.1 mg/ml DNase I.     
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Cell purification, in vitro culture and proliferation assay. CD4 subsets were purified from 
spleen and lymph nodes (inguinal, axillary and mesenteric regions) or TILs using 
Cytomation MoFlo cytometer (Fort Collins, CO), yielding a purity of ~98% for both 
subsets. For in vitro assays of inhibition of proliferation by Treg, CFSE-labelled (2 μM, 8 
min at room temperature) responder cells (5×104 
 
cells/well) were seeded in a U-bottom 96-
well plate with 2×105 cells/well of APCs (T cell-depleted, irradiated spleen cells) plus 
0.5 μg/ml of functional grade anti-CD3e antibody. Subsets of CD4 cells were added to the 
wells at the desired ratio. After 48 h, CFSE dilution was determined with FACS.   
Flow Cytometry. After blocking FcR, cells were incubated with appropriately diluted 
antibodies. Data were acquired on a FACSort (BD Biosciences, Mountain View, CA) and 
data analysis was conducted using CellQuest software (BD Biosciences).  
Results and Discussion 
Phenotype and distribution of mouse TNFR2+ Tregs  
As shown for normal C57BL/6 (B6) mice in Fig 1A, the expression of TNFR2 was largely 
restricted to splenic CD4+ cells. Similar results were observed by LN cells (data not 
shown). CD4+CD25+ T cells were the primary cell type expressing TNFR2, while fewer 
CD4+CD25- T cells expressed this receptor (Fig 1B). The proportions of CD25+TNFR2+ 
cells, CD25+TNFR2- cells and CD25-TNFR2+ splenic CD4 cells were 3.6%, 6.1% and 
2.8%, respectively (Fig 1C).  
Tregs are heterogeneous and consist of activated/memory as well as naïve cells. As shown 
in Fig 1D, TNFR2+ Treg cells were CD45RBlo, CD62Llo, CD44hi and expressed relatively 
high levels of CD69, CD103, GITR and CTLA-4, indicative of the memory and activated 
phenotype. In contrast, naïve Tregs were CD45RBhi, CD62Lhi, CD44lo and expressed 
relative low levels of CD69, CD103, GITR and CTLA-4, and were TNFR2-. CD4+CD25-
TNFR2+ cells contained fewer CD45RBhi and CD62Lhi, and more CD44hi and CD69+ cells, 
compared with CD4+CD25+TNFR2- cells. Furthermore, TNFR2 showed a closer 
relationship than CD25 to the subset of memory and activated mouse peripheral FoxP3+ 
Treg cells. Both TNFR2+ and TNFR2- subsets of CD4+CD25+ cells expressed comparably 
high levels of FoxP3. However, the intensity of FoxP3 expression was consistently higher 
in CD4+CD25+TNFR2+ cells than in CD4+CD25+TNFR2- cells. Although only about 1% of 
CD4+CD25-TNFR2- cells were FoxP3+ cells, 25~40% of CD4+CD25-TNFR2+ cells 
expressed FoxP3 (Fig 1D).    
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In normal C57BL/6 mice, ~80% of CD8-CD4+CD25+ thymocytes were TNFR2+, which 
resembles the reported high TNFR2 expression by human thymic Tregs (4). In peripheral 
LNs, spleen and Peyer’s patches, 30%~40% of CD4+CD25+ cells expressed TNFR2. In 
Figure 1. Phenotypic characterization and distribution of normal C57BL/6 mouse 
CD4+CD25+TNFR2+ Tregs. (A) Splenocytes were stained with anti CD4 and TNFR2 Abs and 
analyzed by FACS. (B) Splenocytes were stained with anti CD3, CD4, CD25 and TNFR2 Abs. The 
expression of TNFR2 by CD4+CD25+ cells (grey histogram) and CD4+CD25- cells (solid line 
histogram) was analyzed by FACS, gating on CD3+ cells. Dashed line represents isotype control. (C) 
Splenocytes were stained with anti CD3, CD4, CD25 and TNFR2. Expression of CD25 and TNFR2 
was analyzed with FACS by gating on CD3+CD4+ cells. (D) Splenocytes were stained with anti CD4, 
CD25, TNFR2 and CD45RB, or CD62L, or CD44, or CD69, or CD103, or GITR, or CTLA-4, or 
FoxP3 Abs. CTLA-4 and FoxP3 were stained intracellularly. Expression of phenotypic markers was 
analyzed with FACS by gating on indicated CD4 subsets. (E) Cells from indicated lymphoid tissues 
and peripheral blood were stained with anti CD3 (or CD8 for thymocytes), CD4, CD25 and TNFR2 
Abs. The percentage of TNFR2+ cells was analyzed with FACS by gating on CD3+CD4+CD25+ 
population (except for thymocytes which were gated on CD8-CD4+CD25+ cells). Error bars indicate SE 
derived from 3 mice (n=3). Numbers in the quadrants represent percentage of positive staining cells 
(%).The numbers in the histograms show percentage of positive cells (%) and MFI. Data shown are 
representatives of at least 3 separate experiments with similar results.  
 
Chapter 3. Mouse TNFR2+ Tregs are highly potent suppressors 
 
38 
 
contrast, in mouse peripheral blood, less than 10% of CD4+CD25+ cells were TNFR2+ (Fig 
1E). 
Mouse TNFR2+ Tregs are the most highly suppressive cells 
Upon stimulation with APC and anti-CD3, only CD4+CD25-TNFR2- T cells were readily 
activated to proliferate and produce IFNγ, whereas CD4+CD25+TNFR2+ and 
CD4+CD25+TNFR2- cells were unreactive. Interestingly, TNFR2-expressing CD4+CD25- T 
cells were also non-responsive to TCR stimulation (data not shown). 
Next, we examined the suppressive potential of these CD4 subsets. Flow-sorted CD4 
subsets were co-cultured as shown in Fig 2A. As we expected, CD4+CD25+TNFR2+ T cells 
were potent suppressor cells and inhibited replication of responder CD4+CD25-TNFR2- T 
cells. Surprisingly, CD4+CD25+TNFR2-, comprising the majority of classical Tregs (60-
Figure 2. CD4+CD25+TNFR2+ T cells 
were highly potent suppressor cells. 
Flow-sorted CD4+CD25-TNFR2- or 
CD4+CD25- T cells (5×104 cells/well) 
were labeled with CFSE and cultured 
alone or co-cultured with indicated 
number or ratio of flow-sorted CD4 
subsets from spleen and LNs of normal 
C57BL/6 mice. The percentage of 
CFSE-diluted cells was shown in the 
histograms. (A), (C) and (D) show a 
representative data of at least 3 separate 
experiments with similar results and (B) 
shows summary of percent inhibition of 
replication (%) from 6 separate 
experiments.      
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70% of CD4+CD25+FoxP3+ T cells), had only minimal suppressive activity. Although not 
usually considered to be Tregs, TNFR2-expressing CD4+CD25- T cells had moderate and 
consistently more potent suppressive capacity than CD4+CD25+TNFR2- cells. Due to 
technical difficulty of sorting FoxP3+ cells from normal C57BL/6 mice, we have not 
examined whether FoxP3+ cells present in CD4+CD25-TNFR2+ subset are solely 
responsible for the suppressive activity. We very carefully repeated this experiment and 
obtained highly consistent results (Fig 2B). Furthermore, Balb/c mouse TNFR2+ Tregs also 
had a memory/activated phenotype and were upto10 fold more suppressive than TNFR2- 
Tregs (data not shown).  
TNFR2 is a better phenotypic marker of highly suppressive cells than CD103  
It has been reported that CD103 expression can define the most potent suppressive subset 
of CD4+CD25+ Tregs (5). Since CD4+CD25+TNFR2+ T cells expressed the highest level of 
CD103, it is possible that the expression of CD103 may more accurately predict the 
suppressive potential of CD4 subsets. We confirmed the previous report (5) that 
CD4+CD25+CD103+ T cells were more potent suppressors than CD4+CD25+CD103- T cells 
(data not shown). However, the inhibition of proliferation by CD103+ Tregs was 
significantly less potent than by TNFR2+ Tregs, as shown by both CFSE-dilution assay (Fig 
2C) and [3H] thymidine incorporation assay and also in the inhibition of cytokine 
production (P<0.01~0.05, data not shown). Furthermore, CD4+TNFR2+ T cells exhibited 
more suppressive effects than CD4+CD103+ T cells, and both of these subsets were more 
suppressive than the more heterogeneous CD4+CD25+ T cells (Fig 2D). Consequently, 
TNFR2 is superior to both CD103 and CD25 in defining functional CD4 T suppressor cells.  
Tumor infiltrating Tregs express higher TNFR2 level and are more suppressive    
Tregs accumulate intratumorally and promote tumor growth by inhibiting anti- tumor 
immune response (6). Based on reports that TNFR2 is expressed by TILs isolated from 
several human solid tumors (7), we hypothesized that TNFR2+ Tregs with enhanced 
suppressive potential may be more prevalent in the tumor microenvironment. For this 
purpose, we examined the C57BL/6 mouse Lewis lung carcinoma (LLC) tumor model. As 
predicted, 75~100% of CD4+CD25+ TILs expressed TNFR2. The proportion of TNFR2+ 
cells present in the subset of CD4+CD25- TILs was also increased over the low levels 
present in splenic and LN cells (Fig 3A). Similar results were also observed in the Balb/c 
mouse 4T1 breast tumor model (data not shown).  
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We next tested the prediction that the inhibitory activity of LLC CD4+CD25+ TILs should 
be greater than that of peripheral LN CD4+CD25+ cells. As shown in Fig 3B, there was no 
difference in the suppressive potency of Tregs over various ratios of Teff:Treg from 
peripheral LNs of tumor bearing and control mice. In contrast, TIL CD4+CD25+ cells 
retrieved from LLC tumors exhibited far more potent suppressive activity than LN 
CD4+CD25+ cells from tumor-free mice (Fig 3C). Thus, the suppressive effects of 
peripheral LN Tregs and TIL Tregs correlated well with their level of TNFR2 expression. 
As shown in Fig. 3B-C, the potent inhibitory effect exerted by CD4+CD25+ TILs was not 
Figure 3. Highly suppressive TNFR2+ Tregs accumulated in the TILs of LLC mouse model. (A) 
LN cells, spleen cells (SPL) and TILs from LLC tumor bearing mice were stained with CD4, CD25 and 
TNFR2. Expression of TNFR2 was analyzed with FACS by gating on CD4+CD25+ or CD4+CD25- cells 
from LLC bearing mouse TIL (LLC TIL) or spleen (LLC SPL) or LNs (LLC LN) or from tumor free 
C57BL/6 mouse spleen (Ctrl SPL) or LNs (Ctrl LN). (B-C) CD4+CD25- T cells from normal control 
mouse LNs (5×104 cells/well) were labeled with CFSE and cultured alone or co-cultured with indicated 
source of Tregs at desired ration. The percentage of CFSE-diluted cells was shown in the histograms. 
Data shown are representatives of 3 separate experiments with similar results. 
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antigen specific, since both targeted responder cells and APCs were from tumor-free mice. 
The phenotype of TIL CD4+CD25+ cells, which were 75~100% TNFR2+, resembled that of 
normal mouse LN TNFR2+ Tregs and were indicative of an activated/memory subset (data 
not shown).  
Although other factors in the tumor microenvironment may also contribute to the activation 
of TIL Tregs, the presence of TNF in the inflammatory tumor site is most likely to 
contribute to up-regulating the number of functional Tregs by activating TNFR2 (3). It has 
been reported that TGFβ, a cytokine crucial for de novo generation of Tregs, is also able to 
induce TNF and TNFR2 expression on CD4 cells (8) and may therefore be responsible for 
the increase of TNFR2+ Tregs in the tumor. TNFR2 has also been reported to be a co-
stimulator for antigen-driven T cell responses (1), thus, this receptor can also serve as a co-
stimulator for the response of Treg to tumor antigen. Indeed, it has been shown that anti-
TNF as well as anti-TNFR2 antibodies can inhibit proliferation of TNFR2-expressing TILs 
isolated from human solid tumors (7). Despite reports that anti-TNF therapy increases Treg 
activity in rheumatoid arthritis (9), our preliminary observations also indicate that anti-TNF 
therapy actually decreased the proportion of FoxP3+ Tregs in TILs of various mouse tumor 
models (our unpublished data). Thus blockade of TNF-TNFR2 interaction may result in 
down-regulation of Treg activity and this may provide the mechanistic basis for the 
reported therapeutic efficacy of anti-TNF therapy in cancer (2).   
Several lines of evidence suggest that immunosuppressive action of TNF is mediated by 
TNFR2. For example, in experimental autoimmune encephalomyelitis (EAE) mouse model, 
TNFR1 deficient mice were completely resistant to induction of disease, while TNFR2 
deficient mice exhibited more severe EAE (10). The immunosuppressive action of TNFR2-
dependent effects of TNF is most compatible with our observations that TNF is a potent 
and selective activator of Tregs (3).   
It was reported that CD103 expression defines a potent suppressive subset of Tregs (5) and 
CCR6 expression defines an effector/memory-like subset of Tregs (11). Expression of 
CD103 partially correlated with TNFR2 expression by Tregs (Fig. 1D), however, the 
reported low thymic level of CD103+ Tregs (5) as well as high level in peripheral blood of 
CCR6+ Tregs (11) is distinct from TNFR2+ Tregs in distribution. Furthermore, CD103  
(integrin αEβ7) serves as a homing receptor for mucosa-seeking populations and has no 
clear relationship to the suppressive function of Tregs (5).  In addition, while CD103 is only 
expressed by mouse Tregs, TNFR2 is also expressed by human Tregs (4) and correlates 
with their greater suppressive effects (our unpublished data). CCR6 is expressed by both 
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memory type Tregs as well as T effector cells and serves to direct trafficking of CCR6+ 
cells to inflammatory sites. Although CCR6+ Tregs were described as effector/memory-like 
cells, CCR6+ Tregs and CCR6- Tregs do not show any differences in suppressive activity 
(11). Unlike CD103 and CCR6, TNFR2 is a functional receptor for TNF and therefore is 
likely to respond to TNF by activating and expanding Tregs at inflammatory sites (3). 
Nevertheless, TNFR2 knockout mice have a normal functional CD4+CD25+ Tregs. Thus 
TNFR2 is not necessary to maintain Treg activity, but it may play a crucial role in the 
activation and expansion of Tregs at inflammatory or tumor sites. Presumably this function 
of TNFR2 reflects down-regulatory effect of TNF, but not IL-1 and IL-6, on the 
inflammatory response (3).  
Foxp3 is reported as both a specific marker and commitment factor for the Treg cell lineage 
(6). Both TNFR2+ and TNFR2- CD4+CD25+ T cells from normal C57BL/6 mice expressed 
comparable high level of FoxP3. Nevertheless, the suppressive function of FoxP3+TNFR2- 
cells is not appropriately “turned on” or is intrinsically deficient. Furthermore, CD4+CD25-
TNFR2+ cells were more suppressive than CD4+CD25+TNFR2- cells, even though the 
former contained much less FoxP3+ cells than the latter. Thus, FoxP3 expression by resting 
mouse CD4 cells may not be sufficient to confer suppressive capacity. Our data suggest that 
expression of TNFR2 is more relevant to suppressive phenotype than expression of CD25 
and even FoxP3.  
Apparently, TGFβ and IL-10 did not contribute to the in vitro suppressive activity of 
TNFR2+ Tregs, because neutralizing antibodies against TGFβ and IL-10 failed to attenuate 
activity of TNFR2+ Treg (data not shown). Soluble TNFR2 potentially shed by TNFR2+ 
Tregs is also unlikely to influence Treg activity, since the level of soluble TNFR2 in the 
supernatant of co-cultures containing TNFR2+ Tregs was not increased in our in vitro Treg 
function assay (48 h, data not shown). CTLA4 expression is only detected in the Treg 
compartment of CD4 cells in normal mice and its expression is implicated in the 
suppressive function of Tregs (6).  This suppressive molecule was expressed by >80% of 
TNFR2+ Tregs, which is in agreement with the potent suppressive capacity of this subset of 
Tregs. Intriguingly, the superior suppressive activity of CD4+CD25-TNFR2+ cells over 
CD4+CD25+TNFR2- cells correlate directly with the intensity of CTLA4 expression by 
these two subsets (Fig 1D). TNFR2 just like CTLA4 is selectively expressed by functional 
Tregs rather than Teffs, even in the absence of CD25 and FoxP3.  
Taking together, our data demonstrate that TNFR2 expression defines a unique subset of 
mouse Tregs with an activated/memory phenotype and highly potent suppressive activity. 
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In mouse tumor models, the proportion of tumor infiltrating suppressive TNFR2+ Tregs was 
dramatically increased, suggesting therapeutic value by targeting TNFR2+ Tregs in tumor 
immunotherapy.  
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Summary 
Previously we found that co-expression of CD25 and TNFR2 identified the most 
suppressive subset of mouse regulatory T cells (Tregs). Here, we report that human 
peripheral blood (PB) FoxP3+ cells present in CD25high, CD25low and even CD25- subsets of 
CD4 cells expressed high levels of TNFR2. Consequently, TNFR2-expressing CD4+CD25+ 
Tregs included all of FoxP3+ cells present in CD4+CD25high subset as well as a substantial 
proportion of FoxP3+ cells present in CD4+CD25low subset. CD4+CD25+TNFR2+ cells 
identified 5-fold greater number of PB CD4 lymphocytes as Tregs than identified by 
CD4+CD25high cells, and expressed comparable levels of FoxP3+ cells as reported 
CD4+CD25+CD127low/- Tregs. Furthermore, this population of cells exhibited the 
characteristic Treg phenotype, including expression of high levels of CTLA-4, CD45RO, 
CCR4 and low levels of CD45RA and CD127. Upon TCR stimulation, human PB 
CD4+CD25+TNFR2+ cells were anergic and markedly inhibited the proliferation and 
cytokine production of co-cultured T responder cells. In contrast, CD4+CD25+TNFR2- and 
CD4+CD25-TNFR2+ T cells did not show inhibitory activity. Since some non-Tregs express 
TNFR2, the combination of CD25 and TNFR2 must be used to identify larger population of 
human Tregs, which may prove to be of diagnostic and therapeutic benefit in cancer and 
autoimmune diseases.  
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Introduction 
Identification of CD25-expressing CD4 cells in Balb/c mice as regulatory T cells (Tregs) 
has greatly advanced our understanding of the basic processes that control immune 
tolerance (1). These suppressor cells, comprising 5-10% of mouse peripheral CD4+ T cells 
and expressing the X chromosome-encoded forkhead transcription factor, FoxP3, play an 
important role in preventing immunopathology by suppressing immune responses to 
autoantigens, however, they also attenuate natural immune responses against tumor 
antigens (2, 3). Tregs are a good target for therapeutic manipulation to induce or abrogate 
immunological tolerance to self and non-self antigens (4, 5). 
The quantitative identification and enrichment of viable Treg cells requires reliable surface 
markers that are selectively expressed on Tregs. Utilization of CD25 to define human Treg 
is problematic since this IL-2 receptor α chain does not discriminate regulatory from 
antigen-responsive activated effector T cells (Teffs). Only ~1% of normal human 
circulating CD4 cells that express the highest levels of CD25, termed CD25high, reliably 
exhibit suppressive activity (6, 7) and have high levels of FoxP3 expression (8, 9). 
Although the identification of CD25high as a marker for human Tregs by Baecher-
Allan/Hafler and colleagues has greatly advanced in the purification of viable human Tregs 
(6, 7),  it is difficult to accurately quantitate Treg cells based on CD25high and this criterion 
may underestimate Treg levels. In addition, the low frequency of CD25high makes it difficult 
to isolate sufficient number of Tregs for either in vitro study or for in vivo cellular therapy. 
Unfortunately, FoxP3 and CTLA-4 expressed by Tregs become detectable only when cells 
are fixed and permeabilized, and thus can not be used as a biomarker to isolate viable cells. 
Other reported markers of human Tregs, although helpful in the further characterizing 
Tregs, also have their limitations when they are used to define human Tregs. For example, 
HLA-DR expressing Tregs represent an even lower percentage (often <1%) of CD4+ T cells 
(10). CD27 has been proposed as a surface marker of human Tregs (11), however, the vast 
majority of PB antigen-activated CD25+ effector T cells (Teffs) also express high levels of 
CD27 (12). Recently, major progress in the identification of biomarker of Tregs has been 
made by Liu/Bluestone and Seddiki/Fazekas de St Groth and their colleagues who reported 
that human Tregs expressed low levels of CD127, the IL-7 receptor α chain, and that the 
absence of this molecule therefore can be used with CD25 to define human Tregs (9, 13). 
Nevertheless, an additional surface marker which positively correlates with FoxP3 
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expression and immunosuppressive function may improve the identification and isolation 
of human Tregs.   
It has been shown that human thymic CD4+CD25+ Tregs constitutively express TNFR2, 
while thymic CD4+CD25- cells do not express this receptor (14). We found that the 
majority (~80%) of mouse thymic Tregs (CD8-CD4+CD25+) are also TNFR2-expressing 
cells (15). Normally 30~40% of CD4+CD25+ cells comprised greater than  90% FoxP3+ 
cells in peripheral lymphoid tissues of unstimulated Balb/c mice and C57BL/6 (B6) mice 
expressed TNFR2, while only <10% of CD4+CD25- Teffs were TNFR2+ cells and up to 
40% of them expressed FoxP3  (15, 16). Thus, TNFR2 is predominantly expressed on 
mouse as well as on human Tregs (14, 16). Furthermore, TNFR2 expression identified the 
most potent suppressive subset of mouse CD4+CD25+ Tregs, while CD4+CD25+TNFR2- T 
cells in normal C57BL/6 mice have only minimal or no suppressive activity (15). The 
findings concerning mouse Tregs could often be extrapolated to human. For example, 
CD25 as a mouse CD4 Treg marker led to the discovery that CD25high could define human 
CD4 Tregs (6). Recently, it was reported that human CD8+CXCR3+ cells were actually the 
counterpart of mouse CD8+CD122+CXCR3+ Tregs (17). We therefore hypothesized that the 
expression of TNFR2 might help identify functional human suppressor cells. In this report, 
we show that human PB CD4+CD25+TNFR2+ T cells also consistently exhibited the 
phenotypic and functional attributes of Tregs.  
Materials and Methods  
Cells and reagents. Human peripheral blood enriched in mononuclear cells was obtained 
from normal donors by leukapheresis (Transfusion Medicine Department, Clinical Center, 
National Institutes of Health, Bethesda, MD, with an approved human subjects agreement). 
The blood was centrifuged through Ficoll-Hypaque (Sigma), and PBMCs collected at the 
interface were washed with PBS and centrifuged through isoosmotic Percoll (Pharmacia, 
Uppsala, Sweden) gradient. CD4-FITC/-APC, CD25-PE/-PE-Cy5/-APC, CD152 (CTLA-
4)-APC, CD45RO-PE-Cy5, CCR4-biotin, CD120b (TNFR2)-biotin, purified CD3 and 
various fluorochrome conjugated streptavidin were from BD Pharmingen (San Diego, CA). 
CD45RA-PerCP Cy5.5, CD127-PerCP Cy5.5, HLA DR-PerCP Cy5.5 and FoxP3-APC 
staining set were from eBioscience (San Diego, CA). CD120b (TNFR2, MR2-1)-PE was 
from Serotec (Raleigh, NC). CCR7-PE was from R&D systems, Inc. (Minneapolis, MN).  
Cell purification, in vitro cell culture and proliferation assay. CD4+ cells were purified 
from freshly isolated human PBMCs with human CD4 microbeads and LS column 
Chapter 4. CD25 and TNFR2 define human Tregs 
49 
 
(Miltenyi Biotec Inc., Auburn, CA). CD4+CD25+TNFR2+, CD4+CD25+TNFR2-, 
CD4+CD25-TNFR2+ and CD4+CD2-TNFR2- cells were purified from CD4+ cells using 
Cytomation MoFlo cytometer (Fort Collins, CO), yielding a purity of ~98% for all subsets. 
Autologous PBMCs were used as APCs by depletion of CD4+
 
cells with anti-human CD4 
microbeads (Miltenyi Biotec Inc.). APCs were irradiated with 4,000 R.  
For in vitro assays of inhibition of proliferation by Treg, CD4+CD2-TNFR2-  cells 
(2.5~5×104 
 
cells/well) were seeded in a U-bottom 96-well plate in medium [RPMI 1640 
with 10% fetal bovine serum (FBS, Hyclone, Logan, UT) containing 2 mM glutamine, 100 
IU/ml penicillin, and 100 μg/ml streptomycin, 10 mM HEPES]. They were co-cultured with 
2×105 /well of APCs and 0.5 μg/ml of soluble anti human CD3 Ab. CD4+ subsets were 
added to the wells at a desired ratio to CD4+CD25-TNFR2- cells. Cells were pulsed with 1 
µCi [3H]thymidine (Amersham Pharmacia Biotech, Piscataway, NJ) per well for the last 6 h 
of a three day culture period. For CFSE dilution assay, CFSE-labelled (2 μM, 8 min at 
room temperature) responder cells (MACS-purified autologous CD4 cells, 5×104 
 
cells/well) 
were seeded in a U-bottom 96-well plate together with 2×105 cells/well of APCs and 
0.5 μg/ml of anti-CD3 antibody. FACS-purified CD4+CD25+TNFR2+ cells or other CD4 
subsets were added to the wells at the desired ratio. After 48~72 h, CFSE dilution was 
determined with FACS. In some experiments, IFNγ levels in the supernatants of cultures 
were determined by SearchLight Human Cytokine Array (Pierce Biotechnology, Woburn, 
MA). 
Flow Cytometry. After blocking FcR, cells were incubated with appropriately diluted 
antibodies. Data were acquired on a FACSort (BD Biosciences, Mountain View, CA) and 
analysis was conducted using CellQuest software (BD Biosciences).  
Statistical analysis. Comparisons of two groups of data were analyzed by two-tailed 
Student’s t test using Graphpad Prism 4.0. 
Results  
Relationship between expression of TNFR2 and FoxP3 on human PB CD4 cells 
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It was recently reported that TNFR2 expression was highest on human peripheral blood (PB) 
CD4+CD25high T cells, but could also be detected on CD4+CD25int and on a minor fraction 
of CD4+CD25– T cells (18). We confirmed this observation and further examined the 
relationship between TNFR2 and FoxP3 expression in human PB CD4 subsets with 
different CD25 expression levels, since to date, FoxP3 remains the most specific marker of 
the Treg lineage (3).  Normal human peripheral lymphocytes contained ~40% of CD4 cells  
and ~12% of CD25+ cells (data not shown). About 1% of the brightest CD25-expressing 
CD4 cells were defined as CD25high (or CD25hi) cells (6). For convenience sake, all CD25+ 
cells except for the CD25high were defined as CD25low (or CD25lo) cells. Consistent with the 
report that human PB CD4 cells with high levels of CD25 have repeatedly been shown to 
be functional Tregs (6), most of the CD25high cells were FoxP3+ and almost all of them 
Figure 1. Human PB FoxP3+ Tregs express high levels of TNFR2. Freshly isolated human PBMCs were 
stained for CD4, CD25 and TNFR2 and then were fixed and stained intracellularly for FoxP3. CD4 cells 
were analyzed by FACS, gating on lymphocytes via their forward and side scatter properties and CD4 
staining. (A) FoxP3 and TNFR2 expression by CD25hi, CD25lo and CD25- subsets of CD4 cells. (B) 
Percentage of  TNFR2-expressing cells in CD4 subsets. (C) FoxP3 and TNFR2 expression by total CD4 
cells, CD4+CD25hi cells, CD4+CD25lo cells and CD4+CD25- cells. Date shown in (A) and (C) are 
representative of at least three separate experiments on different donors with similar results. Data shown in 
(B) are summarized from three different donors (mean ± SEM, N=3). The numbers in the quadrants 
indicate the percentage of positive cells. The numbers in histograms are mean fluorescence intensity (MFI) 
and percentage of positive cells (%). Dashed line histogram shows isotype control. Comparison of TNFR2 
expression on CD25loFoxP3+ and CD25loFoxP3- or CD25-FoxP3- and CD25-FoxP3+ cells: ** P<0.01.  
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(97.4~100%) expressed the highest levels of TNFR2 (Fig 1A). We have found that 
although usually not considered to be Tregs, human PB CD4+CD25low cells still consisted 
of about 40% of FoxP3+ cells. From 83.3~89.6% of FoxP3+ cells in this CD25low subset 
were TNFR2+ cells while, in contrast, only 36.1~48.4% of FoxP3- presumably effector T 
cells (Teffs) in this population expressed TNFR2. Furthermore, a small but detectable 
3~5% of CD25- cells also expressed FoxP3. 67~83.3% of CD25-FoxP3+ cells did express 
TNFR2, while only 16.0~17.9% of CD25-FoxP3- cells expressed low levels of TNFR2 per 
cell (Fig 1A). The high levels of TNFR2 expression on FoxP3+ cell, regardless CD25 
expression, were consistently observed in this study. The percentage of TNFR2+ cells 
present in CD25lowFoxP3+ and CD25-FoxP3+ subsets was also markedly higher than in the 
CD25lowFoxP3- and CD25-FoxP3- subsets, respectively (P<0.01, Fig 1B). Thus TNFR2 and 
FoxP3 expression in CD4 subsets were directly correlated (Fig 1C). Approximately 85% of 
PB CD4+FoxP3+ cells expressed high levels of TNFR2, in contrast, only ~20% of FoxP3- 
cells expressed low levels of TNFR2. Therefore, both the proportion of cells and the level 
of expression (MFI) of TNFR2 are highly correlated with FoxP3 expression in human PB 
CD4 cells.  
Relationship of combination of CD25 and TNFR2 expression in PB CD4 cells to FoxP3 
expression 
In normal healthy donors, CD25+TNFR2+ cells represented 5~12% of freshly isolated PB 
CD4 population (Fig 2A), which is substantially higher than the previously reported 1~2% 
CD25high Tregs (6) or <1% HLA-DR+ Tregs (10), or 5.8% CD25+CD127lo/- Tregs (9). The 
proportion of human circulating CD4+CD25+TNFR2+ cells is comparable to the reported 
5~10% of CD4+CD25+ Tregs present in mouse peripheral lymphoid tissues (16, 19, 20). All 
human CD25hi cells were TNFR2+ and therefore were included in the CD25+TNFR2+ 
subpopulation of CD4 cells (Fig 2A).  
Since both CD4+CD25high cells and CD25lowFoxP3+ cells expressed high levels of TNFR2, 
we hypothesized that co-expression of TNFR2 and CD25 might identify more FoxP3+ 
Tregs. As shown in Figure 2B~C, analysis of multiple donors revealed that greater than 
85.3% on average (range: 72.8~94.1%) of CD4+CD25+TNFR2+ cells expressed FoxP3. 
This is comparable to FoxP3 profile reported for human PB CD4+CD25high cells 
(79.4~95.5%) (8) and CD4+CD25+CD127low/- Tregs (67.4~93.6%) (9). Consequently, the 
CD4+CD25high/lowTNFR2+ subset included a greater number of cells with FoxP3-expressing 
Treg phenotype than CD4+CD25high cells. In contrast, CD4+CD25+TNFR2- cells, uniformly 
expressed low levels of CD25, only comprised 33.1% on average of FoxP3+ cells (range:  
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20.0~54.8%), which was markedly lower than the 85.3% FoxP3-expressing cells present  
the CD25+TNFR2+ cells (P<0.001). Furthermore, only 18.1% on average of CD25-TNFR2+ 
cells were FoxP3+ (range: 15.1~22.1%), while ~1% of CD25-TNFR2- cells expressed 
FoxP3 (P<0.001). The intensity of FoxP3 expression on a per cell basis by CD25+TNFR2+ 
cells was also higher, than CD25+TNFR2- cells and by CD25-TNFR2+ cells (data not 
shown). Therefore, co-expression of CD25 and TNFR2 is able to identify CD4 Tregs 
expressing high levels of FoxP3+.  
Phenotype of human PB CD4+CD25+TNFR2+ cells  
Surface expression of antigens by Tregs allows characterization of their phenotype and may 
also provide insight into their mechanism of action. Mouse CD4+CD25+TNFR2+ T cells 
represent a subset of Tregs that have a memory/activated phenotype (15). We therefore 
investigated whether human PB CD4+CD25+TNFR2+ T cells had similar phenotypic 
characteristics as their mouse counterparts. This was determined by comparing the HLA-
DR, CTLA-4, FoxP3, CD45RO, CD45RA, CCR4 and CCR7 levels of the various 
subpopulations. As shown in Figure 3, CD4+CD25+TNFR2+ cells expressed the highest 
Figure 2. FoxP3 expression by human PB 
CD4+CD25+TNFR2+ cells. Freshly isolated human PBMCs 
were stained for CD4, CD25 and TNFR2. The cells then 
were fixed and stained intracellularly for FoxP3. For FACS 
analysis, the PBMCs were gated on CD4+ lymphocytes 
based on forward and side light scatter and CD4 staining. 
(A) Expression of CD25 and TNFR2 on PB CD4 cells. 
Data from three different donors are shown. The numbers 
in the quadrants indicate the percentage of positive cells. 
(B) Expression of FoxP3 by CD4+CD25hi cells (upper 
panel) and CD4+CD25+TNFR2+ cells (lower panel). Data 
shown are representatives of at least three separate 
experiments on different donors with similar results. The 
numbers in the dot plots are the number of gated cells. The 
numbers in histograms are the percentage of positive cells 
(%). (C) Expression of FoxP3 by different subsets of PB 
CD4 cells. The data shown are summarized from eight 
different donors (mean ± SEM, N=8). Comparison of 
percentage of FoxP3+ cells in CD25+TNFR2+ subset and 
CD25+TNFR2- subset or CD25-TNFR2+ subset and CD25-
TNFR2- subset: ** P<0.001.  
 
Chapter 4. CD25 and TNFR2 define human Tregs 
53 
 
level of CD45RO (70.08%), a marker that is associated with proliferative responses to 
recall antigens, but the lowest level of CD45RA (4.85%), a marker of naïve CD4 cells, 
similar to the low level expression of CD45RB by mouse TNFR2+ Tregs (15), indicative of 
a memory/activated phenotype. CTLA-4 is expressed predominantly by the Treg 
compartment of resting mouse CD4 cells and is critical for Treg function (21, 22). Human 
CD4+CD25+TNFR2+ cells expressed markedly higher intracellular levels of CTLA-4 
(80.24%) than CD4+CD25+TNFR2- cells (38.45%), CD4+CD25-TNFR2+ cells (42.94%) or 
CD4+CD25-TNFR2- cells (9.01%). It has been shown that a CCL22-CCR4 signal was 
responsible for the trafficking of Tregs to human ovarian tumor (23). Of the CD4+ subsets, 
CD4+CD25+TNFR2+ cells expressed the highest level of CCR4 (60.06%), while other 
subsets only contained 12.49~28.39% of CCR4+ cells. In contrast, human 
CD4+CD25+TNFR2+ cells expressed a relatively low level of CCR7 (43.27%), a chemokine 
receptor responsible for directing traffic of naïve CD4 cells to the lymph nodes, as 
compared with 60~84% CCR7+ cells in the other 3 subsets. As expected, 
CD4+CD25+TNFR2+ cells were low in expression of CD127(9, 13), indicative of an inverse 
correlation of TNFR2 and CD127 as markers of Tregs. MHC-DR+ Tregs (10) were largely 
Figure 3.  Phenotype of human PB CD4 subsets. Freshly isolated human PBMCs were stained for CD4, 
CD25, TNFR2 and additional phenotypic markers. Intracellular expression of CTLA-4 and surface 
expression of CD45RO, CD45RA, CCR4, CCR7, CD127 and HLA-DR by different subsets of PB CD4 
cells, gating on indicated populations were analyzed by FACS. Black filled histogram: antibody staining; 
grey histogram: isotype control. Numbers in the figures indicate the percentage of gated cells expressing 
relevant marker. Data shown are representative of at least three separate experiments on different donors 
with similar results.   
 
Chapter 4. CD25 and TNFR2 define human Tregs 
 
54 
 
confined to the CD4+CD25+TNFR2+ subset of cells. Thus, in addition to their high level of 
FoxP3 expression, human CD4+CD25+TNFR2+ cells exhibited the phenotypic 
characteristics of functional Tregs.  
Human PB CD4+CD25+TNFR2+ cells are hyporesponsive to TCR stimulation and suppress 
responder T cells 
The in vitro functional hallmarks of Tregs are that they are anergic to TCR stimulation and 
markedly suppress activation of co-cultured responder T cells. We therefore compared the 
response to TCR stimulation of CD4+CD25+TNFR2+ and CD4+CD25-TNFR2- cells. TCR 
stimulation of CD4+CD25-TNFR2- Teffs resulted in robust proliferation and INFγ 
production. In contrast, CD4+CD25+TNFR2+ cells were hyporesponsive, both in term of 
proliferation (Fig 4A) and INFγ production (Fig 4B), to TCR stimulation. Both 
CD4+CD25+TNFR2- cells and CD4+CD25-TNFR2+ cells were more responsive than 
CD4+CD25+TNFR2+ cells, but less responsive than CD4+CD25-TNFR2- cells, to TCR 
stimulation (data not shown).  
Next, we examined the ability of CD4+CD25+TNFR2+ T cells to suppress the proliferation 
of co-cultured responder Teffs. As shown in Figure 5A, CD4+CD25+TNFR2+ T cells 
potently inhibited proliferation of co-cultured Teffs (Fig 5A) in a cell number dependent 
manner (Fig 5B), while CD4+CD25+TNFR2- and CD4+CD25-TNFR2+ cells usually did not 
show inhibitory activity. Since CD4+CD25+TNFR2- and CD4+CD25-TNFR2+ cells were not 
anergic and proliferated in response to TCR stimulation (data not shown), the [3H] 
thymidine incorporation assay might not have revealed their suppressive potential. We 
therefore performed CFSE dilution assay in which MACS-purified autologous CD4 cells  
Figure 4. Comparison of functional capacities of 
human PB CD4 T cell subsets. 
CD4+CD25+TNFR2+ and CD4+CD25-TNFR2- T 
cells were FACS-sorted from freshly isolated 
PBMCs. 2.5×104 cells/well of different CD4 
subsets were cultured alone. The cells were 
stimulated with APCs and anti CD3 Ab for 72 h. 
Proliferation was determined by [3H] thymidine 
incorporation assay (A). IFNγ level in the 
supernatants were determined (B). Data shown are 
two separate experiments on different donors.      
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Figure 5. Suppressive activities of human PB CD4 T cell subsets. CD4+CD25+TNFR2+, CD4+CD25+TNFR2-, 
CD4+CD25-TNFR2+ and CD4+CD25-TNFR2- T cells were FACS-sorted from freshly isolated PBMCs. In some 
experiment MACS-purified CD4 cells were used as responder cells. (A) 2.5×104 cells/well of CD4+CD25-TNFR2- 
cells, used as responder cells, were cultured alone or co-cultured with indicated CD4 subsets at ratio of 1:1. 
Background proliferation (APC alone, cpm: 1888.7) was subtracted. (B) 2.5×104 cells/well of CD4+CD25-TNFR2- 
cells were cultured alone or co-cultured with CD4+CD25+TNFR2+ cells at indicated ratios. Proliferation was 
determined by [3H] thymidine incorporation assay. (C) 5×104 cells/well of CD4 cells were labeled with CFSE, 
cultured alone or co-cultured with indicated CD4 subsets at 1:1 ratio. (D) 5×104 cells/well of MACS-purified CD4 
cells were labeled with CFSE, cultured alone or co-cultured with indicated ratio with FACS-purified 
CD4+CD25+TNFR2+ cells. After 72 h incubation, dilution of CFSE by responder CD4 cells was determined by 
FACS. The cultured cells were stimulated with APCs and anti CD3 Ab. (A~D) Representative data from 3 separate 
experiments on different donors with similar results were shown. (E) Percent inhibition of proliferation of 
CD4+CD25-TNFR2- T cells by CD4+CD25+TNFR2- cells and CD4+CD25+TNFR2+ cells [(CPM (responder cells 
alone)-CPM (responder cells co-cultured with Treg cells))/CPM (responder cells alone)×100%]. Data shown were 
summarized from three separate experiments on different donors. (F) MACS-purified CD4 cells and FACS-purified 
CD4+CD25+TNFR2+ cells were cultured alone or co-cultured at ratio of 1:1. The cells were stimulated with APCs and 
anti CD3 Ab for 72 h. IFNγ level in the supernatants were determined. Data shown are representative of three 
separate experiments on different donors with similar results. Data in (E-F) are presented as Mean and SEM.  
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were labeled with CFSE and co-cultured with FACS-purified CD4 subsets. 
CD4+CD25+TNFR2+ T cells consistently markedly suppressed the replication of responder 
CD4 cells (Fig 5C) in a dose-dependent manner (Fig 5D). In contrast, the other three CD4 
subsets, including CD4+CD25+TNFR2- and CD4+CD25-TNFR2+ cells, did not show 
inhibitory activity. The anti-proliferative activity of CD4+CD25+TNFR2+ cells was 
consistently seen with multiple donors (Fig 5E). Furthermore, CD4+CD25+TNFR2+ T cells 
almost completely inhibited cytokine (INFγ) production by co-cultured Teffs (Fig 5F). 
Thus, co-expression of CD25 and TNFR2 on CD4 cells was able to identify functional 
suppressive human PB CD4 Tregs which were also anergic.     
Discussion 
Here we report that the phenotypic and functional characteristics of human 
CD4+CD25+TNFR2+ Tregs present in normal donor peripheral blood closely resemble 
mouse CD4+CD25+TNFR2+ Tregs. Virtually all human CD4+CD25highFoxP3+ cells plus a 
substantial proportion of CD4+CD25lowFoxP3+ cells expressed TNFR2. Thus, the 
population of CD4+CD25high/lowTNFR2+ cells include 5-fold or more FoxP3+ Tregs as 
compared with the number of Tregs identified by CD25high. More than 90% of human PB 
CD4+CD25+TNFR2+ cells were FoxP3+, which is comparable to the FoxP3 profile of 
mouse CD4+CD25+ Tregs (~90%) (16, 19) and FoxP3 profile of reported human 
CD4+CD25+CD127low/- Tregs (86.6%) (9).  
These PB CD4+CD25+TNFR2+ cells co-expressed high levels of FoxP3 and also functioned 
as Tregs. As revealed in a standard in vitro Treg function assay, CD4+CD25+TNFR2+ cells 
at a 1:1 ratio to CD4+CD25-TNFR2- cells reproducibly reduced proliferation by the co-
cultured Teffs by greater than 60%. It was previously reported that human PB 
CD4+CD25high Tregs reduced [3H] thymidine incorporation of co-cultured CD4+CD25- 
responder cells by 69% at day 5 and >98% by day 7 (6). Thus, the average inhibition of > 
60% of CD4+CD25+TNFR2+ cells on day 3 in our study is comparable to the level of 
inhibition exerted by CD4+CD25high at day 5. We evaluated the suppressive effect on highly 
proliferative CD4+CD25-TNFR2- cells were used as responder cells. Other investigators 
have reported more profound suppression because they used less proliferative CD4 cells or 
CD4+CD25- cells which still contained CD4+CD25-TNFR2+FoxP3+ cells as responder cells. 
Production of cytokines by Teffs is usually more susceptible to inhibition by Tregs than 
their proliferation. Indeed, at a 1:1 ratio of CD4+CD25+TNFR2+ cells to CD4 responder 
cells, the production of INFγ by responder cells was almost completely inhibited. 
Consequently, the subset of human PB CD4+CD25+TNFR2+ cells is profoundly suppressive.   
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It was recently reported that both human and mouse Tregs were able to shed large amounts 
of soluble TNFR2 (sTNFR2) upon stimulation with IL-2 and plate-bound anti-CD3,  and 
consequently, the resultant sTNFR2 was proposed to provide a means by which Tregs 
inhibited the activation of Teffs (18).  However, we did not detect an elevated level of 
soluble TNFR2 in the supernatant in our in vitro culture of human CD4+TNFR2+ cells 
stimulated with APCs and soluble anti CD3 for 72 hrs (data not shown), conditions 
commonly used to exhibit inhibitory activity of Tregs in vitro (24). Furthermore, FACS-
purified mouse and human CD4+CD25+TNFR2+ cells did not release TNFR2 into the 
supernatants under same conditions (data not shown). Although CD4+CD25+TNFR2+ cells 
had potent suppressive capacity, another CD4 subset which also expressed TNFR2, e.g. 
CD4+CD25-TNFR2+ cells, did not have any suppressive activity, mitigating against an 
inhibitory role for sTNFR2. Although we have not ruled out a role for sTNFR2 as a basis 
for suppressive effects of Tregs in vivo, shedding of sTNFR2 can not explain the potent 
suppression mediated by CD4+CD25+TNFR2+ cells in the in vitro Treg functional assay.   
Human PB CD4+CD25+TNFR2+ cells, akin to their mouse counterpart, expressed strikingly 
high levels of CTLA-4 (Fig 3), as compared with the other CD4 subsets. CTLA-4 has been 
recently found to play a key role in the Treg suppressive effect in mice (22, 25). Whether 
CTLA-4 accounts for the suppressive activity of human PB CD4+CD25+TNFR2+ Tregs will 
be addressed in a future study.  
TNFR2 is one of two receptors for TNF,  a pleiotropic cytokine which is a major participant 
in the initiation and orchestration of inflammation and immunity (26). Unlike TNFR1 
which can mediate cytotoxic effect through its death domain, TNFR2 does not have a death 
domain and is largely confined to lymphoid cells (26). Several lines of evidence indicate 
that TNFR2 acts as a co-stimulator for antigen-driven T cell responses (26-29). The 
preferential expression of TNFR2 on mouse and human Tregs suggest that this receptor 
may mediate the activating effect of TNF on Tregs (16). Similar to our observation that 
TNF plus IL-2 selectively promotes the proliferation of mouse FoxP3+ Tregs (16), human 
FoxP3+ cells present in the CD4 population were also expanded in response to TNF 
stimulation in conjunction with IL-2 (data not shown), suggestive of a functional role of 
TNFR2 in the expansion of human Tregs. Presumably, high levels of TNFR2 expression by 
human Tregs may mediate a quick response to inflammation followed by a negative 
feedback attenuation of inflammatory responses that serves to prevent collateral self-tissue 
damage. Thus, IL-2 is essential for the homeostatic survival and proliferation of Tregs, 
whereas TNF results in a proliferative expansion of Tregs in an inflammatory environment 
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(15, 16). A recent report showing that expansion of TNFR2+ Tregs with enhanced 
suppressive activity occurs in malaria patients may reflect this scenario (30).  
One of the difficulties in studies of human Tregs is to identify active Tregs present in the 
subset of CD25int/low/- CD4 cells with suppressive biological function. For example, it was 
recently reported that CD45RA+FoxP3+ “naive Tregs”, which have the capacity to be 
expanded in vitro into homogenous functional Tregs (31), were CD25int cells (32). Our data 
showed that FoxP3-expressing cells, including those present in CD25- population, 
expressed high levels of TNFR2 (Fig 1). To date, it is impossible to study the function of 
CD25-FoxP3+ cells, since their specific surface markers for viable isolation are not clear.  
How to exploit TNFR2 expression to identify these CD25-FoxP3+ cells therefore merit 
more study.  
Taken together, our data demonstrate that the combination of CD4, CD25 and TNFR2 
identifies a larger population of functional Tregs in the circulation of normal humans. This 
population of T cells was practically identical to mouse CD4+ Tregs, in manifesting high 
level expression of FoxP3 and CTLA-4, hypo-responsiveness to TCR cross-linking and 
potent inhibition of activation of co-cultured T responder cells. Identification of human 
Tregs with CD4, CD25 and TNFR2 provides over 5-fold better detection and viable 
enrichment of human Tregs than commonly used CD25high method for in vitro studies and 
potentially for in vivo therapy. 
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Abstract 
TNF is a pleiotropic cytokine with intriguing biphasic pro-inflammatory and anti-
inflammatory effects. Our previous studies demonstrated that TNF up-regulated FoxP3 
expression and activated and expanded CD4+FoxP3+ regulatory T cells (Tregs) by utilizing 
TNFR2. Further, TNFR2-expressing Tregs exhibited maximal suppressive activity. In this 
study, we show that TNF, in concert with IL-2, preferentially up-regulated mRNA and 
surface expression of TNFR2, 4-1BB and OX40 on Tregs. Agonistic antibodies against 4-
1BB and OX40 also induced the proliferation of suppressive Tregs. Thus, TNF amplifies its 
stimulatory effect on Tregs by inducing TNF receptor superfamily (TNFRSF) members. In 
addition, administration of neutralizing anti-TNF Ab blocked LPS-induced expansion of 
splenic Tregs and up-regulation of TNFR2, OX40 and 4-1BB receptors on Tregs in vivo, 
indicating that the expansion of Tregs expressing these co-stimulatory TNFRSF members 
in response to LPS is mediated by TNF. Taken together, our novel data indicate that TNF 
preferentially up-regulates TNFR2 on Tregs, and this is amplified by the stimulation of 4-
1BB and OX40, resulting in the optimal activation of Tregs and augmented attenuation of 
excessive inflammatory responses.         
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Introduction 
CD4+FoxP3+ regulatory T cells (Tregs) comprise only a minor fraction (~10%) of 
peripheral CD4 cells, but play a critical role in the establishment and maintenance of 
immunological tolerance to self antigens as well as to foreign antigens (1, 2). Certain 
cytokine receptors preferentially expressed by Tregs not only serve as surface markers for 
the identification of Tregs, but also promote the function of Tregs. CD25, the α chain of IL-
2 receptor, is the prototype of such cytokine receptors (1, 2). Our previous studies indicate 
that TNFR2 is an important cytokine receptor preferentially expressed by the highly 
suppressive human and mouse Tregs (3-5). 
TNFR2 is one of two receptors transducing the biological function of TNF,  a pleiotropic 
cytokine which is a major participant in the initiation and orchestration of inflammation and 
immunity (6). TNFR2 expression is restricted to certain T cell subpopulations (6), and acts 
as a co-stimulator for antigen-driven T cell responses (7). We have found that TNF 
surprisingly was an activator of Tregs, resulting in their proliferative expansion, up-
regulation of FoxP3 expression and increase of suppressive activity (3). This data, albeit 
counterintuitive, is supported by the emerging evidence that TNF-TNFR2 interaction plays 
a critical role in the generation, expansion and function of human and mouse Tregs (8-12).  
TNFR2 is constitutively expressed by human and mouse thymic Tregs (5, 13). Normal 
human circulating Tregs expressed markedly higher levels of TNFR2 than CD4+FoxP3- 
effector T cells (Teffs) (4, 14, 15). Normally 30~40% of Tregs present in the peripheral 
lymphoid tissues of unstimulated Balb/c mice and C57BL/6 (B6) mice expressed a high 
level of TNFR2, while less than 10% of Teffs expressed a lower level of TNFR2 (3, 16). 
Furthermore, TNFR2-expresssing Tregs exhibited the most potent suppressive activity, 
while TNFR2- Tregs even though CD25+ and FoxP3+ in normal C57BL/6 mice had only 
minimal or no suppressive activity (5, 16). Intratumoral Tregs are maximally 
immunosuppressive, since the majority of tumor infiltrating Tregs were highly suppressive 
TNFR2+ cells (5, 16), and depletion of TNFR2+ Tregs was associated with tumor 
eradication after cyclophosphamide treatment (17). When transferred to LPS-challenged 
recipient mice, Tregs from wild-type mice were able to inhibit inflammatory responses, 
while Tregs from TNFR2-deficient mice failed to do so (14). In normal human peripheral 
blood (PB), TNFR2-expressing CD4+CD25+ cells comprised a high level of FoxP3+ cells 
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and were functionally suppressive (4). In malaria patients, proliferating TNFR2+ Tregs 
exhibited an enhanced suppressive activity (18). These studies clearly demonstrate that 
TNFR2 not only serves as a marker, but also promotes Treg function.  
We have investigated the effect of TNF on TNFR2 expression on Tregs. Since TNFR2 is a 
member of TNF receptor superfamily (TNFRSF) and other co-stimulatory TNFRSF 
members, such as 4-1BB (19) and OX40 (20) also have been reported to participate in Treg 
activity, we also investigated their response to TNF. We found that TNF preferentially up-
regulates these TNFRSF on Tregs, which contribute to the optimal activation of Tregs and 
result in attenuation of excessive inflammatory responses.         
Materials and Method 
Mice and reagents. Female wild type (wt) C57BL/6 mice were provided by the Animal 
Production Area of the National Cancer Institute (Frederick, MD). NCI-Frederick is 
accredited by American Association for the Accreditation of Laboratory Animal Care 
International and follows the Public Health Service Policy for the Care and Use of 
Laboratory Animals. Animal care was provided in accordance with the Procedures outlined 
in the “Guide for Care and Use of Laboratory Animals” published by the National Research 
Council (National Research Council, National Academy of Sciences. (1996) Guide for Care 
and Use of Laboratory Animals. National Academy Press, Washington D.C. FoxP3/gfp KI 
mice were kindly provided by Dr. Yasmine Belkaid at Laboratory of Parasitic Diseases, 
NIAID, NIH, and maintained in the Animal Production Area of the NCI-Frederick. 
Antibodies purchased from BD Pharmingen (San Diego, CA) consisted of PerCP anti-
mouse CD3 (145-2C11), PE and APC and Pacific blue anti-mouse CD4 (RM4-5), FITC 
anti-mouse CD44 (IM7), PE anti-mouse CD120b/TNFR2 (TR75-89) and FITC anti-mouse 
CD90/FAS (Jo2). FITC and PerCP Cy5.5 anti-mouse CD4 (L3T4), FITC anti-mouse CD69 
(H1.2F3), FITC anti-mouse GITR (DTA-1), PE anti-mouse CD134/OX40 (OX-86), PE 
anti-mouse CD137/4-1BB (17B5), PE and APC and eFuor 450 anti-mouse/rat FoxP3 
staining set (FJK-16s), and functional grade purified anti-mouse IL-2 (JES6-1A12), CD137 
(17B5) and CD134 (OX-86) were purchased from eBioscience (San Diego, CA). LEAF™ 
purified anti-mouse CD252 (OX40 ligand, RM134L) and LEAF™ purified anti-mouse 
CD137 ligand (4-1BB ligand, TKS-1) was purchased from Biolegend (San Diego, CA). 
Alexa 647 anti-mouse CD120b/TNFR2 (TR75-89) was purchased from Serotec (Raleigh, 
NC). Murine IL-2, IL-7 and TNF were purchased from PeproTech (Rocky Hill, NJ). A 
neutralizing anti-mouse TNF Ab (5E5) and murine IgG1 were generously provided by Drs. 
Teresa Born and John E. Sims (Amgen Inc., Seattle, WA). 
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Cell purification. Mouse lymphocytes were harvested from mouse spleens, axillary lymph 
nodes, inguinal lymph nodes and mesenteric lymph nodes. CD4+ cells were purified from 
lymphocytes with mouse CD4 (L3T4) MicroBeads and LS column (Miltenyi Biotec, 
Auburn, CA). CD4 subsets were purified using Cytomation MoFlo cytometer (Fort Collins, 
CO), yielding a purity of ~98% for each subsets. T-depleted spleen cells were used as APCs 
and were prepared by depletion of CD90+ cells with anti-mouse CD90 MicroBeads and LD 
column (Miltenyi Biotec). APCs were irradiated with 3,000 R.  
In vitro cell culture and Treg function assay. In order to examine surface expression of 
TNFRSFs, CD4+ cells were cultured at 105 cells/well in a 96-well plate with medium (3) 
alone or IL-2 or IL-7 with or without TNF, or with neutralizing anti-IL-2 Ab, for desired 
time. Unless otherwise specified, the concentration of cytokines used in vitro cultures was 
10 ng/ml, and the concentration of antibodies was 10 µg/ml. The surface expression of 
TNFRSFs and other markers on Tregs or Teffs was analyzed with FACS, by gating on 
FoxP3+ or FoxP3- cells. In some experiments, flow-sorted CD4+FoxP3/gfp+TNFR2- cells or 
CD4+FoxP3/gfp-TNFR2- cells from FoxP3/gfp KI mouse spleen and LNs were treated with 
IL-2 or IL-2 plus TNF. After 72-hr incubation, surface expression of TNFR2 was 
determined with FACS.  
In some experiments, Flow-sorted CD4+FoxP3/gfp+ Tregs (2~5×104 cells/well) were 
cultured in a U-bottom 96-well plate with IL-7 or with IL-2, with or without TNF, or with 
agonistic Abs for OX40 or 4-1BB, or with antagonistic Abs for OX40 L or 4-1BB L. The 
cells were stimulated with 2×105 APCs/well plus 0.5 μg/ml of soluble anti-CD3 Ab. Cells 
were pulsed with 1 µCi [3H]thymidine (Perkin Elmer Life Sciences, Boston, MA) per well 
for the last 6 hr of the culture period.  
In order to determine Treg function, CFSE-labelled responder Teffs (5×104 cells/well) were 
seeded in a U-bottom 96-well plate together with 2×105 cells/well of APCs and 0.5 μg/ml 
of anti-CD3 antibody. Flow-purified CD4+CD25+ cells were added to the wells at the 
desired ratio. After 48 hours, CFSE dilution was determined with FACS. In some 
experiments, flow-sorted Tregs were treated with TNF/IL-2, with or without agonistic anti-
4-1BB Ab or agonist anti-OX40 Ab, for 72 hours. After thoroughly washing, pretreated 
Tregs were co-cultured with freshly isolated Teffs at the desired ratio to observe their 
suppressive potential.  
In vivo administration of LPS and anti-mouse TNF Ab. Normal C57BL/6 mice were 
injected intraperitoneally with 200 µg of LPS (Sigma-Aldrich, St. Louis, MO, Cat#: L9764) 
in PBS. In some experiments, mice were injected (i.p.) with 200 μg of a neutralizing anti-
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mouse TNF Ab (5E5) or Mu IgG1 24 hours and 1 hour before injection of LPS. Mouse 
spleens and mesenteric LNs were harvested at 0, 6, 24, 48 and 72 hours after injection for 
the FACS analysis of phenotype.  
Quantitative real time RT-PCR assay analysis of Tnfrsf genes. RNA samples were extracted 
from flow-sorted CD4+FoxP3/gfp+ or CD4+FoxP3/gfp- cells as described and reverse 
transcribed. Quantitative real time PCR was performed to determine relative mRNA 
expression using primers specific to Tnfrsf genes (SABiosciences RT² qPCR Primer 
Assays). Ct values from each gene in each sample were normalized using the 2 -∆∆Ct 
calculation method with Gapdh gene as housekeeping gene by following SABiosciences’ 
instruction.  
Flow Cytometry. After blocking FcR, cells were incubated with appropriately diluted 
antibodies. Acquisition was performed using a FACSort or a LSRII (BD Biosciences, 
Mountain View, CA) and data analysis was conducted using FlowJo software (Tree Star 
Inc., Ashland, OR).  
Statistical analysis. Comparisons of two groups of data were analyzed by two-tailed 
Student’s t test using GraphPad Prism 4.0. (GraphPad, San Diego, CA) 
Results 
TNF, in the presence of IL-2, induces Tregs to express genes encoding costimulatory 
TNFRSF members  
In order to test the effect of TNF on the expression of TNFR2 and other co-stimulatory 
TNFRSF members on Tregs, we performed gene profiling assay using the Mouse Tumor 
Necrosis Factor (TNF) Ligand and Receptor Signaling Pathways RT² Profiler™ PCR Array 
(SABiosciences, Frederick, MD). This showed that, by comparison with freshly isolated 
Tregs or with TNF/IL-2-treated Teffs, Tregs treated with TNF/IL-2 for 12 hrs up-regulated 
their expression of genes encoding a number of TNFRSF members, including Tnfrsf1b 
(TNFR2), Tnfrsf4 (OX40), Tnfrsf6 (FAS), Tnfrsf9 (4-1BB), and Tnfrsf18 (GITR), by 
greater than 2-fold (data not shown). Our results are in agreement with a recent microarray 
study in human Tregs (15). We next performed real time PCR assay to verify their changes 
in gene expression. As shown in Fig 1A, the expression of mRNA for TNFR2, OX40, 4-
1BB and GITR was two-fold higher in freshly isolated Tregs than freshly isolated Teffs 
(left). After treatment with TNF/IL-2, the expression of mRNA for these TNFRSF 
members and FAS was at least two-fold higher in Tregs than in Teffs (middle). Treatment 
with TNF/IL-2 further up-regulated their mRNA expressions greater than 4-fold in Tregs,  
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Figure 1. Up-regulation of genes and surface expression of co-stimulatory TNFRSF members on 
Tregs by TNF. (A) Flow-sorted CD4+FoxP3/gfp+ Tregs and CD4+FoxP3/gfp- Teffs were cultured with 
TNF and IL-2 for 12 hours. RNA from freshly purified cells and TNF/IL-2-treated cells was isolated and 
gene expression of TNFRSF members was analyzed by real time PCR. Fold changes in gene expression 
between two indicated groups are shown. The data (means ± SEM, n=4) are summarized from four 
separate experiments with similar results. (B-D) CD4 cells were incubated with IL-2 or TNF/TNF for 3 
days. The surface markers were analyzed with FACS by gating on FoxP3+ Tregs or FoxP3- Teffs. (B) 
Typical results of FACS analysis. Grey: TNF/IL-2; solid line: IL-2; dashed line: isotype control. (C) 
Summary of the percentage of TNFR2+, OX40+, and 4-1BB+ cells in Tregs. (D) In the presence of 
consistent concentration of IL-2, TNF up-regulated TNFR2 expression on FoxP3+ Tregs in a dose-
dependent manner. Data shown are fold change in percentage of TNFR2+ Tregs over that of freshly 
isolated Tregs. Comparison of two indicated groups: *p<0.05, ** p<0.01, *** p<0.001. Data shown in C-D 
(means ± SEM, n=3) are representative of at least three separate experiments with similar results. 
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as compared with freshly isolated Tregs (right). Thus, in the presence of IL-2, TNF up-
regulated the gene expression of TNFR2 and other co-stimulatory TNFRSF members in 
Tregs.   
TNF, in concert with IL-2, up-regulates surface expression of co-stimulatory TNFRSF 
members on Tregs 
Treatment with TNF/IL-2 for three days preferentially up-regulated the surface expression 
of TNFR2, OX40, 4-1BB and FAS on Tregs, but not on Teffs (Fig 1B). TNFR2, OX40 and 
4-1BB expressed on IL-2/TNF-treated Tregs were increased by 2.1±0.2, 2.4±0.2 and 
6.0±0.7 fold, respectively, over their expression on freshly isolated Tregs (p<0.05~0.001, 
Fig 1C). IL-2 alone also increased their 
surface expression (p<0.05), however, 
addition of TNF further increased their 
expression by up to ~2-fold over IL-2 
alone (p<0.05~0.01, Fig 1C). TNF-
induced up-regulation in the case of 
TNFR2 was dose-dependent (Fig 1D). 
TNF was also able to up-regulate surface 
expression of TNFR2, OX40 and 4-1BB 
on FACS-purified CD4+FoxP3/gfp+ Tregs 
(data not shown), indicating that TNF 
directly acts on Tregs. The increased 
expression of these co-stimulatory 
TNFRSF members has been reported to 
be a consequence of the activation of 
CD4 cells (21). Indeed, IL-2/TNF 
treatment markedly and preferentially 
enhanced the expression of the 
activation markers, CD44 and CD69, on 
Tregs (Fig 1B). Therefore, IL-2/TNF led 
to greater activation of Tregs.   
TNF/IL-2 induces TNFR2 expression on 
TNFR2- Tregs 
It is possible that TNF, in addition to 
expanding TNFR2+ Tregs, also converts 
Figure 2. Induction of the expression of TNFR2 by IL-2 
and TNF/IL-2 on FoxP3+TNFR2- Tregs. 
CD4+FoxP3/gfp+TNFR2- cells and CD4+FoxP3/gfp-
TNFR2- cells were flow-sorted. The cells were cultured 
with IL-2 or TNF/IL-2 for 3 days. The surface expression 
of TNFR2 was determined with FACS. Data (means ± 
SEM, n=3) in the left panel show the MFI of TNFR2 
expression, and in the middle panel show the percentage of 
TNFR2+ cells. The comparison of IL-2 and TNF/IL-2: *** 
p<0.001. Data in the right panel show results of a 
representative FACS analysis. Grey: TNF/IL-2; solid line: 
IL-2 alone; dashed line: isotype control. Data shown are 
representative of three separate experiments with similar 
results.  
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TNFR2- Tregs into TNFR2+ Tregs. To test this, flow-sorted CD4+FoxP3/gfp+TNFR2- cells 
and CD4+FoxP3/gfp-TNFR2- cells were treated with IL-2 or TNF/IL-2. As shown in Fig 2A, 
IL-2 alone induced the expression of TNFR2 on FoxP3/gfp+TNFR2- Tregs. Presumably 
based on the initial induction of TNFR2 by IL-2, TNF further amplifies the expression 
levels of TNFR2 on FoxP3/gfp+TNFR2- Tregs (p<0.001). In contrast, neither IL-2 nor 
TNF/IL-2 was able to induce TNFR2 expression on FoxP3/gfp-TNFR2- Teffs (Fig 2B). 
Thus, TNF does have the capacity to induce nonfunctional TNFR2- Tregs into functional 
TNFR2+ Tregs.  
IL-2-independent effect of TNF on the up-regulation of FoxP3 and TNFR2 expression by 
Tregs 
Treatment with TNF/IL-2 was previously shown to up-regulate the expression of CD25 on 
Tregs(3). Thus the activating effects of TNF/IL-2 on Tregs and their stimulation of TNFR2 
expression may depend entirely on the enhanced interaction of IL-2 with CD25. To test this 
hypothesis, we examined the effect of the combination of TNF and IL-7, another cytokine 
that uses common gamma chain and maintains the survival of Tregs in vitro (22). Only 6% 
of Tregs, and approximately same proportion of Teffs, were induced to proliferate when 
CD4 cells were cultured with IL-7 alone (Fig 3A left panels). In the presence of IL-7, TNF 
stimulation resulted in 37.8% replicating cells in the FoxP3+ subset. In contrast, TNF 
treatment resulted in replication of only 10.8% of FoxP3- cells (Fig 3A right panels). Thus, 
IL-7 also enabled TNF to preferentially stimulate the proliferation of Tregs (p<0.001, Fig 
3B). We also investigated the effect of IL-7 with or without TNF on the proliferative 
responses of flow-sorted CD4+FoxP3/gfp+ Tregs to TCR stimulation. As shown in Fig 3C, 
although IL-7 by itself only had minimal effect, a combination of TNF and IL-7 
synergistically promoted the proliferation of Tregs.  
Next, we examined the effects of TNF/IL-7 on the expression of FoxP3 and TNFR2 on 
Tregs. As shown in Fig 3D, after 3-day treatment with IL-7 alone, the proportion of FoxP3+ 
Tregs present in CD4 cells was only ~4%, which was lower than that in freshly isolated 
CD4 cells (~10%) or CD4 cells cultured with IL-2 (10 ng/ml, >10%) for 3 days. Even at the 
higher molar concentration of IL-7 was not as effective as IL-2 in the maintenance of  
survival of Tregs. Nevertheless, TNF in conjunction with IL-7 was able to increase the 
proportion of FoxP3+ cells (Fig 3D), in a dose-dependent manner (Fig 3E). Furthermore, in 
the presence of IL-7, TNF increased the proportion of TNFR2+ cells in the FoxP3+ subset,  
but not in FoxP3- cells (Fig 3F), indicating that IL-7 could also promulgate the Treg-
activating effect of TNF. In order to eliminate a possible effect of IL-2 released by  
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Figure 3. Stimulation of Tregs in the presence of IL-7 by TNF. (A-B) CD4 cells were labeled with CFSE and 
cultured with IL-7, in the absence or presence of TNF. After 3 days, the cell replication, as shown by dilution of 
CFSE, on Tregs and Teffs was analyzed with FACS. (C) Flow-sorted CD4+FoxP3/gfp+ T cells were stimulated 
with APCs and anti-CD3, in the presence of medium, or IL-7, or TNF, or TNF/IL-7. After 72-hour incubation, cell 
proliferation was determined by [3]H thymidine incorporation assay. (D-E) CD4 cells were cultured with 
increasing concentrations of IL-7 alone or with consistent concentration of TNF (D), or cultured with consistent 
concentration of IL-7 and increasing concentrations of TNF (E), for 3 days. The proportion of FoxP3+ cells was 
analyzed by FACS. (B-E): ** p<0.01, *** p<0.0001, as compared with indicated group. (F) CD4 cells were 
cultured same as (D). The proportion of TNFR2+ cells was analyzed with FACS by gating on FoxP3+ cells or 
FoxP3- cells. *p<0.05; ** p<0.01, as compared with lowest dose of TNF (0.1 ng/ml). (G-H) CD4 cells were 
cultured with IL-7 plus 0.1 ng/ml of TNF as control or 10 ng/ml of TNF, with Rat IgG or neutralizing anti-IL-2 
Ab. The proportion of TNFR2 (G) or FoxP3 (H) expression on Tregs was analyzed with FACS. Data shown are 
percentage of control (%). Comparison with respective control, * p<0.05. (I-J) CD4 cells were cultured with TNF 
alone, with or without neutralizing anti-IL-2 Ab, for 24 hours. The expression of TNFR2 was analyzed with 
FACS, by gating on FoxP3+ cells or FoxP3- cells. Comparison of indicated two groups, *** p<0.001. NS: no 
statistical significance. Data in (B-H, J) are means ± SEM (N=3). Data shown are representatives of at least three 
separate experiments with similar results. 
Chapter 5. TNF up-regulates co-stimulatory TNFRSFs on Tregs 
 
71 
 
activated FoxP3- Teffs present in the unfractionated CD4 cells, neutralizing anti-IL-2 Ab 
was used. As shown in Fig 3G-H, in the presence of as high as 10 μg/ml of neutralizing 
anti-IL-2 Ab, TNF/IL-7 still up-regulated TNFR2 expression on Tregs and expanded 
FoxP3+ cells (p<0.05). Furthermore, treatment with TNF alone for 24 hrs also resulted in an 
increase of TNFR2 expression on Tregs, which was not blocked by the neutralizing anti-IL-
2 Ab (Fig 3I-J). Thus, the effect of TNF on the proliferation of Tregs and up-regulation of 
TNFR2 on Tregs can occur independently of IL-2.  
 Effects of Activation of 4-1BB and OX40 on Tregs 
Next we examined whether 4-1BB and OX40 induced on Tregs by TNF were functional. 
As shown in Fig 4A-B, both agonistic anti-4-1BB and anti-OX40 Abs were able to partially 
overcome the anergic status of Tregs and induced proliferation of Tregs. Furthermore, the 
combination of TNF and anti-4-1BB Ab or anti-OX40 Ab synergistically stimulated the 
proliferation of Tregs (p<0.05~0.001. Fig 4A-B). In contrast, isotype control IgGs did not 
have any effect (data not shown). CD4-depleted splenocytes were used as APCs in this 
study and they expressed OX40 L and 4-1BB L (data not shown). We thereforeexamined 
the effect of blockade of OX40 L and 4-1BB L on the proliferation of Tregs. As shown in 
Fig 4C, TNF-induced the proliferative responses of CD4+FoxP3/gfp+ Tregs to APCs 
stimulation was partially abrogated by blocking antibodies to OX40 L and to a greater 
extent by anti-4-1BB L Ab (p<0.05). Thus, TNF-induced up-regulation of 4-1BB and 
OX40 appeared to augment the stimulatory signaling of agonistic Abs or their cognate 
ligands. In order to examine the effect of OX40 and 4-1BB activation on FoxP3 expression, 
CD4+FoxP3/gfp+ Treg cells were cultured in vitro with IL-2, or TNF/IL-2 with or without 
agonistic Abs for OX40 or 4-1BB. After 3-day culture, the levels of FoxP3 expression on a 
per cell basis (MFI) on Tregs was increased by ~2-fold after TNF/IL-2 treatment, as 
compared with IL-2 treatment alone (p<0.001, Fig 4D). Importantly, the TNF/IL-2-induced 
enhancement of FoxP3 expression in Tregs was preserved and even modestly increased by 
treatment with the 4-1BB agonistic Ab (p<0.05, Fig 4D). However, in our experimental 
system, the agonistic Abs for OX40 and 4-1BB did not further enhance TNFR2 expression 
on Tregs (data not shown), suggesting that the effect of TNF on the up-regulation of co-
stimulatory TNFRSFs was unidirectional.         
Next, the suppressive capability of Tregs expanded by the combination of TNF and anti-4-
1BB Ab or anti-OX40 Ab was investigated. Consistent with our previous report (3), the  
suppressive activity of Tregs pre-treated with TNF/IL-2 on the proliferation by Teffs was 
markedly enhanced (Fig 4E). Moreover, Tregs pre-treated with TNF/IL-2 in combination  
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Figure 4. Activation of 4-1BB and OX40 expands potent suppressive Tregs. (A-B) CD4+FoxP3/gfp+ 
Tregs were stimulated with APCs and anti-CD3, with or without TNF, or with agonistic anti-OX40 Ab, A) or 
with agonistic anti-4-1BB Ab (B). After 72-hr incubation, proliferation was determined by [3]H thymidine 
incorporation assay. (C) CD4+FoxP3/gfp+ Tregs were stimulated with APCs and anti-CD3, with medium, or 
with TNF, or TNF plus blocking anti-OX40 L Ab or anti-4-1BB L Ab. After 72-hr incubation, proliferation 
was determined by [3]H thymidine incorporation assay. (C) CD4+FoxP3/gfp+ Tregs were cultured with IL-2 
with or without TNF, or TNF plus agonistic anti-OX40 Ab, or anti-4-1BB Ab. After 3 days, MFI of FoxP3 
expression was analyzed with FACS. Data (means ± SEM, n=3) shown in (A~D) are representative of three 
experiments with similar results. The comparison of two indicated groups, * p<0.05; *** p<0.001. (E) 
CD4+CD25+ Tregs were treated with medium which contained TNF/IL-2 for 3 days. After washing, pre-
treated Tregs or freshly FACS-purified CD4+CD25+ Tregs were added into the freshly flow-sorted, CFSE-
labeled CD4+CD25- T cells at 10:5 ration (Teff:Treg). (F) CD4+CD25+ Tregs were treated with medium which 
contained TNF/IL-2, with or without agonistic anti-4-1BB Ab or anti-OX40 Ab for 3 days. After washing, 
pre-treated Tregs were added into the freshly flow-sorted, CFSE-labeled CD4+CD25- Teffs at 10:1 and 10:5 
ration (Teff:Treg). The cells were stimulated with APCs and anti-CD3 Ab. After 48-hr incubation, the 
proliferation was measured by CFSE dilution on Teffs with FACS. Dashed histogram: CFSE expression 
profile of Teffs alone; grey histogram: CFSE expression profile of Teffs co-cultured with Tregs. The number 
in the histogram stands for the proportion of CFSE-diluted cells in the presence of Tregs (%). Data shown are 
representatives of three separate experiments with similar results. (G) The summary of percent inhibition 
exerted by Tregs pretreated with medium alone (with TNF/IL-2) or with medium plus agonistic anti-OX40 
Ab or anti-4-1BB Ab. Data shown (means ± SEM, n=6) were summarized from two separate experiments 
with similar results. Comparison with indicated two groups: *p<0.05. N.S., no statistical significance.   
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with anti-4-1BB Ab or anti-OX40 Ab retained and in the case of anti-4-1BB Ab could 
enhance their potent suppressive potential, as compared with Tregs pre-treated with 
TNF/IL-2 (Medium) alone (p<0.05, Fig 4F-G). Our data therefore indicate that up-
regulation of 4-1BB and OX40 by TNF/IL-2 on Tregs could further promote their 
proliferation, while preserving or even enhancing their potent suppressive activity.  
Neutralization of TNF blocks in vivo expansion of splenic Tregs after LPS challenge  
It has been reported that LPS was able to activate and expand Tregs by interacting with 
TLR4 expressed on their surface (23). Since LPS is a potent inducer of TNF(24), we 
hypothesized that TNF produced in response to LPS challenge may also contribute to the 
LPS-induced expansion of Tregs. The results showed that, in vivo injection of LPS resulted 
in ~2-fold and >3-fold increase in the proportion of FoxP3+ cells in the splenic CD4+ 
subsets by 24 and 72 hrs after injection, respectively (Fig 5A). Similarly, the proportion of 
FoxP3+ cells present in the draining mesenteric LN CD4 subset following intraperitoneal 
LPS injection was also increased from 8.54% in control mice to 14.24% (Fig 5B). The 
expansion of Tregs in CD4+ subset persisted until day 5 (data not shown). Moreover, the 
surface expression levels of TNFR2, 4-1BB and OX40 was markedly preferentially 
increased by 6 hrs on Tregs (Fig 5C). The up-regulation of these TNFRSF members on 
Tregs was transient, with a peak expression at 24 hrs for both TNFR2 and OX40, and 6 hrs 
for 4-1BB, respectively (Fig 5C). Thus, our data shows that in vivo administration of LPS 
also results in the activation and proliferation of Tregs. In order to confirm the role of TNF 
in the expansion of splenic Tregs, a neutralizing Ab against mouse TNF was injected 24 hrs 
and 1 hr before LPS challenge. The results showed that the neutralization of TNF markedly 
blocked the expansion of splenic Tregs (p<0.001, Fig 5D, E). Furthermore, expression of 
TNFR2, OX40 and 4-1BB on the splenic Tregs was also down-regulated by anti-TNF 
treatment (Fig 5F). Thus, TNF and TNFRSF contribute to the in vivo expansion of Tregs 
after LPS challenge.   
Discussion 
In this study, we for the first time report that TNF, in the presence of common gamma chain 
interleukins, had the capacity to up-regulate the expression of a number of co-stimulatory 
TNFRSF members, including its own receptor, TNFR2, as well as 4-1BB and OX40, 
preferentially on Tregs. This provides a means of amplifying Treg numbers to optimally 
attenuate the harmful excessive inflammatory responses.     
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Figure 5. Neutralizing anti-TNF Ab blocked LPS-induced the expansion of Tregs and up-regulation of 
TNFRSFs on Tregs. Normal B6 mice were injected with 200 µg of LPS (i.p.) or PBS. Mouse spleens and 
mesenteric LNs were harvested at indicated time after injection. The proportion of FoxP3+ cells present in the 
spleen (A) or mesenteric LNs (B) was analyzed with FACS, by gating on CD4+ T cells. (C) Expression of 
TNFR2, OX40 and 4-1BB on Tregs or Teffs present in the spleen was analyzed with FACS, by gating on 
CD4+FoxP3+ cells or CD4+FoxP3- cells. (D~F) Mice were i.p. injected with 200 μg of neutralizing anti-mouse 
TNF Ab (5E5) or control mouse IgG1 24 hrs and 1 hr before challenge of 200 μg of LPS or PBS (i.p.). On day 5 
after LPS injection, the proportion of FoxP3+ cells was analyzed with FACS, by gating on CD4+ T cells. (D) 
Typical dot plot of FACS analysis. (E) The summary of percentage of FoxP3+ cells in splenic CD4 subset 
(means ± SEM, n=5). Comparison of indicated two groups, *** p<0.001. (F) Expression of TNFR2, OX40 (24 
hrs after LPS injection) and 4-1BB (6 hrs after LPS injection) was analyzed with FACS, by gating on FoxP3+ 
CD4 cells. Grey: PBS treatment control; dashed line: isotype control; solid line: LPS and Mu IgG (left panel) or 
anti-TNF Ab (right panel) treatment. The number in the dot plot indicates the percentage of cells in the 
respective quadrants (%). The number in the histogram indicates the percentage of positive cells (%). Data 
shown are representative of three separate experiments with similar results. 
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TNF is not sufficient to support the in vitro survival of Tregs and thus either IL-2 or IL-7 
was used. TNF and IL-2 up-regulate both TNFR2 and CD25 on Tregs, resulting in a 
reciprocal-amplification loop in the activation of Tregs. Although Tregs express low levels 
of IL-7 receptor α chain (CD127) which could not be up-regulated by TNF (data not 
shown), IL-7 and TNF nevertheless synergistically promoted the proliferative response of 
Tregs to TCR stimulation. In addition, TNF, in combination with IL-15, also activated 
Tregs (data not shown). The relative potency in support of Treg-activating effect of TNF 
were IL-2>IL-7>IL-15. Further, the effect of TNF/IL-7 or TNF alone on Tregs was not 
blocked by neutralizing anti-IL-2 Abs. Thus, the activating effects of both TNF and 
TNF/IL-7 on Tregs were not mediated by IL-2. The synergistic effects of TNF with other 
Cγ chain cytokines and TCR stimulation also likely contribute to the expansion and 
activation of Tregs at inflammatory site. We favor the idea that TNF-TNFR2 signaling 
pathway plays an important role in the activation of Tregs. A greater understanding of these 
fundamental mechanisms is needed for the discovery of novel approach to up- or down-
regulate Treg activity at signal transduction and molecular levels.  
4-1BB and OX40 are members of TNFRSF whose genes are clustered on mouse 
chromosome 4 together with TNFR2 (25). These molecules have some activities in 
common, such as regulating the expression of anti-apoptotic members of Bcl-2 family, 
promoting proliferation and survival of CD4 cells (21). The effects of these two molecules, 
especially of OX40, on the function of Tregs remain controversial. It has been reported that 
the anti-tumor effect of OX86, an agonistic antibody for OX40, was associated with 
attenuation of the suppressive function of Tregs (26). However, when used together with 
cyclophosphamide, OX86 actually induced the overactivation of tumor infiltrating Tregs, 
leading to selective apoptosis and eventual depletion of Tregs (27). It has been proposed 
that, if the “cytokine milieu is right”, OX40 agonist could promote Treg activity (20). Our 
data presented in this study indicate that TNF appear to be the “right cytokine” to provide 
activating effect of OX40 signaling on Tregs. Actually, OX40 signaling contributes to 
TNF-induced proliferative response of Tregs to APCs, since Treg proliferation was 
promoted by agonistic anti-OX40 Ab and partially abrogated by antagonistic anti-OX40 Ab 
(Fig 4A, C). This confirms a recent report of the contribution of OX40-OX40 ligand 
interaction to APC (DC)-mediated proliferation of Tregs (28). The physiological relevance 
of our findings is supported by the emerging evidence showing the crucial role of OX40 in 
the expansion, accumulation and function of Tregs in control of TNF-enriched 
inflammation, such as EAE (20) and colitis (29, 30). In fact, the stimulatory effects of 
OX40 and 4-1BB on Tregs have been harnessed in protocols aimed at expanding Tregs for 
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therapeutic purposes (19, 31)  Thus, in addition to their known co-stimulatory effects on 
Teffs (21), OX40 and 4-1BB are also potent activators of Tregs.    
Nagar and colleagues recently reported that stimulation with TNF up-regulated the 
transcription and surface expression of OX40 and 4-1BB in human Treg cells (15). 
However, they concluded that TNF decreased the suppressive activity of Tregs, based on 
their evidence that TNF stimulated the proliferation and cytokine production in co-cultures 
of Tregs and Teffs (15). Rather than decreasing Treg activity, their results can be attributed 
to the capacity of TNF to enhance the response of Teffs to TCR stimulation. Indeed, we 
have reported that TNF stimulated the activation of Teffs, which acquire the capacity to 
proliferate in spite of presence of Tregs in the early stage of co-culturing (3). Furthermore, 
TCR-activated mouse Teffs up-regulated their TNFR2 expression and become relatively 
resistant to suppression by Tregs (16). However, rather than impairing function of Tregs, 
TNF actually preferentially activated and expanded Tregs and eventually restored the 
suppression of co-cultures of mouse Tregs and Teffs (3). This viewpoint is favored by their 
data showing that the levels of TNF-induced INFγ in their Treg-Teff co-cultures paralleled 
the levels in unstimulated co-cultures (15), indicating that the degree of suppression by 
Tregs was not diminished by TNF. Nevertheless, we do not exclude the possibility that 
differences in species, experimental methods and time frame of observation may also 
contribute to the discrepancy between our data ((3) and this study) and Nagar et al’s data 
(15) regarding the impact of TNF on the inhibition of proliferation in co-cultures.   
The evidence that inflammatory responses can actually drive the proliferative expansion as 
well as enhancing the suppressive activity of Tregs is compelling, and is compatible with 
our conclusion that the interaction of TNF and TNFR2 promote both proliferation and 
suppressive activities of Tregs (32). Although counterintuitive and contradictory to most 
previous reports, our finding that TNF has the capacity to activate and expand Tregs has 
been supported by more recent studies. For example, TNF-TNFR2 interaction has been 
shown to be crucial for the generation and function of human CD4+ as well as CD8+ Tregs 
(8, 9), as well as to promote survival of human Tregs in an inflammatory environment by 
inducing anti-oxidative thioredoxin-1 (11). Interestingly, pathogenic Teff cell-derived TNF 
had the capacity to boost Treg activity in vivo and consequently suppressed autoimmunity 
in a mouse model (12).                   
Overall, our data indicate that, in concert with a common gamma chain cytokine (IL-2, IL-7 
or IL-15), TNF preferentially up-regulates the expression of co-stimulatory members of 
TNFRSF such as TNFR2, 4-1BB and OX40 on Tregs, resulting in a positive feedback 
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amplification of the stimulatory effect of TNF on Tregs. Thus, TNF enhances multiple 
TNFRSF pathways by up-regulating a number of receptors that can cooperate to curtail 
excessive inflammation and prevent self destructive tissue damage.  
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Abstract 
Several lines of evidence indicate the instability of CD4+Foxp3+ regulatory T cells (Tregs). 
We have therefore investigated means of promoting the stability of Tregs. In this study, we 
found that the proportion of Tregs in mouse strains deficient in TNFR2 or its ligands was 
reduced in the thymus and peripheral lymphoid tissues, suggesting a potential role of 
TNFR2 in promoting the sustained expression of Foxp3. We observed that upon in vitro 
activation with plate-bound anti-CD3 Ab and soluble anti-CD28 Ab, Foxp3 expression by 
highly purified mouse Tregs was markedly down-regulated. Importantly, TNF partially 
abrogated this effect of TCR stimulation and stabilized Foxp3 expression. This effect of 
TNF was blocked by anti-TNFR2 Ab, but not by anti-TNFR1 Ab. Furthermore, TNF was 
not able to maintain Foxp3 expression by TNFR2-deficient Tregs. In mouse colitis model 
induced by transfer of naïve CD4 cells into Rag1-/- mice, the disease could be inhibited by 
co-transfer of WT Tregs, but not by co-transfer of TNFR2-deficient Tregs. Furthermore, in 
the lamina propria of the colitis model, the majority of WT Tregs maintained Foxp3 
expression. In contrast, increased number of TNFR2-deficient Tregs lost Foxp3 expression. 
Thus, our data clearly show that TNFR2 is critical for the phenotypic and functional 
stability of Treg in the inflammatory environment. This effect of TNF should be taken into 
account when designing future therapy of autoimmunity and GVHD by using TNF 
inhibitors.  
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Introduction 
CD4+Foxp3+ regulatory T cells (Tregs) play a nonredundant role in the maintenance of 
immunological homeostasis and in the prevention of autoimmune disorders, and they also 
represent a major cellular mechanism in immune evasion by tumors (1, 2). It is now well 
established that the transcription factor Foxp3 (forkhead box P3) is a unique marker 
specific for the Treg lineage, which determines their phenotype and immunosuppressive 
function (3). Abrogation of Foxp3 gene function leads to the development of lethal multi-
organ autoimmune disorders in mice and humans (4, 5). In contrast, forced expression of 
Foxp3 in CD4+CD25− effector T cells (Teffs) is sufficient to convert them into functional 
Tregs (6, 7).  
Contrary to the previous notion that Tregs were stable and terminally differentiated cells, 
recent evidence revealed the phenotypic and functional plasticity of Tregs in response to 
inflammatory stimulation. For example, IL-1β and IL-6 each re-programmed Treg cells and 
induced them to express IL-17 (8-10). However, there is compelling contrasting evidence 
that the number of highly suppressive Foxp3-expressing cells actually increased in various 
inflammatory sites (11). Therefore, the inflammatory environment seems to have the 
capacity to restrain the plasticity and promote the phenotypic and functional stability of 
Tregs. Clarification of the molecular basis of such an effect may be therapeutically 
beneficial and can further improve our understanding of Treg biology.  
TNF is a pleiotropic cytokine and up-regulation of TNF expression is a benchmark of 
inflammatory responses. The biological functions of TNF are mediated by two structurally 
related, but functionally distinct receptors, TNFR1 (tumor necrosis factor receptor type I or 
p55) and TNFR2 (tumor necrosis factor receptor type II or p75) (12). With a death domain 
(DD) in its cytoplasmic tail, TNFR1 is the primary signaling receptor on most cell types 
and accounts for the majority of the proinflammatory, cytotoxic and apoptotic effects 
classically attributed to TNF (13, 14). In contrast, TNFR2 lacks an intracellular death 
domain and predominantly mediates signals promoting lymphocyte activation and 
proliferation (15, 16). Although counterintuitive, the accumulated evidence indicates that 
TNF by signaling through TNFR2 promotes Treg activity. For example, we reported that 
TNF by activating TNFR2 is able to activate and expand Tregs (17), and TNFR2 
expression identifies the maximal suppressive (18) and replicating Tregs (19) in mice and 
helps identify functional Tregs in human PBMCs (20). Furthermore, TNF preferentially up-
regulates TNFR2 expression on Tregs (21). In confirmation of our observation, Housley 
and Clark et al have shown that TNFR2 is critical for the in vivo immunosuppressive 
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function of naturally occurring Tregs (22). Grinber-Bleyer and Salomon et al showed that 
pathogenic Teffs stimulated the activation of Tregs in vivo, at least partially through TNF-
TNFR2 interaction (23). Mougiakakos and Kiessling et al found that TNF-TNFR2 
interaction enhanced thioredoxin-1 expression on human Tregs, but not on Teffs, and 
therefore preferentially promoted Treg survival and activity within inflammatory milieu 
(24).  However, it remains elusive whether the replicating Tregs driven by TNF-TNFR2 
interaction retain phenotypic and functional attributes of naturally occurring Tregs, 
especially in the chronic inflammatory condition.  This question is clinically relevant now 
that TNF blockage therapy has become an important tool in the treatment of autoimmune 
disorders.  
In this study, we observed that the frequency of Tregs in the thymus of mouse strains 
genetically deficient in TNFR2 or its ligands is reduced. Expression of Foxp3 is induced in 
developing thymocytes upon self-reactive TCR engagement (25). Thus, stimulation of 
TNFR2 may stabilize Foxp3 expression in response to activation of TCR of Treg cells in 
immune or inflammatory responses, as shown by our in vitro and in vivo studies.     
Materials and Methods 
Mice and reagents. Wild-type C57BL/6 mice, congenic Ly5.2 C57BL/6 mice, Rag1-/- mice, 
TNFR2-/- mice, TNF-/- mice, TNN/LTα/LTβ-/- mice were provided by the Animal 
Production Area of the NCI (Frederick, MD). Foxp3/gfp KI (knock in) mice were kindly 
provided by Dr. Yasmine Belkaid at Laboratory of Parasitic Diseases, NIAID, NIH, and 
maintained in the Animal Production Area of the NCI (Frederick, MD). Frederick National 
Laboratory for Cancer Research is accredited by AAALAC International and follows the 
Public Health Service Policy for the Care and Use of Laboratory Animals. Animal care was 
provided in accordance with the procedures outlined in the "Guide for Care and Use of 
Laboratory Animals" (National Research Council; 1996; National Academy Press; 
Washington, D.C.). Anti-mouse antibodies (Abs) were purchased from BD Biosciences 
(San Diego, CA) consisted of anti-mouse CD3 (145-2C11), CD4 (GK1.5), CD25 (PC61), 
CD45, TNFR2 (TR75-89), Ki-67 (B56), INFγ (XMG1.2) and IL-17A (TC11-18H10). 
Leukocyte Activation Cocktail was also purchased from BD Biosciences. Functional grade 
purified anti-mouse CD3e (eBio500A2), CD28 (37.51) and IL-4 (11B11) Abs, Foxp3 
Staining Set (FJK-16s) and anti-mouse TCRβ Ab (H57-597) were purchased from 
eBioscience (San Diego, CA). Functional grade anti-mouse TNFR1 (55R-170), TNFR2 
(TR75-32.4) Ab and Ham IgG were purchased from Biolegend (San Diego, CA). Murine 
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IL-6, IL-12 and TNF were purchased from PeproTech (Rocky Hill, NJ). Human rTGFβ1 
was from R&D Systems (Minneapolis, MN).  
T cell transfer model of colitis. Naive CD4+CD25−CD45RBhi T cells were isolated from 
WT congenic B6 (CD45.1+) mice and injected i.p. into Rag1−/− immunodeficient recipients 
(4 × 105 cells/mouse) alone, or co-transferred with WT or TNFR2−/− CD4+CD25+CD45RBlo 
Treg cells (1.6 × 105/mouse, CD45.2+). In Tregs transfer experiments, 
CD4+CD25+CD45RBlo Treg cells flow-sorted from WT congenic B6 mice (CD45.1+) and 
TNFR2−/− mice (CD45.2+) were mixed at 1:1 ratio and i.p. injected into Rag1-/- mice (1.2 × 
105/mouse, each). Mice were monitored weekly for the clinical symptoms of colitis such as 
rectal bleeding, loose feces/diarrhea, rough/hunched posture and body weight by animal 
facility staff. Any mice losing >20% of its starting body weight or showing severe signs of 
disease were euthanized.  
Cell isolation. Single cell suspensions from spleen and mLNs (mesenteric LNs) were 
prepared by filtration through a 70 µm cell strainer (BD Labware, San Jose, CA). 
Preparation of colon lamina propria (cLP) cells was as previously described (26). Briefly, 
colons were rinsed in PBS and cut into ~0.3 cm pieces. Intestinal epithelial cells were 
removed by incubation with Ca- and Mg-free PBS containing 10% FCS and 5 mM EDTA. 
Colon tissues then were incubated with RPMI 1640 containing 10% FCS and 1 mg/ml 
collagenase type 4 (Worthington Biochemical Corporation, Lakewood, NJ) for 30 min at 
37°C.  
In vitro T cell activation and differentiation. Flow-sorted CD4+Foxp3/gfp+ cells or 
CD4+Foxp3/gfp- cells from Foxp3/gfp KI mice, or CD4+CD25+ cells from WT C57BL/6 
mice or TNFR2-/- mice were seeded at 5×104 cells/well in 96-well plate. The cells were 
stimulated with plate-bound anti-CD3e Ab (10 µg/ml) and soluble anti-CD28 Ab (2 µg/ml) 
for 5 days. In some experiments, the cells were activated in Th0, Th1 and Th17 polarizing 
conditions by adding medium alone, or IL-12 (10 ng/ml) plus anti-IL-4 Ab (10 µg/ml), or 
IL-6 (10 ng/ml) or IL-6 plus TGFβ (1 ng/ml), respectively. In some experiment, the cells 
were activated in the presence of TNF (10 ng/ml) and/or IL-6 (10 ng/ml), without or with 
10 µg/ml of Ham IgG, or anti-TNFR1 Ab or anti-TNFR2 Ab. Iscove's modified Dulbecco's 
medium (IMDM, Sigma-Aldrich) was used in Th17 polarizing culture, and RPMI-1640 
(Lonza BioWhittaker, Walkersville, MD) was used in all other cultures. The medium was 
supplemented with 10% fetal bovine serum (FBS, Hyclone, Logan, UT) containing 2 mM 
glutamine, 100 IU/ml penicillin, and 100 μg/ml streptomycin, 10 mM HEPES, 1 mM 
sodium pyruvate, 0.1 mM nonessential amino acids and 50 μM 2-ME.      
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Flow cytometry. After blocking FcR, cells were incubated with appropriately diluted 
antibodies. Acquisition was performed using a SLRII (BD Biosciences, Mountain View, 
CA) and data analysis was conducted using FlowJo software (Tree Star Inc., Ashland, OR). 
For intracellular cytokines staining, cells were re-stimulated with BD Leukocyte Activation 
Cocktail for 4 h. FACS analysis was gated on the live cells only by using LIVE/DEAD® 
Fixable Dead Cell Stain Kit.  
Statistical analysis. Cumulative incidence of colitis was graphed as survival plot and 
analyzed with Logrank test, and comparison of other data was analyzed by two-tailed 
Student’s t test using Graphpad Prism 4.0. 
RESULTS  
Reduction of thymic and peripheral Tregs in mice deficient in TNFR2 or its ligands  
In normal mice, most thymic Tregs express TNFR2 (18). All human thymic CD4+CD25+ 
Tregs constitutively express TNFR2, while thymic CD4+CD25- cells do not express this 
receptor (27). TNF is expressed in the thymus of mice and humans, and participates in the 
development of thymocytes (28). Thus, we investigated the possibility that TNF or LTα 
(lymphotoxin alpha), the ligands for TNFR2, contribute to the thymic differentiation and 
generation of Tregs.  
We first compared the Foxp3-expressing Tregs in TNFR2-/- and normal WT mice. In adult 
TNFR2-/- mouse thymus, the proportion of CD4+Foxp3+ Tregs in total thymocytes was 
reduced by 45%, as compared with WT control B6 mice (Fig 1A, *P<0.05). The proportion 
of Foxp3+ cells in CD4 SP (single positive) thymocytes was also reduced by ~30% (Fig 1B, 
p<0.05). It was reported that the cellularity of the thymus of TNFR2-/- mice was greater 
than that of WT mice, however, the most affected subset of thymocytes were naïve triple 
negative cells (CD3-CD4-CD8-), while both CD4 and CD8 subsets were not altered (29). 
Since thymic Tregs were almost exclusively contained in the CD4 SP population, the 
absolute number of Tregs in the thymus of TNFR2-/- mice was reduced proportionally.  
In the periphery, the percent of CD4+Foxp3+ cells in total splenic cells and LN cells was 
decreased by 42% and 21%, respectively (P<0.01~0.05, Fig 1C~D). The proportion of 
Foxp3+ cells in the CD4+ splenic cells and CD4+ LN cells was decreased by 36% and 22%, 
respectively (p<0.05, Fig 1E~F). The absolute number of splenic Tregs in TNFR2-/- mouse 
was reduced by ~50% (p<0.05, Fig 1G). These data suggest that TNFR2 may participate in 
the development of Tregs in the thymus. Although TNFR2-/- mouse does not spontaneously 
develop apparent autoimmune disorders, this strain of mouse nevertheless shows more 
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Figure 1. Reduced number of Tregs in TNFR2 deficient mice. Cells from thymus, spleen and LNs in 
WT mice (C57BL/6) and TNFR2-/- mice were stained with CD3, CD4, CD8, TNFR2, and Foxp3. The 
expression of Foxp3 was analyzed by FACS, gating on CD3+CD4+ cells or CD3+CD4+CD8- cells (CD4 
single positive cells, e.g., CD4 SP cells). (A) Proportion of CD4+Foxp3+ cells in the total thymocytes 
derived from WT or TNFR2-/- mice. (B) Expression of Foxp3 and TNFR2 on CD4 SP thymocytes from 
WT or TNFR2-/- mice. (C~D) Proportion of CD4+Foxp3+ cells in the total splenic and LN cells from WT 
or TNFR2-/- mice. In (A and B), left shows the typical FACS plots, and right shows summary (N=3). (C) 
shows the typical FACS plots and (D) shows the summary (N=3). (E-F) Expression of Foxp3 and TNFR2 
on CD4+ T cells in the spleen and LNs from WT or TNFR2-/- mice. (E) Shows the typical FACS plots and 
(F) shows the summary (N=3). (G) Number of CD4+Foxp3+ Tregs in the spleen from WT or TNFR2-/- 
mouse. Number in the FACS plot shows the proportion of positive cells in the indicated gating or 
respective quadrants. Comparison between two indicated groups: * p<0.05; ** p<0.01. Data shown are 
representatives of at least 3 separate experiments with same results.  
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 Figure 2. Reduced number of Tregs in TNFR2 ligands deficient mice. Cells from thymus, spleen and 
LNs in WT mice (C57BL/6) or TNF/LTα/LTβ triple KO mice were stained with CD3, CD4, CD8, 
TNFR2, and Foxp3. The expression of Foxp3 was analyzed by FACS, gating on CD3+CD4+ cells or 
CD3+CD4+CD8- cells. (A) Proportion of CD4+Foxp3+ cells in total thymocytes from WT or Triple KO 
mice. (B) Proportion of Foxp3+ cells in the CD4+CD8- thymocytes from WT or Triple KO mouse. In (A 
and B), left shows the typical FACS plots, and right shows summary (N=3~6). (C) Proportion of 
CD4+Foxp3+ cells in the spleen from WT or Triple KO mice. (D) Proportion of Foxp3+ cells in CD4+ 
splenic cells from WT or Triple KO mice. Number in the FACS data shows the proportion of cells in the 
indicated gating. Comparison between two indicated groups: * p<0.05; ** p<0.01. Data shown are 
representative of at least 3 separate experiments with same results.  
 
severe inflammation upon induction of autoimmune disease (30), presumably attributed by 
the reduced number of Tregs.     
The development of Foxp3+ Tregs in mice with depletion of TNFR2 ligands was also 
investigated. Both TNF-/- mice or LTα/β-/- mice did not exhibit any deficiency in Tregs in 
the spleen (data not shown). However, the proportion of Tregs in the periphery and thymus 
of TNF/LTα/LTβ-/- (triple KO) mice was decreased. Despite a profound defect of peripheral 
lymphoid organs of triple KO mice, this strain of mouse had no change in the major 
thymocyte populations and T/B ratio in the spleen (31).  In the thymus, the proportion of 
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Figure 3. Plasticity of Tregs under proinflammatory stimulation in 
vitro. Splenic and LN cells from Foxp3/gfp KI mice were stained with 
CD4. Foxp3/gfp+ or Foxp3/gfp- CD4 cells were flow-sorted. The cells 
were activated in vitro with plate-bound anti-CD3 and soluble anti-
CD28 Abs, in Th0 (no cytokine added) or in Th1 (IL-12 plus anti-IL-4 
Ab) or Th17 (IL-6, or IL-6 plus TGFβ) polarizing culture condition. 
After 5 days, the cells were re-stimulated with BD Leukocyte 
Activation Cocktail and intracellular IFNγ and IL-17A were analyzed 
by FACS. Numbers in FACS plots indicate the percentage of cells in 
the respective quadrant. The data shown are representative of at least 
three separate experiments with the same results. 
 
CD4+Foxp3+ Tregs in total thymocytes was reduced by ~50% (p<0.05, Fig 2A). The 
proportion of Foxp3+ Tregs in CD4 SP thymocytes was reduced by 31% (p<0.05, Fig 2B). 
In the spleen, the proportion of CD4+Foxp3+ Tregs in total splenic cells was reduced by 
37% (p<0.01, Fig 2C). The proportion of Foxp3+ Tregs in CD4+ splenic cells was reduced 
by 26% (p<0.01, Fig 2D). TNF treatment in vitro largely restored the proportion of Foxp3+ 
Tregs in CD4 cells derived from triple KO mice (data not shown). Therefore, genetic 
ablation of TNFR2 or its 
ligands resulted in a 
reduction of Tregs in both 
thymus and peripheral 
lymphoid tissue.  
TNF stabilizes Foxp3 
expression by TCR-
stimulated Tregs in vitro  
Self-reactive TCR signaling 
plays a central role in the 
thymic generation of Tregs 
(25). Reduced thymic Tregs 
in mice deficient in TNFR2 
and its ligands suggest that 
TNF-TNFR2 signaling may 
play a role in stabilizing 
Foxp3 expression by Tregs in 
response to TCR stimulation. 
We therefore examined the 
effect of exogenous TNF on 
Foxp3 expression by highly purified Tregs, which were stimulated in vitro with plate bound 
anti-CD3 Ab and soluble anti-CD28 Ab. It was reported that, in the presence of 
proinflammatory cytokine, in vitro TCR stimulation could change the phenotype of Tregs 
(30). We confirmed this result and found that IL-6+TGFβ induced IL-17 expression by both 
Tregs and Teffs (effector T cells), IL-6 alone only induced IL-17 expression by TCR-
stimulated Tregs, but not by Teffs. In contrast, Th1 polarizing culture condition only 
induced IFNγ expression by TCR-stimulated Teffs, but not by Tregs (Fig 3). Unexpectedly, 
TCR-stimulation alone markedly down-regulated Foxp3 expression by Tregs (Fig 4). This 
was not caused by activation induced cell death (AICD), since FACS analysis only gated on 
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the live cells by using 
LIVE/DEAD® Fixable Dead 
Cell Stain Kit described in 
Methods and Materials. 
Although IL-6 induced IL-17 
expression by a substantial 
proportion of initial Tregs, 
which all down-regulated their 
Foxp3 expression, this 
proinflammatory cytokine 
paradoxically supported the 
persistent expression of 
Foxp3 by 30% of input cells 
(Fig 4). In contrast, TNF by 
itself consistently maintained 
high levels of Foxp3 
expression by 20~30% of 
initial input Tregs, and can cooperate with IL-6 to further enhanced the proportion of 
Foxp3-expressing cells without further increasing IL-17-producing cells (Fig 4). Therefore, 
in addition to activate and expand Tregs (17), TNF can also stabilize Foxp3 expression on 
Tregs.  
TNFR2 mediates the effect of TNF in maintenance of Foxp3 expression in vitro  
To further determine which TNF receptor was responsible for stabilizing Foxp3 expression, 
anti-TNFR1 or anti-TNFR2 neutralizing antibodies were added to the TNF-treated Tregs. 
The anti-TNFR2 Ab, but not anti-TNFR1 Ab, markedly reduced the proportion of Foxp3-
expressing cells (p<0.05, Fig 5A). We further clarified this issue by comparing the response 
of Tregs from WT mice or TNFR2-/- mice. Although TNFR2-/- mice had reduced number of 
Tregs, the residual Tregs nevertheless expressed the same levels of Foxp3 as WT Tregs 
(Fig 5B). As shown in Fig 5C, TCR stimulation reduced Foxp3 expression by TNFR2-/- 
Tregs and this was not reversed by TNF. In contrast, Foxp3 expression by TNFR2-/- Tregs 
was partially sustained by IL-6 (data not shown). Thus, our data clearly show that TNF 
activation of TNFR2 is able to stabilize Foxp3 expression by Tregs upon potent TCR 
stimulation.   
TNFR2 is required for the in vivo immunosuppressive function of Tregs 
Figure 4. TNF stabilizes Foxp3 expression on Tregs in vitro. Flow-
sorted CD4+Foxp3/gfp+ cells were stimulated as described in Fig 3, 
with medium alone or with IL-6, in the presence of TNF or not. After 
re-activation, intracellular expression of Foxp3 and IL-17A was 
analyzed with FACS. Numbers indicate the percentage of cells in the 
respective quadrant. The data shown are representative of at least 
three separate experiments with the same results.  
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The critical role of functional Tregs in immune homeostasis can be demonstrated in a 
mouse colitis model induced by transfer of naïve CD4 T cells into Rag1-/- mice (26). In a 
preliminary experiment, we found that eight weeks after transfer, TNF can be expressed by 
both host cells and adoptively transferred cells in the cLP (data not shown), while TNFR2 
expression was up-regulated by both co-transferred initial naïve CD4 cells and Tregs (data 
not shown). Thus, this model is appropriate to determine the role of interaction of TNF-
TNFR2 on the function of Tregs. We confirmed that TNFR2 expression on Tregs was 
required for the suppression of colitis induced by transfer of naïve CD4 cells (22) (Fig 6A, 
p<0.05). Furthermore, we compared the effect of WT or TNFR2-deficient Tregs on the 
development of Th1 or Th17 responses by co-transferred naïve CD4 cells. As shown in Fig 
6B, naïve CD4 cells transferred alone (without Tregs) into Rag1-/- mice could develop into 
Figure 5. TNFR2 mediates the effect of TNF in maintaining Foxp3 expression in vitro. (A) Flow-sorted 
CD4+Foxp3/gfp+ cells were stimulated as in Fig 3, in the presence of TNF (10 ng/mL), and 10 µg/mL of 
isotype control Ham IgG, or anti-TNFR1 Ab or anti-TNFR2 Ab. Foxp3 expression was analyzed by FACS. 
Typical histograms and summary (N=3) are shown. (B) Tregs were flow-sorted from WT and TNFR2-/- mice, 
based on surface expression of CD4+CD25+. The expression of Foxp3 was analyzed by FACS. (C) CD4+ 
CD25+ cells from TNFR2 KO mice were activated as described in Fig 3, in the presence of TNF (10 ng/mL) or 
not. The expression of Foxp3 was analyzed by FACS. Typical FACS plot and summary (N=3) are shown. 
Numbers represent the percentage of cells within the indicated gate. The data shown are representative of at 
least three separate experiments with the same results. Compared with indicated group, * p<0.05;  **p<0.01.  
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both Th1 and Th17 cells in the colon, as indicated by their expression of IFNγ and IL-17A. 
Consistent with a previous report (22), WT Tregs markedly inhibited a proportion of IFNγ-
producing cells (p<0.01), while TNFR2-/- Tregs failed to do so. It has been shown that, in 
mouse colitis model induced by transfer of naïve CD4 cells, Th17 cells had paradoxically 
tissue protective and immunosuppressive effect and consequently suppressed colon 
inflammation, by inhibiting pathogenic Th1 responses (31) or by enhancing barrier function 
of intestinal epithelial cells (32). In agreement with a number of recent studies (33, 34), we 
also found that transfer of WT Tregs resulted in greater than a 2-fold increase in the 
proportion of IL-17A-producing cells developed from the initial naïve CD4 cells, as 
compared with naïve CD4 cells transfer alone (p<0.01). In contrast, co-transfer of TNFR2-
deficient Tregs failed to promote the generation of Th17 cells (p>0.05, Fig 6B). Therefore, 
TNFR2 is required for Tregs to suppress pathogenic Th1 response in this model.   
TNFR2 is required for maintenance of Foxp3 expression on Tregs in vivo 
The accumulation of Tregs and their Foxp3 expression were examined when full-fledged 
colitis was developed which occurred typically 6 to 8 weeks after cell transfer. As shown in 
Fig 7A, the proportion of WT Tregs present in the total numbers of transferred cells was  
Figure 6. TNFR2 is required for the 
immunosuppressive function of Tregs in 
vivo. CD45.1+ CD4+CD25-CD45RBhi naïve T 
(nCD4) cells were transferred alone or co-
transferred with CD45.2+ WT or TNFR2−/− 
Treg cells into Rag1−/− mice. (A). Cumulative 
incidence of colitis. Incidence of colitis in 
mice co-transferred with naïve CD4 cells and 
WT Tregs was markedly decreased, by 
comparison with mice transferred with naïve 
CD4 cells alone or co-transferred with naïve 
CD4 cells and TNFR2-/- Tregs (p=0.0132 and 
0.0163, respectively).  (B) After eight weeks, 
cLP cells were isolated. The intraceullar 
expression of IFNγ and IL-17A by initial 
transferred naïve WT CD4 cells was analyzed 
by FACS, gating on CD45.1+ cells. Typical 
FACS plot and summary (N=3~5) are shown. 
Data shown are representative of three 
separate experiments with similar results.  
* p<0.05; ** p<0.01.   
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reduced from 28.6% to 12.5%, which may be based on the homeostatic restoration of Tregs 
to the normal 10~15% range in total CD4 pool. However, the proportion of Foxp3+TNFR2-
/- Tregs was reduced to 3.88%, which is markedly lower than 12.5% WT Tregs (p<0.05).   
Flow-sorted Tregs from WT and TNFR2-/- mice expressed the same high levels of Foxp3 
(Fig 7B). By 8 weeks after transfer, the majority of WT Tregs (>80%) maintained their 
Foxp3 expression in cLP. However, Foxp3 expression by TNFR2-deficient Tregs was 
markedly reduced (~40%), as compared with WT Tregs (p<0.01, Fig 7B). The reduction of 
Figure 7. Critical role of TNFR2 in stabilizing Foxp3 expression in vivo. CD45.1+ CD4+CD25-CD45RBhi 
naïve T cells were transferred alone or co-transferred with CD45.2+ WT or TNFR2−/− Treg cells into Rag1−/− 
mice. After eight weeks, cLP cells were analyzed by FACS. (A) Reduced relative number of co-transferred 
TNFR2-/- Tregs. Proportion of CD45.2+ initial Treg cells in total transferred CD4 cells was determined. For 
comparison, pre-transferred cells were shown in the upper panel. (B) Reduced Foxp3 expression by initial 
Tregs from TNFR2-/- mice in cLP. Expression of IL-17A and Foxp3 was analyzed by FACS, by gating on 
CD45.2+ initial Tregs. Numbers in the FACS plots represent the percentage of cells in the indicated gate or 
quadrant. Typical FACS plot and summary (N=3~5) are shown. Data shown are representative of three 
separate experiments with similar results. * p<0.05; ** p<0.01.  
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Foxp3 by TNFR2-/- Tregs was more 
profound in the cLP, while there was not a 
significant change in the spleen and 
mesenteric lymph nodes (data not shown), 
suggesting a role of proinflammatory 
response in the colon. Therefore, TNFR2 
expression is critical for the phenotypic 
stability of Tregs in the inflammatory 
environment and for the capacity of Tregs 
to compete efficiently with colitogenic T 
cells. The latter effect may be attributable 
to the lack of suppressive function of 
TNFR2-deficient Tregs in vivo found in 
our study and others (22, 35).   
TNFR2 expression is critical for the 
expansion of Tregs in competitive 
environment 
The magnitude of inflammation was 
greater in Rag1-/- mice co-transferred with 
WT naïve CD4 cells containing TNFR2-/- 
Tregs, which might be attributable to the 
profound loss of Foxp3 expression in 
TNFR2-/- Tregs. To clarify this issue, we 
injected a mixture of WT and TNFR2-/- 
Tregs into Rag1-/- mice, in order to 
compare phenotypic stability of WT and 
TNFR2-/- Tregs in vivo in the identical 
environment. Tregs were flow-sorted from 
CD45.1+ WT and CD45.2+ TNFR2-/- mice 
and transferred at a 1:1 ratio into Rag1-/- 
mice (Fig 8A). Purified Tregs from these 
two strains of mice expressed the same 
high levels of Foxp3 (Fig 8B). Ten weeks 
after transfer, the proportion of WT Tregs 
to TNFR2-/- Tregs was changed from 1:1 
Figure 8. TNFR2 expression is critical for the 
expansion of Tregs in competitive environment. 
CD45.1+ Tregs and CD45.2+ Tregs were flow-sorted 
from WT mice and TNFR2-/- mice respectively and 
co-transferred into Rag1-/- mice at ratio of 1:1. (A) 
Profile of pre-transferred Tregs. Left shows 
expression of TNFR2 and CD45.2 and right shows 
CD45.2 expression alone. (B) Flow-sorted Tregs 
from WT mice (solid histogram) and TNFR2-/- mice 
(grey histogram) express comparable levels of 
Foxp3. Dashed line: isotype control. (C) Ten weeks 
after transfer, Tregs present in the cLP were analyzed 
by FACS, gating on CD45+TCRβ+ cells. Left: 
expression of TCRβ and CD45.2 on cLP Tregs; 
right: summary of proportion of WT and TNFR2-/- 
Tregs in total transferred cells present in cLP (N=5). 
(D) Foxp3 expression on initial Tregs from WT or 
TNFR2-/- mice co-transferred into Rag1-/- mice (left) 
and summary of proportion of Foxp3-expressing 
cells in total transferred cells (right, N=5). The 
number shown in the FACS plots represent the 
proportion of cells in the respective quadrant or gate. 
Data shown are representatives of three separate 
experiments with similar results. * p<0.05; *** 
p<0.001.  
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to roughly 4:1 (Fig 8C, p<0.05), indicating a greater capacity of WT Tregs than TNFR2-/- 
Tregs to re-constitute the lymphopenic environment (Fig 8C). The majority of WT Tregs 
lost their Foxp3 expression and <40% expressed Foxp3 (Fig 8D), which is much lower than 
Tregs co-transferred with naïve CD4 cells (Fig 7B). These data are consistent with previous 
studies showing that a majority of transferred Foxp3/gfp+ Tregs in cLP of recipient 
lymphopenic mice lose their Foxp3 expression, while co-transfer of Teffs resulted in 
maintaining Foxp3 expression by Tregs (36, 37), presumably by producing cytokines such 
as IL-2 and/or TNF.  The reduction in Foxp3 expression by TNFR2-deficient Tregs was 
considerably greater than by WT Tregs, and more than 95% of initial Tregs derived from 
TNFR2-/- mice lost their Foxp3 expression (Fig 8D). Consequently, less than 10% of 
Foxp3-expressing cells in cLP were derived from TNFR2-/- Tregs which was markedly 
lower than those from WT mice (p<0.0005, Fig 8D). These data clearly show that TNFR2 
per se is critical to sustain Foxp3 expression by Tregs in this model. In our experimental 
system, after transfer into Rag1-/- mice (CD45.2+), TNFR2-/- Tregs isolated from CD45.2+ 
mice were outnumbered by WT Tregs derived from either CD45.2+ mice (Fig 7) or 
CD45.1+ mice (Fig 8), mitigating the potential impact of different congenic marker 
expressed by WT Tregs and TNFR2-/- Tregs.      
Discussion 
Our data presented in this study clearly show that TNFR2 plays a critical role in sustaining 
Foxp3 expression, and consequently maintaining the phenotypic and functional stability of 
Tregs. Therefore, at least in the inflammatory environment, the TNF/TNFR2 pathway is 
critical for the stabilization of Treg pool that is required to restrain the magnitude and 
length of an inflammatory immune response and to avoid harmful damage to self tissues.  
A previous study reported that, in the same mouse colitis model, the accumulation and 
Foxp3 expression by TNFR2-/- Tregs in cLP were not changed when cells were harvested 
two weeks after transfer (22). Since the development of colitis in this model usually starts 5 
weeks after transfer of naïve cells, we examined accumulation of Tregs and their Foxp3 
expression when full-fledged colitis was developed which occurred typically 8 weeks after 
cell transfer. In our transfer experiments, both WT and TNFR2-/- Tregs were flow-sorted 
CD4+CD25+CD45RBlo cells and contained similar high levels of Foxp3+ cells (>95%). The 
expansion of contaminating Foxp3- Teff cells present in the initial Treg population may 
partially account for the reduction in Foxp3-expressing cells after transfer into Rag1-/- mice. 
However, the impact of this contamination population is very limited since it has been 
shown that the transferred Foxp3+ and Foxp3- T cells were replicating similarly in the 
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lymphopenic mouse. There was no marked outgrowth of an intentionally added 3% Foxp3- 
Teffs in Tregs after transfer (36, 37). Further, TNFR2 is well known for its co-stimulatory 
effect on Teffs (38),  thus it is likely that TNFR2-/- Teffs present in TNFR2-/- Tregs are less 
proliferative than WT Teffs.     
IL-2 produced by Teffs has been proposed to be a paracrine factor to maintain Foxp3 
expression and phenotypic as well as functional stability of Tregs (39). There are number of 
observations challenging the dispensable role of IL-2 on Tregs. 1) Only ~50% reduction of 
Foxp3+ Tregs in CD4 cells was found in the thymus and peripheral lymphoid tissues of Il2-/- 
mice or Il2ra-/- mice, and residual Tregs had normal suppressive function (40). 2) A recent 
study found that the stability of transferred Tregs in the lymphopenic mouse was 
maintained by Teff cells independent of IL-2, since the administration of IL-2 did not 
promote the maintenance of Foxp3 expression by Tregs (37). 3) The stimulatory effect of 
Teffs on Tregs in vivo was not abrogated by neutralization of IL-2, and IL-2 deficient Teffs 
still had the capacity to stimulate the activation of Tregs (23). TGFβ is able to induce 
Foxp3 expression (41) and thus may play a role in the persistent expression of Foxp3 on 
Tregs. Nevertheless, conditional deletion of TGFβ receptor I (T RI) in T cells also only 
delayed the appearance of Foxp3+ Tregs in neonatal mouse thymus, however, beginning 1 
week after birth, the same TβRI-mutant mice showed accelerated expansion of thymic 
Tregs (42). The proportion of Tregs in mice devoid of TNFR2 or its ligand reduced by 
~50% in both thymus and periphery. These data suggest that multiple factors, including 
TNF-TNFR2 signaling, contribute to the thymic generation and peripheral homeostasis of 
Tregs. Recently, Cuss and Green reported that thymic Tregs actually were heterogeneic and 
contained resident Tregs and newly developed Tregs. They proposed that resident Tregs 
were IL-2 dependent for their homeostasis, whereas newly developed Tregs were not (43). 
Further study is warranted to determine which subset of thymic Tregs is defective in mouse 
strains deficient in TNFR2 or its ligands, as well as in Il2-/- or Il2ra-/- and T RI-/- mice.       
In conclusion, TNFR2 is a key factor in maintaining sustained Foxp3 expression and 
function of Tregs contributing to immune regulation in the inflammatory environment, 
which may explain why anti-TNF therapy fails or even at times exacerbates some 
autoimmune disorders (44). This should be taken into account when designing future 
therapy of autoimmunity by using TNF inhibitors.   
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Abstract 
Our previous study showed that TNFR2 is preferentially expressed by CD4+FoxP3+ 
regulatory T (Treg) cells and expression of this receptor identified maximally suppressive 
Treg cells. TNFR2 is also expressed by a small fraction of CD4+FoxP3- conventional T 
(Tconv) cells in normal mice and its expression is up-regulated by T cell activation. This 
raises questions concerning the role of TNFR2 signaling in the function of Tconv cells. In 
this study, by using FoxP3/gfp KI mice, we showed that TNFR2 signaling did not induce 
FoxP3- CD4 cells to become suppressive. Ki-67, a marker of proliferation, was 
concomitantly expressed with TNFR2 by CD4 cells, independent of FoxP3 expression, in 
both normal mice and Lewis Lung Carcinoma (LLC)-bearing mice. TNFR2 is associated 
with greater suppressive functions when expressed by Treg cells and is associated with 
greater resistance to suppression when expressed by Tconv cells. In mice bearing 4T1 
breast tumor or LLC, intratumoral Tconv cells expressing elevated levels of TNFR2 
acquired the capacity to resist suppression by LN-derived Treg cells. However, they 
remained susceptible to inhibition by more suppressive tumor infiltrating Treg cells which 
expressed higher levels of TNFR2. Our data indicate that TNFR2 also co-stimulates Tconv 
cells. However, intratumoral Treg cells expressing more TNFR2 are able to overcome the 
greater resistance to suppression of intratumoral Tconv cells, resulting in a dominant 
immunosuppressive tumor environment.  
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Introduction 
Naturally arising CD4+FoxP3+ regulatory T (Treg) cells, comprising ~10% of peripheral 
CD4+ T cells, play an important role in preventing immunopathology by suppressing 
immune responses to autoantigens (1). However, they also attenuate natural and induced 
immune responses against tumor antigens and therefore represent a mechanism by which 
tumors evade immune destruction (2). It has been reported that the intratumoral removal or 
inactivation of Treg cells enhanced anti-tumor immunity and resulted in eradicating 
advanced tumors (3-4), suggesting that the suppression of anti-tumor immunity by Treg 
cells occurs predominantly at the tumor site. Intratumoral CD4+ effector T cells are crucial 
helpers of cytotoxic CD8 cell-mediated antitumor effect (5-6). Therefore, the balance 
maintained by Treg and Tconv subsets of CD4 cells in the tumor microenvironment is 
likely to determine whether the host immune responses evoked by tumor antigen results in 
tolerance or anti-tumor responses.  
TNFR2 has co-stimulatory function and enhances the responses of lymphocyte to TCR-
mediated signaling (7-9). Our previous study revealed that TNFR2 identifies a subset of 
Treg cells with maximally suppressive capacity in normal mouse lymphoid tissue. 
Furthermore, tumor infiltrating Treg cells were characterized by a high level of TNFR2  
expression and markedly enhanced suppressive activity (10), presumably activated by TNF, 
a major proinflammatory mediator in the tumor microenvironment (11). We and other have 
reported that, in both human and mouse resting CD4 cells, TNFR2 is predominantly 
expressed by Treg cells (10, 12-13). Although only a minor fraction of normal mouse 
CD4+CD25- Tconv cells express TNFR2, their expression of this receptor was also up-
regulated in the tumor environment (10) or upon activation by in vitro TCR stimulation 
(14). Thus, endogenous TNF present in the tumor environment may also co-stimulate 
Tconv cells through TNFR2. It is crucial to further define the effect of the intratumoral co-
stimulatory TNF-TNFR2 pathway on Tconv cells and Treg cells, since both TNF and anti-
TNF have been used to treat cancer (11).    
We report our novel observations that intratumoral Tconv cells with enhanced TNFR2 
expression exhibited an activated phenotype and acquired the capacity to completely resist 
the suppressive effects of lymph node (LN)-derived Treg cells. However, intratumoral Treg 
cells expressed much higher level of TNFR2 and retained the capacity to markedly suppress 
intratumoral Tconv cells and consequently resulted in a dominant immunosuppressive 
tumor environment.  
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Material and methods 
Mice, cells and reagents. Female wild type 8 to 12 wk old C57BL/6, Balb/c mice were 
provided by the Animal Production Area of the NCI (Frederick, MD). FoxP3/gfp KI mice 
were kindly provided by Dr. Yasmine Belkaid at Laboratory of Parasitic Diseases, NIAID, 
NIH, and maintained in the Animal Production Area of the NCI (Frederick, MD). NCI-
Frederick is accredited by AAALAC International and follows the Public Health Service 
Policy for the Care and Use of Laboratory Animals. Animal care was provided in 
accordance with the procedures outlined in the "Guide for Care and Use of Laboratory 
Animals" (National Research Council; 1996; National Academy Press; Washington, D.C.). 
C57BL/6-derived Lewis lung carcinoma (LLC) cell line and Balb/c-derived 4T1 breast 
tumor cell line were obtained from ATCC. Antibodies (Abs) purchased from BD 
Biosciences (San Diego, CA) consisted of anti-CD3 (145-2C11), CD4 (GK1.5), anti-CD25 
(PC61), CD45RB (16A), CD62L (MEL-14), CD44 (IM4), CD69 (H1.2F3), CD103 
(M290), TNFR2 (TR75-89), CTLA4 (UC10-4F10-11), CD16/CD32 (2.4G2) and Ki-67 
(B56). Functional grade purified anti-mouse CD3e Ab (eBio500A2), Foxp3 Staining Set 
(FJK-16s) and GITR (DTA-1) Abs were purchased from eBioscience (San Diego, CA). 
Anti-mouse CD120b (TR75-89) Ab was from AbD SeroTec (Kidlington, Oxford, UK).  
Mouse tumor inoculation and separation of tumor infiltrating lymphocytes (TILs). LLC 
tumor cells were inoculated subcutaneously in the right flank of C57BL/6 mice in a single 
cell suspension of 500,000 cells in 0.1 ml PBS per mouse. 4T1 tumor cells were injected 
into both left and right mammary fat pads (thoracic #2 mammary glands) of recipient 
Balb/c mice in single cells suspension with 100,000 cells in 0.1 ml PBS per mouse. After 
two weeks, tumors were excised, minced and digested in RPMI 1640 supplemented with 1 
mg/ml collagenase IV and 0.1 mg/ml DNase I. The fragments were pushed through a 70-µm 
pore size cell strainer to create a single-cell suspension. After density centrifugation of 
40%-80% percoll, lymphocytes enriched interphase was collected, washed and stained with 
antibody for flow cytometry purification of TIL Treg cells. In some experiments, LLC 
tumor bearing mice were sacrificed at day 1, 5, 10 and 15 after inoculation of tumor cells, 
and Tregs present in the lymphoid tissues and TILs were analyzed.        
Cell purification. CD4 subsets were purified and pooled from spleen and lymph nodes 
(inguinal, axillary and mesenteric regions) or TILs using Cytomation MoFlo cytometer 
(Fort Collins, CO), yielding a purity of ~98% for both subsets. T-depleted spleen cells were 
used as APCs and were prepared by depletion of CD90+ cells with anti-mouse CD90 
MicroBead and LD column (Miltenyi Biotec Inc.). APC were irradiated with 3000 R.  
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In vitro T cell proliferation assay. CD4+CD25- T cells and CD4+CD25+ T cells from tumor 
bearing mouse LNs or tumor infiltrating lymphocytes, or CD4+FoxP3/gfp+ and  
CD4+FoxP3/gfp- cells, with or without TNFR2 expression, were flow-sorted. The sorted 
cells were cultured alone or co-cultured at the desired ratio in a U-bottom 96-well plate in a 
medium with 2×105 APCs/well plus 0.5 μg/ml of soluble anti CD3 Ab. Cells were pulsed 
with 1 µCi [3H]thymidine (Perkin Elmer Life Sciences, Boston, MA) per well for the last 6 
h of the culture period. In some experiments, CD4+FoxP3/gfp+ Tregs were co-cultured with 
freshly isolated CD4+FoxP3/gfp-TNFR2- Tconv cells, or added to CD4+FoxP3/gfp-TNFR2- 
Tconv cells which were pre-activated with APCs (2×105 APCs/well) and anti-CD3 
(0.5 μg/ml) for 24 hours. In some experiments, flow-sorted CD4+CD25-TNFR2- Tconv 
cells from normal Balb/c mice were cultured with 2-fold APCs and anti-CD3 (0.5 μg/ml) 
for 72 h. The cells were flow-sorted into TNFR2+ and TNFR2- fractions. The re-sorted cells 
(2.5×104 cells/well) were cultured alone or co-cultured with freshly isolated Tregs at a 
desired ratio. The cells were stimulated with APCs (2×105 APCs/well) and anti-CD3 Ab 
(0.5 μg/ml). After incubation for 72 h, the proliferation was determined by [3] thymidine 
incorporation assay. IFNγ levels in the cell culture medium were determined by 
SearchLight Mouse Cytokine Array (Pierce Biotechnology, Woburn, MA). 
Flow Cytometry. After blocking FcR, cells were incubated with appropriately diluted 
antibodies. Acquisition was performed using a FACSort or a SLRII (BD Biosciences, 
Mountain View, CA) and data analysis was conducted using FlowJo software (Tree Star 
Inc., Ashland, OR).  
Statistical analysis. Comparison of data was analyzed by two-tailed Student’s t test using 
Graphpad Prism 4.0. 
Results 
Both TNFR2-expressing Treg cells and Tconv cells in normal mice are more proliferative 
To date, FoxP3 remains the best marker to identify mouse Treg cells (15). Some of the 
FoxP3+ Treg cells are CD25- even in the normal mice (10). We therefore further defined the 
relationship of the expression of TNFR2 to FoxP3 expression by CD4 cells in normal 
C57BL/6 mice and FoxP3/gfp KI mice. Our current data corroborate our previous 
observations showing the greater TNFR2 expression on CD4+CD25+ Treg cells (10, 14). As 
shown in Figure 1A, TNFR2 was preferentially expressed by 47% of unstimulated FoxP3+ 
splenic CD4 cells, while only ~4% of resting FoxP3- CD4 cells expressed low levels of 
TNFR2. Treg cells, which can be unequivocally identified by GFP expression in FoxP3/gfp 
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KI mice, showed a similar pattern of TNFR2 expression on CD4 subsets from wild type 
mice: 45.9% of FoxP3/gfp+ cells were TNFR2 expressing cells, and only 6.4% of 
FoxP3/gfp- CD4 cells expressed TNFR2 (data not shown).  
TNFR2 has co-stimulatory functions which markedly enhances the activation of 
lymphocytes by TCR signals (7-9). This led us to hypothesize that TNFR2-expressing Treg 
cells and Tconv cells are likely to be more proliferative. We therefore assayed for Ki-67 
expression because Ki-67 is exclusively expressed by proliferating cells (16). Furthermore, 
Ki-67hi CD4 cells are reported to express an increased level of TNFR2 (17). Consistent with 
this observation, normal C57BL/6 mouse splenic CD4+FoxP3+ cells with higher expression 
of TNFR2 comprised 2-fold higher Ki-67+ cells (24%) than CD4+FoxP3- cells (12%). In 
LNs from inguinal and axillary regions, 16.2% of CD4+FoxP3+ cells were Ki-67+ cells, 
compared with 6.5% of CD4+FoxP3- cells, although the overall Ki-67 levels were lower 
Figure 1. Concomitant expression of 
TNFR2 and Ki-67 by CD4 subsets from 
normal mice. (A) Spleen cells from 
normal C57BL/6 mice were stained with 
anti CD4, TNFR2 and FoxP3 Abs. The 
expression of TNFR2 by CD4+FoxP3+ and 
CD4+FoxP3- cells was analyzed by FACS. 
(B) Spleen cells and axillary and inguinal 
LN cells from normal C57BL/6 mice were 
stained with anti CD4, Ki-67 and FoxP3 
Abs. The expression of Ki-67 and FoxP3 
was analyzed with FACS by gating on 
CD4. (C) Spleen cells from normal 
C57BL/6 mice were stained with anti 
CD4, TNFR2, FoxP3 and Ki-67 Abs. The 
expression of Ki-67 by FoxP3-TNFR2+, 
FoxP3-TNFR2-, FoxP3+TNFR2- and 
FoxP3+TNFR2+ subsets was analyzed with 
FACS by gating on CD4 cells. Numbers 
indicate the percentage of cells in the 
respective quadrant. Data shown are 
representatives of at least three separate 
experiments with similar results.  
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than in splenocytes (Fig 1B). The Ki-67+ cells in the FoxP3+ splenic CD4 subset were 
largely present in the TNFR2+ subset (26%). Although a low level of Ki-67 was expressed 
in the population of FoxP3- CD4 cells, 28% of the TNFR2-expressing cells in this subset 
also were Ki-67+ cells. In contrast, only 14% and 9.7% of Ki-67+ cells were present in 
TNFR2 negative FoxP3+ and FoxP3- CD4 cells respectively (Fig 1C). Thus, Tregs and 
Tconv cells in normal mouse lymphoid tissues exhibited concomitant expression of TNFR2 
and Ki-67. 
TNFR2+ Treg cells potently inhibited proliferation of more resistant TNFR2+ Tconv cells  
We next sought to determine whether TNFR2+ Tconv cells may be more resistant to 
suppression by Treg cells, by taking the advantage of FoxP3/gfp KI mice which allows 
purification of viable FoxP3+ Treg subsets based on GFP expression. First, we confirmed 
our previous observation that the suppressive capacity of TNFR2+ Tregs were considerably 
greater than those of TNFR2- Tregs over various ratios of Tconv:Treg (P<0.001~0.05, Fig 
2A, C) or of unfractionated Tregs (CD4+FoxP3/gfp+ cells) which usually consist of ~40% 
of TNFR2+ cells (p<0.01, Fig 2C). In fact, unfractionated Tregs were more suppressive than 
Figure 2. Suppressive activity of CD4 subsets from 
FoxP3/gfp KI mice. Flow-sorted CD4+FoxP3/gfp-TNFR2- cells 
(Tconv cells), 5×104 cells/well, were cultured alone or co-
cultured with flow-sorted CD4+FoxP3/gfp+TNFR2+ or 
CD4+FoxP3/gfp+TNFR2- cells (A), or CD4+FoxP3/gfp+TNFR2+ 
or CD4+FoxP3/gfp-TNFR2+ cells (B) from FoxP3/gfp KI mice, 
at a ratio of 10:2, 10:5 and 10:10 (Tconv cells: Treg cells). In 
other experiment, 2.5×104 cells/well of CD4+FoxP3/gfp-TNFR2- 
cells (Tconv) were cultured alone or co-cultured at ratio of 1:1 
with CD4+FoxP3/gfp+TNFR2+ (TNFR2+ Tregs), or 
CD4+FoxP3/gfp+TNFR2- cells (TNFR2- Tregs), or 
unfractionated CD4+FoxP3/gfp+ cells (Total Tregs) (C). The cells 
were stimulated with APCs (2×105 cells/well) and anti-CD3 (0.5 
µg/ml) for 72 hours. Proliferation was measured by 
[3H]thymidine incorporation. Comparison of proliferation of co-
cultures including FoxP3/gfp+TNFR2+ with co-cultures 
including FoxP3/gfp+TNFR2- cells in (A), * p<0.05; ** p<0.01. 
Comparison of proliferation of indicated co-cultures in (C), ** 
p<0.01, ***p<0.001. Data (mean ± SD, N=3) shown are 
representatives of at least 3 separate experiments with similar 
results.  
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TNFR2- Tregs (p<0.01, Fig 2C). In 
contrast, TNFR2-expressing FoxP3/gfp- 
CD4 cells did not have any suppressive 
activity at all (Fig 2B), indicating that 
TNFR2 by itself was not a specific 
indicator of CD4 suppressive cells. 
Therefore, the suppressive activity of 
CD4+CD25-TNFR2+ T cells present in 
normal C57BL/6 mice (10) was solely 
attributable to the more highly 
suppressive subset of TNFR2+FoxP3+ 
cells present in this CD4+CD25- 
subpopulation.  
Furthermore, TNFR2+ Treg cells 
Figure 3. TNFR2+ Tconv cells are resistant to Treg-
mediated inhibition. TNFR2- Tconv cells 
(CD4+FoxP3/gfp-TNFR2-) (left) or TNFR2+ Tconv cells 
(CD4+FoxP3/gfp-TNFR2+) (right), 5×104 cells/well, were 
cultured alone or co-cultured with TNFR2+ Treg cells 
(CD4+FoxP3/gfp+TNFR2+) or TNFR2- Treg cells 
(CD4+FoxP3/gfp+TNFR2-) at a ratio of 1:1. The cells 
were stimulated with APCs (2×105 cells/well) and anti-
CD3 (0.5 µg/ml) for 72 hours. Proliferation was 
measured by [3H]thymidine incorporation. (B) IFNγ 
levels in TNFR2- and TNFR2+ Tconv cells which were 
cultured alone with same condition as in (A). 
Comparison of two gropus, *** p<0.001. (C) Flow-
sorted CD4+FoxP3/gfp+TNFR2- Tconv cells, fresh 
isolated (left) or cultured with APCs (2×105 cells/well) 
and anti-CD3 (0.5 µg/ml) for 24 hours were stained with 
anti CD4 and TNFR2 Abs. Expression of TNFR2 was 
analyzed by gating on CD4 cells. (D) Flow-sorted 
CD4+FoxP3/gfp+TNFR2- Tconv cells, fresh isolated (left) 
or cultured with APCs (2×105 cells/well) and anti-CD3 
(0.5 µg/ml) for 24 hours, were cultured alone or co-
cultured at 1:1 ratio with flow-sorted Tregs. The cells 
were stimulated with APCs and anti CD3 Ab for 72 
hours. Proliferation was measured by [3H]thymidine 
incorporation. Comparision of proliferation of 
Treg/Tconv co-cultures with that of Tconv culture alone, 
* p<0.05. (E) Flow-sorted CD4+CD25-TNFR2- Tconv 
cells from normal Balb/c mice were cultured with 2-fold 
APCs and anti CD3 Ab (0.5 μg/ml). After 72 h 
incubation, the cells were flow-sorted into TNFR2+ and 
TNFR2- fractions. The re-sorted cells (2.5×104 cells/well) 
were cultured alone or co-cultured with freshly isolated 
CD4+CD25+ Tregs at a ratio of 2:1 (Teffs: Tregs). 
Freshly flow-sorted CD4+CD25-TNFR2- Tconv cells 
were used as a comparison. The cells were stimulated 
with APCs (2×105 cells/well) and anti-CD3 Ab (0.5 
μg/ml) for 72 h, and proliferation was determined by 
[3]H thymidine incorporation assay. Percent inhibition 
(%) was shown. Comparison of two groups, * p<0.05. ns 
= not significant. Data in (A, B, D and E) stand for mean 
± SD (N=3). Data shown are representatives of at least 3 
separate experiments with similar results.  
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potently inhibited proliferation of both TNFR2- and TNFR2+ Tconv cells. In contrast, 
although TNFR2- Treg cells exerted a weaker but detectable inhibitory effect on TNFR2- 
Tconv cells, this subset of Treg cells had no suppressive activity when co-culture with 
TNFR2+ Tconv cells (Fig 3A). Upon stimulation with APC and anti-CD3, these more 
resistant TNFR2+ Tconv cells produced ~5-fold more INFγ than TNFR2- Tconv cells 
(p<0.001, Fig 3B), indicating that TNFR2+ Tconv cells were more activated.  Thus, TNFR2 
expression on Tconv cells enhances their capacity to resist Treg-mediated suppression, 
however, they were still susceptible to suppression by TNFR2-expressing Treg cells.   
This led us to hypothesize that induced expression of TNFR2 on Tconv cells would render 
them refractory to suppression by Tregs. To test this, we activated flow-sorted 
CD4+FoxP3/gfp-TNFR2- cells with APC and anti-CD3 for 24 hours and found their 
expression of TNFR2 to be markedly up-regulated (Fig 3C). Unfractionated Tregs 
(CD4+FoxP3/gfp+) lost their capacity to inhibit the proliferation of these pre-activated 
Tconv cells (Fig 3D, right).  In contrast, unfractionated Tregs potently inhibited the 
proliferation of unactivated TNFR2- Tconv cells (p<0.05, Fig 3D, left).  
We further investigated whether only TNFR2-expressing Tconv cells acquired the Treg-
resistant capacity or all pre-activated Tconv cells developed this property. To provide a 
definite answer to this question, we re-sorted pre-activated Tconv cells based on their 
TNFR2 expression and studied their responses to Tregs. Since our previous study showed 
that Tconv cells from Balb/c mice were more susceptible to inhibition by Tregs, as 
compared with Tconv cells from C57BL/6 mice (18), and we used Tconv cells from this 
mouse strain to examine the induction of Treg-resistance. First, we isolated CD4+CD25-
TNFR2- cells from LNs and spleens of normal Balb/c mice by FACS cell sorting and the 
cells were stimulated with APCs and anti-CD3 Ab. After three days culture, ~30% of cells 
became TNFR2-expressing cells, which confirmed our previous report (14). The cells were 
re-sorted into TNFR2+ and TNFR2- fractions, and their responses to Tregs were assessed by 
co-culturing them with freshly isolated CD4+CD25+ Tregs from normal Balb/c mice. As 
shown in Fig 3E, re-sorted TNFR2+ Tconv cells were markedly more resistant than re-
sorted TNFR2- Tconv cells to suppression of proliferation by Tregs (P<0.05). Interestingly, 
re-sorted TNFR2- Tconv cells were as susceptible as freshly isolated TNFR2- Tconv cells to 
suppression by freshly isolated Tregs (P>0.05), indicating that the enhanced Treg-resistant 
capacity of activated Tconv cells was exclusively restricted to Tconv cells which were 
induced to express TNFR2. Thus, induced expression of TNFR2 on Tconv cells by TCR 
stimulation also enhanced their resistance to Tregs.  
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TNFR2+ Tregs and Tconv cells in draining LNs are more proliferative than in non-dLNs in 
tumor-bearing mice  
Our previous data showed that tumor infiltrating Tregs and Tconv cells expressed a high 
levels of TNFR2 (10), indicating they were highly proliferating cells. We therefore further 
compared Ki-67 expressed by FoxP3+ and FoxP3- subsets of CD4 cells present in the 
spleen, draining LNs (dLN) and non-draining LNs (ndLN) of mice inoculated with LLC 
tumor cells for 15 days when the average tumor volume reached 301.6 mm3 (N=6).  As 
shown in Fig 4A, the proportion of Ki-67+ cells in both FoxP3+ and FoxP3- CD4 subsets 
was not increased in the spleen and non-dLN of tumor-bearing mice. As expected, FoxP3+ 
cells in the dLNs were more proliferative than in the ndLNs, as evidenced by their higher 
level of Ki-67+ cells (p<0.01, Fig 4A, C). In contrast, the increase in Ki-67+ cells in FoxP3- 
CD4 subsets present in the dLN did not differ from ndLN (P>0.05, Fig 4A, C). Thus, the 
proliferation of Treg cells in the tumor dLN is more robust than that of Tconv cells. 
Furthermore, 50~60% of TNFR2+FoxP3+ cells in dLNs were Ki-67+, which was higher 
(p<0.01) than 20~30% of Ki-67+ cells in ndLNs (Fig 4B, C). Similarly, the percentage of 
Ki-67+ cells in FoxP3-TNFR2+ population, was higher (p<0.05) in the dLN (40~50%) than 
in ndLNs (20~30%, Fig 4B, C).  In contrast, the proportion of Ki-67+ cells in FoxP3+ and 
FoxP3- subsets lacking TNFR2 expression each remained at an equally low level (<10%) in 
the dLNs and ndLNs (P>0.05, Fig 4B, C). We also examined the cellular numbers in the 
spleen, non-dLNs and dLNs. As shown in Table I, the total cellularity in the dLNs 
(34.8×106/mouse on average) was 4-fold greater than in the non-dLNs (8.5×106/mouse on 
average, p<0.001). The proportion of FoxP3+ Tregs in the dLNs was actually more reduced 
(p<0.05) than in non-dLNs, this was presumably due to the increase in other cell type in the 
dLN, since the proportion of FoxP3+ cells in the CD4 subset of dLN cells were not 
decreased (data not shown). It is relevant that, the number of FoxP3+ Tregs in the dLNs 
(1.22×106/mouse on average) was almost 3-fold greater than in the non-dLNs 
(0.41×106/mouse on average, p<0.001). Consistent with the increase in Ki-67+ cells in the 
dLN (Fig 4), the number of Ki-67+ cells (0.37×106/mouse on average) was 4.6-fold greater 
than in the non-dLN (0.08×106/mouse on average, p<0.001). Thus, both the percentage and 
number of Ki-67+ Tregs were increased in the dLN of tumor bearing mice.  
After subcutaneous inoculation of LLC tumor cells into syngeneic C57BL/6 mice, the 
tumor developed over time and the average tumor weight was 25.8±7.3 mg, 88.1±38.0 mg  
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Figure 4. Expression of Ki-67 by CD4 subsets in the lymphoid organs of tumor bearing mice. Spleen 
cells, or non-draining LNs (non-dLNs, left side inguinal and axillary LNs), or draining LNs (dLN, right 
side inguinal and axillary LNs) from mice inoculated with LLC tumor cells for 15 days were stained with 
anti CD45, CD4, FoxP3, Ki-67 and TNFR2 Abs. (A) Expression of Ki-67 by FoxP3- and FoxP3+ cells 
were analyzed by gating on CD45+CD4+ cells. (B) Expression of Ki-67 by FoxP3-TNFR2+, 
FoxP3+TNFR2+, FoxP3+TNFR2- and FoxP3-TNFR2- CD4 subsets present in spleen, Non-dLNs and dLNs 
were analyzed by gating on respective populations. Data shown in (A~B) are representatives of at least 
three separate experiments with similar results. Numbers in the dot plots indicate the percentage of cells in 
the respective quadrant. (C) Comparison of Ki-67 expression by CD4 subset present in non-dLN and dLN 
of tumor-bearing mice, *p<0.05, **p<0.01. Data (means ± SD) shown in (C) are summarized from three 
separate experiments with similar results (N=9). (D) Kinetic expression of Ki-67 by FoxP3+ Tregs and 
TNFR2+FoxP3+ Tregs present in dLNs of mice inoculated with LLC tumor cells for 0, 1, 5, 10 and 15 
days. Compared with tumor free mice (day 0), ** p<0.01. Data (means ± SD) shown in (D) are 
summarized from two separate experiments with similar results (N=6).  
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and 267.4±92.3 mg on day 5, day 10 and day 15 after tumor inoculation (N=6), respectively. 
We further examined the kinetics of Ki-67+ Tregs in the dLN over this period of tumor 
development. The proportion of Ki-67+ cells present in the total FoxP3+ Tregs was 
markedly increased beginning by day 15, and by day 10 in the TNFR2+FoxP3+ subset of 
Tregs, respectively (p<0.01, Fig 4D). Nevertheless, at the earlier stage of tumor 
development, e.g., day 5 of tumor inoculation, the proportion of Ki-67+ Tregs present in the 
dLNs was not different from that in the LNs in the same region of tumor free mice (day 0, 
p>0.05).  
Both TNFR2+ Treg and Tconv subsets of tumor infiltrating lymphocytes (TILs) are more 
proliferative  
To determine the relationship between TNFR2 expresssion and proliferation by Tconv cells 
and Tregs in TILs, we assessed Ki-67 and TNFR2 expression by FoxP3+ and FoxP3- CD4 
TILs in C57BL/6 mice inoculated with LLC tumor cells at 15 days, at a stage of full tumor 
development. As shown in Fig 5A, 88.1% of FoxP3+ cells present in CD4 TILs were 
TNFR2+ cells, while only 52.8% of splenic FoxP3+ cells expressed TNFR2. TNFR2-
expressing FoxP3- CD4 TILs were 40.3%, while only 7% of splenic FoxP3- Tconv cells 
were TNFR2+. Similarly, 84.7% and 48.8% of FoxP3+ and FoxP3- TIL CD4 cells expressed 
Ki-67, respectively. In comparison, 22.4% and 12% of FoxP3+ and FoxP3- splenic CD4 
cells were Ki-67-expressing cells (Fig 5B). Similar data were also observed in LLC-bearing 
FoxP3/gfp KI mice and 4T1 mammary tumor-bearing Balb/c mice (data not shown). These 
data clearly show that TNFR2 expression by both FoxP3+ and FoxP3- CD4 cells in tumors 
Figure 5. Tumor infiltrating FoxP3+ and 
FoxP3- subsets of CD4 cells up-regulated their 
TNFR2 expression and were actively 
replicating. Spleen cells and TILs from 
C57BL/6 mice inoculated with LLC tumor cells 
for 15 days were stained with anti CD45, CD4, 
FoxP3 and Ki-67 Abs or isotype control Abs. (A) 
The expression of TNFR2 by FoxP3- cells and 
FoxP3+ cells were analyzed by gating on 
CD45+CD4+ cells; (B) The expression of Ki-67 
by FoxP3- cells and FoxP3+ cells were analyzed 
by gating on CD45+CD4+ cells. Numbers 
indicate the percentage of cells in the respective 
quadrant. Data shown are representatives of at 
least three separate experiments with similar 
results. 
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was markedly increased, however, more of the FoxP3+ Treg cells expressed TNFR2 and 
TNFR2 expression levels on Treg cells were much higher on a per cell basis than on FoxP3- 
Tconv cells, consistent with their Ki-67 expression.    
We also determined the Ki-67 expression by TIL Tregs and Tconv cells at an earlier stage 
of day 5 after tumor cells inoculation. As shown in Fig 6A, at this stage, the proportion of 
Ki-67+ cells in both FoxP3+ and FoxP3- CD4 subsets present in the spleen, non-dLN and 
dLN was not increased, as compared with that in tumor free mouse (Fig 6A). Nevertheless, 
the proportion of FoxP3+ cells in CD4 TILs was greater than 40%. Furthermore, 49.4% of 
FoxP3- and 87.2% of FoxP3+ CD4 TILs expressed Ki-67 (Fig 6B). Thus, there was a ~2-
fold greater number of Ki-67+ cells in the FoxP3+ subset of TILs than in the FoxP3- subset 
of TILs at both day 5 and day 15 of tumor cell injection, suggesting that Treg cells in the 
tumor are more replicative and have a higher turnover than Tconv cells. 
Tumor infiltrating Treg cells as well as Tconv cells have an activated phenotype 
The enhanced expression of TNFR2 and Ki-67 by tumor infiltrating Treg cells and Tconv 
cells suggests they might have an activated phenotype. Isolation of Treg cells in wild type 
Figure 6. The expression of Ki-67 by FoxP3+ and FoxP3- subsets of CD4 cells in the lymphoid tissues 
and TILs from mice with early tumor development.  Spleen cells, non-dLN, dLN cells and TILs from 
C57BL/6 mice inoculated with LLC tumor cells for 5 days were stained with anti CD45, CD4, FoxP3 and 
Ki-67 Abs. The expression of Ki-67 by FoxP3- and FoxP3+ cells were analyzed by gating on CD45+CD4+ 
cells. (A) lymphoid tissues; (B) TILs. Numbers indicate the percentage of cells in the respective quadrant. 
Data shown are representatives of two separate experiments with similar results. 
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mice is usually based on CD25 expression. We therefore compared the phenotype of 4T1 
tumor infiltrating CD4+CD25+ cells and CD4+CD25- cells from mice inoculated with tumor 
cells for 15 days. CD4+CD25+ cells in tumor-free Balb/c mouse LNs consisted of 93% of 
FoxP3+ cells, while only ~2% of CD4+CD25- cells expressed FoxP3 (Fig 7A). 90% of 
CD4+CD25+ TILs expressed FoxP3. In comparison, 10% of CD4+CD25- TILs were FoxP3+ 
(Fig 7A). Thus in 4T1 tumor, proportion of FoxP3+ cells in CD4+CD25- population was  
Figure 7. Phenotype of CD25+ and CD25- subsets of tumor infiltrating CD4 cells from 4T1 tumor bearing 
mice. (A) LN cells from normal Balb/c mice or 4T1 tumor TILs were stained with anti CD45, CD4, CD25 and 
FoxP3 Abs. The expression of FoxP3 was analyzed by FACS, gating on CD4+CD25+ cells (grey histogram) or 
gating on CD4+CD25- cells (solid line histogram, upper panel). The relationship of CD25 and FoxP3 expression 
on CD4 cells present in the control LN cells and in the TILs was shown in the dot plot (lower panel). (B) 
Expression of FoxP3 by total CD4 cells from tumor free Balb/c mouse LN cells (solid line histogram) or by 
tumor infiltrating CD4 cells from 4T1 tumor bearing mice (grey histogram) was analyzed by FACS, gating on 
CD4+ cells (upper). The percentage (%) and MFI of FoxP3+ cells in the CD4 population present in control LNs 
and in the TILs were shown in the lower panel. Data shown are Means ± SD (N=3). Comparison of two groups, 
*p<0.05, ** p<0.01. (C) Splenocytes from tumor free Balb/c mice (solid line histogram) and TILs from 4T1 
tumor bearing mice (grey histogram) were stained with anti CD45, CD4, CD25 and phenotypic markers 
(CD45RB, CD62L, CD44, CD69, CTLA-4 and GITR). Expression of phenotypic marker was analyzed by 
FACS, gating on CD4+CD25+ cells (left panel) or CD4+CD25- cells (right panel). Isotype controls were shown by 
dashed line histogram. Data shown are representatives of three separate experiments with similar results.      
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Figure 8. Tumor infiltrating Treg cells potently inhibit tumor infiltrating Tconv cells. (A~B) 
Proliferative responses of Tconv cells: FACS-sorted CD4+CD25- cells from LNs of tumor free or from 
TILs of 4T1 tumor bearing Balb/c mice (A), or from LNs of tumor free or from TILs of LLC-bearing 
C57BL/6 mice (B) were cultured at 2.5×104 cells/well. The cells were stimulated with APCs (2×105 
cells/well) and anti-CD3 for 72 h. Proliferation was measured by [3]thymidine incorporation. (C~D) 
Proliferative responses of Treg cells: FACS-sorted CD4+CD25+ cells from LNs of tumor free or from 
TILs of 4T1 tumor bearing Balb/c mice (C), or from LNs of tumor free or LLC-bearing C57BL/6 mice 
(D) were cultured at 2.5×104 cells/well. The cells were stimulated with APCs (2×105 cells/well) and 
anti-CD3 for 72 h. Proliferation was measured by [3]thymidine incorporation. (E~F) Suppressive 
activity of Treg cells: flow-sorted CD4+CD25- cells (2.5×104 cells/well) from TILs of 4T1 tumor 
bearing Balb/c mice were cultured alone or co-cultured with same number of CD4+CD25+ cells from 
LNs of tumor free or TILs of 4T1 tumor-bearing Balb/c mice (E),  or CD4+CD25- cells (2.5×104 
cells/well) from TILs of LLC tumor bearing C57BL/6 mice were cultured alone or co-cultured with 
same number of CD4+CD25+ cells from LNs of tumor free or TILs of LLC tumor-bearing C57BL/6 
mice (F). The cells were stimulated with APCs (2×105 cells/well) and anti-CD3 for 72 h. Proliferation 
was measured by [3]thymidine incorporation. Data (mean ± SD, N=3) shown are representatives of at 
least three separate experiments with similar results.    
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increased, as compared with cells from LNs. The proportion of FoxP3+ cells in CD4 TILs 
and the intensity of FoxP3 expression by TIL CD4 cells was greater than that of LN CD4 
cells from tumor free mice (p<0.01 and p<0.05, respectively, Fig 7B), this presumably 
resulted from stimulation by TNF, which has the capacity to increase the expression level 
of FoxP3 by Treg cells on a per cell basis (14). Our results differ from those in a previous 
report showed that Treg cells in 4T1 tumor at a later stage by day 28 after tumor inoculation 
expressed a lower level of FoxP3 expression (5), the reason for this discrepancy will be 
addressed in a future study. 
Consistent with our previous results that TNFR2+ Treg cells in the normal mouse had an 
activated phenotype, CD4+CD25+ TILs also exhibited a lower level of CD62L, higher 
levels of CD44, CD69, CTLA-4 and GITR, as compared with LN CD4+CD25+ cells from 
tumor free mice. Moreover, TIL CD4+CD25- T cells also exhibited an activated phenotype, 
as evidenced by lower levels of CD45RB, CD62L and increased levels of CD44, CTLA-4 
and GITR than CD4+CD25- T cells from tumor free mouse LNs (Fig 7C). Therefore, tumor 
infiltrating Tconv cells are also activated at the tumor site.  
Tumor infiltrating Tconv cells are refractory to suppression by LN Tregs, but remain 
susceptible to inhibition by TIL Tregs 
Next we compared the TCR dependent proliferative responses of tumor infiltrating Treg 
cells and Tconv cells. CD4+CD25- TILs from both 4T1 tumor or LLC tumor exhibited 
lower proliferative responses upon APC/anti-CD3 stimulation than CD4+CD25- T cells 
from LNs (p<0.01~0.05, Fig 8A~B). In contrast, CD4+CD25+ TILs from both 4T1 and LLC 
tumors exhibited an greater proliferative response to APC/anti-CD3 stimulation than the 
hyporesponssive CD4+CD25+ cells from tumor free mouse LNs (Fig 8C~D). Interestingly, 
although CD4+CD25- TILs from both 4T1 and LLC tumors exhibited attenuated 
proliferative responses to TCR stimulation, unlike CD4+CD25- responder cells from tumor 
free Balb/c and C57BL/6 mice (18), they resisted suppression by CD4+CD25+ cells from 
tumor free mouse LNs at a ratio of 1:1 (Figure 8E~F). Thus, consistent with their elevated 
levels of TNFR2 and Ki-67, TIL Tconv cells were more resistant to suppression by LN-
derived Tregs. Nevertheless, when co-cultured at 1:1 ratio, CD4+CD25+ TILs from both 
4T1 and LLC tumors exhibited a potent suppressive effect on the proliferation of tumor 
infiltrating CD4+CD25- cells (Fig 8E~F). Therefore, in the tumor environment, the 
functional capabilities of both Treg cells and Tconv cells were altered, but Treg-mediated 
suppression still remained dominant over the more resistant Tconv TIL cells.      
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Discussion 
The failure of Treg cells to proliferate after TCR stimulation in vitro initially led to their 
classification as naturally anergic cells. Our data show that FoxP3+ CD4 cells actually 
expressed higher frequency of Ki-67+ cells than FoxP3- CD4 cells from normal mice, 
suggesting that even in the steady-state, FoxP3+ CD4 cells are undergoing more robust 
replication and have higher turnover than FoxP3- CD4 cells. Our data are therefore 
consistent with a previous report that a subset of Tregs in normal mice proliferated even in 
the steady state, based on CFSE-dilution and BrdU incorporation assays (19). Furthermore, 
the expression of Ki-67 correlated directly with TNFR2 expression, which is in agreement 
with our current understanding of TNFR2 as a co-stimulator of the proliferative response of 
lymphocytes to TCR stimulation (20-22). The cell source of TNFR2 ligands which 
potentially contribute to the homeostasis of Treg pool in the steady-state remain to be 
defined.  
The basis for the expansion of Treg cells at the tumor site remains elusive. Three 
mechanisms have been proposed to account for the accumulation of Treg cells in the tumor 
mass: 1) the tumor microenvironment actively recruits natural Treg cells by producing 
chemokine ligands which interact with chemokine receptor expressed by Treg cells (23); 2) 
naïve CD4 cells can be converted into tumor-specific FoxP3+ Treg cells by TGFβ produced 
by tumor cells (24) or alternatively by PD-L1 expressed by DCs in the tumor (25); 3) the 
tumor microenvironment stimulates the proliferative expansion of infiltrated Treg cells (26). 
It has been proposed that TGFβ produced by DCs exhibiting an immature phenotype could 
stimulate the proliferation of Treg cells in tumor (27). However, although known to induce 
de novo differentiation of naïve CD4 cells into Treg cells (28), TGFβ is actually a potent 
suppressor of proliferation of T cells (29). We have observed that TGFβ also inhibits TNF-
induced proliferation of Treg cells in vitro (unpublished data). At day 5 after tumor 
inoculation, <20% of the FoxP3+ Tregs in the dLN were proliferating (Fig 4D and Fig 6), 
while more than 80% of TIL FoxP3+ Treg cells are Ki-67+ (Fig 6). These data indicate that 
in situ proliferative expansion contribute substantially to the accumulation of Tregs in the 
tumor. TNF is a key mediator of cancer-associated inflammation, produced either by tumor 
cells and/or by infiltrating leukocytes (11) and has the capacity to activate Treg cells (14). 
IL-2 is known to be critical to the survival and proliferation of Tregs (30). However, the 
expression of IL-2 in the tumor tissue is low or absent (31-32), presumably due to the 
hypoxic tumor environment since IL-2 transcription is exquisitely sensitive to changes in 
oxygen tension (33), thus argue against the likelihood of a major role of IL-2 in the 
expansion of Tregs in the tumor. Although low levels of IL-2 are needed for survival of 
Chapter 7. TNFR2 induces resistance of Tconv cells to Tregs 
 
118 
 
Tregs, the TNF enriched tumor microenvironment likely induces the proliferative 
expansion of TNFR2+ Treg cells through TNF-TNFR2 interaction.  
A small fraction of Tconv cells constitutively express TNFR2 even in the steady-state (Fig 
1) and TNFR2-expressing Tconv cells are increased in the tumor (Fig 5-6). It has been 
shown that memory Tconv cells are refractory to Treg-mediated inhibition (34) and that 
interaction of TNFR2 with its ligands plays a role in the maintenance of T cell memory (35). 
Whether TNFR2+ Tconv cells in normal or tumor bearing mice actually represent memory 
cells merits future study. Furthermore, activated Tconv cells express more TNFR2 [(14) 
and Fig 3C]. Such activated TNFR2+ Tconv cells were refractory to Treg-mediated 
suppression. Indeed, CD4+FoxP3/gfp-TNFR2- cells pre-activated in vitro with APCs/anti-
CD3 also acquired the capacity to resist suppression by Tregs, accompanied by up-
regulation of TNFR2 (Fig 3C~D), indicating that proliferating Tconv cells become more 
resistant than resting Tconv cells to Tregs. Importantly, induction of Treg-resistance by 
TCR-stimulation was restricted to the Tconv cells which were induced to express TNFR2 
(Fig 3E), underscoring the role of TNFR2 in the Treg-resistance. TNFR2 has been shown to 
promote TCR-mediated cellular activation (7-9). A recent study reported that the activation 
of TNFR2, but not TNFR1, on human T cells resulted in p100 processing and induced the 
activation of alternative NFκB pathway (36). Thus, expression of TNFR2 empowers Tconv 
cells to respond to the stimulation of its ligands, and consequently enhances their resistance 
to the inhibition by Tregs. 
It was reported that Tconv cells present in the 4T1 tumor with an activated phenotype were 
hyporesponsive to ex vivo TCR stimulation (5). Similarly, we found that tumor infiltrating 
CD4+CD25- cells exhibited an activated phenotype (Fig 7) and comprised a higher 
proportion of TNFR2+ and Ki-67+ cells (Fig 5~6). Thus, TNF-TNFR2 co-stimulation also 
activates FoxP3- Tconv cells in the tumor, although they have attenuated proliferative 
responses to TCR stimulation in vitro, which may be due to TCR signaling defects of 
Tconv cells in the tumor (37). Presumably the activated TIL Tconv cells become resistant 
to inhibition by LN-derived Treg cells from tumor free mice (Fig 8), but are still susceptible 
to inhibition by more highly activated tumor infiltrating Treg cells. Thus, TIL Treg cells 
which express higher levels of TNFR2 on a greater number of cells, may outcompete TIL 
Tconv cells in utilizing stimulatory factors, including co-stimulatory TNFR2 signaling, 
provided by the tumor environment. It was reported that both human and mouse Treg cells 
expressed high levels of surface TNFR2 and had the capacity to shed TNFR2 which 
contributes to the suppressive action of Treg cells (12). However, we did not detect 
elevated levels of soluble TNFR2 in either human or mouse TNFR2+ Treg culture medium 
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under our in vitro experimental condition (data not shown). Furthermore, 
TNFR2+FoxP3/gfp- T cells did not exhibit suppressive activity at all (Fig 2). Thus, our data 
suggest that shed TNFR2 may not represent a molecular basis for the immunosuppressive 
action of Treg cells. Instead, we hypothesize that Treg cells may outcompete Tconv cells in 
utilizing TNF as co-stimulatory molecules for cellular activation and expansion, which 
consequently further deprive Tconv cells of available TNFR2 ligand.   
TIL Treg cells override the activation of Tconv cells and produce a dominant 
immunosuppressive environment in tumors. Further defining the mechanisms by which the 
tumor environment enhances the resistance of Tconv cells to Treg-mediated inhibition may 
be instrumental in devising effective immunotherapy to circumvent Treg activity and may 
yield anti-tumor immune responses. In contrast to tumor bearing states, the pathogenic 
activated effector T cells present in autoimmune conditions are more likely to outcompete 
Tregs in exploiting the TNF-TNFR2 co-stimulatory pathway. The possibility that this 
contributes to the therapeutic efficacy of anti TNF therapy in autoimmune diseases (38) 
merit future study.         
Collectively, our study demonstrates that TNFR2 was predominantly expressed by 
activated Treg cells and to a markedly lesser extent expressed by activated Tconv cells, and 
enables both Treg cells and Tconv cells to respond to co-stimulatory signaling by TNFR2. 
Up-regulation of TNFR2 was much greater in tumor infiltrating Treg cells than Tconv cells 
and both subsets were activated to proliferate, presumably in response to both tumor 
associated antigens and stimulation by TNF enriched cytokine milleu in the tumor 
microenvironment. However, the activated intratumoral Treg cells still overcame the 
activated Tconv cells and resulted in the predominance of the immunosuppressive 
environment in the tumor. Selectively amplifying TNF-TNFR2 co-stimulation of Tconv 
cells and/or blocking its effect on Treg cells may be able to improve the outcome of 
immunotherapy and therefore merit future study.      
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Although TNF is a major proinflammatory cytokine, increasing evidence indicates that 
TNF also has immunosuppressive feedback effects. In the present thesis several questions 
were asked related to: the capacity of TNF to expand and to activate the function of T-
regulatory cells, the receptor pathways required for these effects, and the ability of 
TNF/TNFR interaction to influence the stabilization of regulatory T-lymphocyte 
phenotypes.  
A first answer to the question on the role of TNF for induction of Treg activity is presented 
in Chapter 2 showing that, in both resting and activated states, mouse peripheral Tregs 
expressed remarkably higher surface levels of TNFR2 than Teffs. In co-cultures of Tregs 
and Teffs, inhibition of proliferation of Teffs by Tregs was initially transiently abrogated by 
exposure to TNF, but longer exposure to TNF restored suppressive effects. The profound 
anergy of Tregs in response to TCR stimulation was overcome by TNF, which expanded 
the Treg population. Furthermore, in synergy with IL-2, TNF expanded Tregs were even 
more suppressive. Thus, the stimulatory effect of TNF on Tregs resembles the reported 
costimulatory effects of TNF on Teffs, but is even more pronounced because of the higher 
expression of TNFR2 by Tregs (1). 
TNFR2 is predominantly expressed by a subset of human and mouse Tregs. In Chapter 3, 
we characterized the phenotype and function of TNFR2+ Tregs in normal and tumor-
bearing C57BL/6 mice. We found that TNFR2 was expressed on 30-40% of the Tregs of 
the peripheral activated/memory subset that were most highly suppressive. In contrast, 
TNFR2- Tregs exhibited the phenotype of naive cells and only had minimal suppressive 
activity. Although not typically considered to be Tregs, CD4+CD25-TNFR2+ cells 
nevertheless possessed moderate suppressive activity. In the Lewis lung carcinoma model, 
more highly suppressive TNFR2+ Tregs accumulated intratumorally than in the periphery. 
Thus, TNFR2 identifies a unique subset of mouse Tregs with an activated/memory 
phenotype and maximal suppressive activity that may account for tumor-infiltrating 
lymphocyte-mediated immune evasion by tumors (2). 
In Chapter 4, we report that human PB FOXP3+ cells present in CD25high, CD25low and 
even CD25- subsets of CD4 cells expressed high levels of TNFR2. Consequently, TNFR2-
expressing CD4+CD25+ Tregs included all of the FOXP3+ cells present in the 
CD4+CD25high subset as well as a substantial proportion of the FOXP3+ cells present in the 
CD4+CD25low subset. Flow cytometric analysis of PB identified five-fold more Tregs, 
determined by FOXP3 expression, in the CD4+CD25+TNFR2+ subset than in the 
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CD4+CD25high subset. Furthermore, the CD4+CD25+TNFR2+ subset expressed high levels 
of CTLA-4, CD45RO, CCR4 and low levels of CD45RA and CD127, a phenotype 
characteristic of Tregs. Upon TCR stimulation, human PB CD4+CD25+TNFR2+ cells were 
anergic and markedly inhibited the proliferation and cytokine production of co-cultured T-
responder cells. Therefore, the combination of CD25 and TNFR2 identifies a larger 
population of human Tregs, a population that may prove to be of diagnostic and therapeutic 
benefit in cancer and autoimmune diseases (3). 
In Chapter 5, we show that TNF, in concert with IL-2, preferentially up-regulated mRNA 
and surface expression of TNFR2, 4-1BB and OX40 on Tregs. Agonistic antibodies against 
4-1BB and OX40 also induced the proliferation of suppressive Tregs. Thus, TNF amplifies 
its stimulatory effect on Tregs by inducing TNF receptor superfamily (TNFRSF) members. 
In addition, administration of neutralizing anti-TNF Ab blocked LPS-induced expansion of 
splenic Tregs and up-regulation of TNFR2, OX40 and 4-1BB receptors on Tregs in vivo, 
indicating that the expansion of Tregs expressing these co-stimulatory TNFRSF members 
in response to LPS is mediated by TNF. Altogether, our novel data indicate that TNF 
preferentially up-regulates TNFR2 on Tregs, and this is amplified by the stimulation of 4-
1BB and OX40, resulting in the optimal activation of Tregs and augmented attenuation of 
excessive inflammatory responses (4). 
Several lines of evidence indicate the instability of CD4+FoxP3+ Tregs. An important 
question we posed at the beginning of the thesis was whether TNF also promotes the 
stability of Tregs, in addition to activate and expand of these cells. In Chapter 6, we 
reported that the proportion of Tregs in mouse strains deficient in TNFR2 or its ligands was 
reduced in the thymus and peripheral lymphoid tissues, suggesting a potential role of 
TNFR2 in promoting the sustained expression of FoxP3. We observed that upon in vitro 
activation with plate-bound anti-CD3 Ab and soluble anti-CD28 Ab, FoxP3 expression by 
highly purified mouse Tregs was markedly down-regulated. Importantly, TNF partially 
abrogated this effect of TCR stimulation and stabilized FoxP3 expression. This effect of 
TNF was blocked by anti-TNFR2 Ab, but not by anti-TNFR1 Ab. Furthermore, TNF was 
not able to maintain FoxP3 expression by TNFR2-deficient Tregs. In mouse colitis model 
induced by transfer of naïve CD4 cells into Rag1-/- mice, the disease could be inhibited by 
co-transfer of WT Tregs, but not by co-transfer of TNFR2-deficient Tregs. Furthermore, in 
the lamina propria of the colitis model, the majority of WT Tregs maintained FoxP3 
expression. In contrast, increased number of TNFR2-deficient Tregs lost FoxP3 expression. 
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Thus, our data clearly show that TNFR2 is critical for the phenotypic and functional 
stability of Treg in the inflammatory environment (5). 
TNFR2 is also expressed by a small fraction of CD4+FoxP3- Teffs in normal mouse, and its 
expression is up-regulated by T cell activation. This raises questions about the role of 
TNFR2 signaling in the function of Teff cells. In Chapter 7, by using FoxP3/gfp knock-in 
mice, we showed that TNFR2 signaling did not induce FoxP3- CD4 cells to become 
suppressive. Ki-67, a marker of proliferation, was concomitantly expressed with TNFR2 by 
CD4 cells, independent of Foxp3 expression, in normal mice and Lewis lung carcinoma-
bearing mice. TNFR2 is associated with greater suppressive functions when expressed by 
Tregs and is associated with greater resistance to suppression when expressed by Teff cells. 
In mice bearing 4T1 breast tumor or Lewis lung carcinoma, intratumoral Teff cells 
expressing elevated levels of TNFR2 acquired the capacity to resist suppression by lymph 
node-derived Tregs. However, they remained susceptible to inhibition by more suppressive 
tumor-infiltrating Tregs, which expressed higher levels of TNFR2. Our data indicate that 
TNFR2 also co-stimulates Teff cells. However, intratumoral Tregs expressing more TNFR2 
are able to overcome the greater resistance to suppression of intratumoral Teff cells, 
resulting in a dominant immunosuppressive tumor environment (6). 
Concluding remarks 
Both Teffs and Tregs are likely to use co-stimulation of TNF-TNFR2 for activation, 
expansion and maintenance of immune equilibrium. Based on the experimental evidence, 
we propose that, at the initial stage, TNF co-stimulates the activation of Teffs and liberates 
them from Tregs to mount an effective immune response against pathogens. At a later stage 
in the inflammatory responses, higher levels of TNFR2 expression by Tregs may enable 
them to outcompete Teffs for TNF and to down-regulate inflammatory responses. The 
stimulatory effect of TNF on Tregs thus represents an important negative feedback 
mechanism results in the attenuation and termination of prolonged or excessive immune 
responses, which otherwise may cause severe collateral damage (as reviewed in (7), see 
Figure 1). 
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Figure 1: Role of TNF-TNFR2 signal on Tregs and Teffs in the immune homeostasis and 
inflammation. In the steady state, the equilibrium of the activation of Tregs and T-effector cells (Teffs) is 
crucial for immune homeostasis (1). In the early stage of inflammation, activated Teffs up-regulate their 
TNFR2 expression and increase their capacity to resist Treg-mediated inhibition, and therefore mount an 
effective immune response (2). In the later stage of inflammation, Tregs outcompete with Teffs for co-
stimulatory TNF-TNFR2 action and enhanced their suppressive activity, resulting in the resolution of 
inflammatory responses and restoration of immune homeostasis (3).          
 
In both steady and activating state, Tregs appear to express higher levels of TNFR2 than 
Teffs, indicating that TNF-TNFR2 costimulatory effect preferentially acts on Tregs. 
Although counterintuitive and contradictory to a previous report (8), our observation is 
supported by the emerging evidence from other investigators (9-15). For example, 
Mougiakakos and Kiessling et al found that TNF-TNFR2 interaction enhanced thioredoxin-
1 expression on human Tregs, but not on Teffs, and therefore preferentially promoted Treg 
survival and activity within inflammatory milieu (10). Grinber-Bleyer and Salomon et al 
showed that pathogenic Teffs stimulated the activation of Tregs in vivo, at least partially 
through TNF-TNFR2 interaction (13). Housley and Clark et al have shown that TNFR2 is 
critical for the in vivo immunosuppressive function of naturally occurring Tregs (14). These 
studies substantiate the notion that TNF-TNFR2 interaction plays a critical role in the 
generation, expansion and function of human and mouse Tregs.  
In the future, the clinical relevance of TNF-TNFR2 pathway in the activation of Tregs 
should also be addressed, which may improve the safety and efficacy of current anti-TNF 
treatment regimen. Furthermore, elucidation of signaling pathways and molecular basis of 
TNFR2 in the activation of Tregs may yield novel strategy to up- or down-regulate Treg 
activity for therapeutic purposes (16, 17).  
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Samenvatting 
Hoewel TNF als cytokine voornamelijk bekend is om zijn belangrijke pro-inflammatoire 
eigenschappen, duiden steeds meer aanwijzingen op een rol van TNF in 
immunosuppressieve ‘feedback’ mechanismen. Deze thesis beoogt meer inzicht te 
verwerven in de volgende vraagstellingen: (i) in hoeverre beïnvloedt TNF de functie en het 
fenotype van regulatoire T cellen (Tregs), (ii) welke receptoren zijn verantwoordelijk voor 
deze effecten en (iii) in welke mate beïnvloedt de TNF/TNFR interactie zowel effector T 
cellen (Teffs) als Tregs. 
Onze verkregen resultaten tonen aan dat, in de muis, de expressie van TNFR2 op het 
celoppervlak van perifere Tregs beduidend hoger was dan in Teffs. TNF stimuleerde via 
TNFR2 voornamelijk de activatie en ontwikkeling van Tregs. De expressie van muis 
TNFR2 was kenmerkend voor een uniek subtype van Tregs, welke een geactiveerd 
geheugen fenotype hebben met maximale activiteit tot supressie. 
In humaan perifeer bloed vertoonden de aanwezige CD4+ cellen die zowel FoxP3-positief 
als mede ook  CD25high, CD25low en zelfs CD25- waren een verhoogde expressie van 
TNFR2. Dit wijst erop dat wanneer cellen die zowel  CD25 en TNFR2 expressie vertonen 
een grotere populatie van humane Tregs identificeert dan wanneer enkel CD25high cellen in 
acht worden genomen. TNF veroorzaakte voornamelijk een verhoogde expressie van 
TNFR2 op Tregs. Dit expressieniveau werd versterkt door het stimuleren van 4-1BB en 
OX40, wat resulteerde in een optimale activatie van Tregs. 
Meerdere studies benadrukken de instabiliteit van Tregs. Onze resultaten laten zien dat  bij 
muizen die deficiënt zijn voor TNFR2 of voor liganden van TNFR2 het aantal Tregs in de 
thymus en in secundaire lymfoïde organen verminderd  was, wat suggereert dat TNFR2 een 
mogelijke rol speelt in het bevorderen van FoxP3 expressie. TNF-TNFR2 interactie was 
cruciaal voor de fenotypische en functionele stabiliteit van Tregs, zowel in vitro als in vivo. 
In muizen brengt een kleine fractie CD4+FoxP3- Teffs ook TNFR2 tot expressie, wat 
gestimuleerd kan worden door T-cel activatie. Onze resultaten toonden aan dat enerzijds de 
specifieke expressie van TNFR2 door Tregs sterkere suppressieve functies impliceert en 
anderzijds expressie van TNFR2 door Teffs geassocieerd is met een verminderde 
suppressieve functie. 
Zowel Teffs als Tregs gebruiken hoogstwaarschijnlijk de co-stimulatie van TNF-TNFR2 
voor hun activatie, ontwikkeling en het behouden van een immunologisch evenwicht. Onze 
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bevindingen suggereren dat in de initiële fase tijdens ontsteking TNF de activatie van Teffs 
co-stimuleert en, los van Tregs, deze cellen in staat zijn om een efficiënte immuunrespons 
te genereren. In een later stadium van ontsteking kunnen Tregs door hun hogere niveau van 
TNFR2-expressie in competitie treden met Teffs voor TNF en hierdoor de inflammatoire 
respons inhiberen. Het stimulerende effect dat TNF uitoefent op Tregs representeert 
alsdusdanig een belangrijk negatief ‘feedback’ mechanisme dat uiteindelijk resulteert in een 
vermindering of het beëindigen van een langdurige of buitensporige immuunrespons. 
In toekomstige studies is het derhalve niet onbelangrijk om de klinische relevantie van de 
TNF-TNFR2 interactie in de activatie van Tregs in kaart te brengen, wat kan resulteren in 
een verbeterde veiligheid en efficiëntie voor de huidige anti-TNF behandelingen. Het 
ophelderen van de betrokken signaalcascades van TNFR2 die leiden tot de activatie van 
Tregs zou mogelijk kunnen resulteren in nieuwe strategieën om de activiteit van Tregs te 
remmen of juist te verhogen.  
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Abbreviations 
 
CLP: cecal ligation and puncture 
cLP: colon lamina propria;  
dLN: draining lymph note 
FoxP3: forkhead box P3 
KI: knock in 
KO: knockout 
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LTα: lymphotoxin-alpha 
LTβ: lymphotoxin-beta 
MFI: mean fluorescence intensity 
mLN: mesenteric lymph nodes 
nCD4: naïve CD4 cells 
non-dLN: non-draining lymph node 
PB: peripheral blood 
SP: single positive 
Tconv cells: conventional T cells 
Teff: CD4+Foxp3- efector T cell 
TIL: tumor infiltrating lymphocyte 
TNFR2: tumor necrosis factor receptor type II 
Treg: CD4+Foxp3+ regulatory T cell 
Tregs: regulatory T cells 
Triple KO: TNF/LTα/LTβ knockout 
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